Date of Document: March 29, 2024

CURRICULUM VITAE

Mary M. Horowitz MD, MS

Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:

Clinical Cancer Center
9200 W Wisconsin Ave
Milwaukee, WI 53226
Fax: 414-805-0714

EDUCATION:

1972 - 1974 State University College of New York at Buffalo
1974 - 1975 B.S., Zoology, University of Wisconsin-Milwaukee
1976 - 1980 M.D., Medical College of Wisconsin
1991 M.S., Biostatistics/Clinical Epidemiology, Medical College of Wisconsin

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

1980 - 1984 Resident, Internal Medicine, Medical College of Wisconsin, Milwaukee, WI
1984 - 1985 Chief Resident, Internal Medicine, Medical College of Wisconsin, Milwaukee, WI
1987 - 1989 Fellow in Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI

FACULTY APPOINTMENTS:

1984 - 1985 Instructor, Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226
1985 - 1991 Assistant Professor, Department of Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226
1986 - 1991 Assistant Scientific Director, International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226
1991 - 2021 Chief Scientific Director, Department of Medicine, Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, 9200 West Wisconsin Avenue, CLCC, Suite C5500, Milwaukee, WI 53226
1991 - 1994 Associate Professor, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226
1994 - Present Professor, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226
2001 - 2006 Interim Director, Bone Marrow Transplant Program, Department of Medicine, Division of Neoplastic Diseases and Related Disorders, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226
2002 - Present Robert A. Uihlein, Jr. Chair in Hematologic Research, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226
2010 - 2017 Chief, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee, WI 53226-3596
2012 - 2015 Global Health Program Liaison, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226
2017 - 2019 Associate Director, Human Molecular Genomics Center, Medical College of Wisconsin, 8701 Watertown Plank Ave, Milwaukee, WI 53226
2021 - Present Deputy Director, Cancer Center, Froedtert & Medical College of Wisconsin, 9200 W

Wisconsin Ave, Milwaukee, WI 53226

AWARDS AND HONORS:

1980 Alpha Omega Alpha
1980 Upjohn Achievement Award for Outstanding Clinical Proficiency
1980 American Women's Medical Association Award for Scholastic Achievement
1980 Community Medicine Award for report on the History of Health Insurance in the United States
1985 Distinguished Service Award, VA Medical Center, Wood, WI
1997 Service Award, U.S. Health Resources and Services Administration
1998 - 1999 Selected by Peers for "The Best Doctors in America"
2001 - 2002 Selected by Peers for "The Best Doctors in America"
2005 Honorary Fellowship, The Royal College of Physicians and Surgeons of Canada
2005 - 2012 Selected by Peers for "The Best Doctors in America"
2006 Distinguished Service Award, Medical College of Wisconsin
2007 Selected by Peers to give the "Mortimer M. Bortin Lecture", BMT Tandem Meetings
2007 Alfredo Pavlovsky Award, XXXI World Congress of the International Society of Hematology
2007 Women of Influence Award, The Business Journal Serving Greater Milwaukee
2008 Medical College of Wisconsin Alumnus of the Year
2008 Selected by The Anthony Nolan Trust to give the "Shirley Nolan Memorial Lecture", 7th International Registry Meeting
2008 DKMS Mechtild Harf Award
2010 American Society of Hematology Clinical Research Mentor Award
2011 Medical College of Wisconsin Women in Science Award
2012 Medical College of Wisconsin Clinical Practice Excellence in Professionalism Award
2013 Inducted into American Association of Physicians
2014 Lifetime Achievement Award, American Society for Blood and Marrow Transplantation
2016 14th Annual Thomas L. Smallwood Award for Patient Care Excellence, Froedtert Hospital
2016 The G. Richard Olds Award for Mentorship in Medicine, Department of Medicine, Medical College of Wisconsin
2017 Mastership, American College of Physicians
2019 American College of Physicians Harriet Dustan Award for Outstanding Work in Science as Related to Medicine
2019 Aplastic Anemia & MDS International Foundation Lifetime Achievement in Science Award
2020 Hector F. DeLuca BioForward Scientific Achievement Award

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

1991 - 1995 International Society for Experimental Hematology (Membership Committee)
1998 - 2001 International Society for Hematotherapy & Graft Engineering (Member, Transplantation Committee)
2003 - 2004 World Marrow Donor Association (President)
2012 - 2016 Worldwide Network for Blood and Marrow Transplantation (Founding Member;Nominating Committee)
2013 - 2017 American Society of Hematology Nominating Committee (Member)
2014 - 2017 American Society of Hematology Committee on Promoting Diversity (Member)
2016 - Present American Society of Hematology Clinical Research Training Institute Advisory Board (Member)
2017 - Present Aplastic Anemia and MDS International Foundation MDS Clinical Research Consortium Advisory Board (Member)
American Medical Association
American College of Physicians (Fellowship, 2011)
American Society of Hematology
Alpha Omega Alpha
American Society of Clinical Oncology
American Society for Blood and Marrow Transplantation (Member, Education and Standards Committee, 1999-present, Chair, Subcommittee on Transplantation Results, 1994-1997, Program Committee 2000-present)
Association of American Physicians

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Editorial Board

Blood

The Journal of Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

1991 - 1992 National Marrow Donor Program, Consultant for design and implementation of data collection system

1992 - 1993 National Heart, Lung and Blood Institute, Advisory Committee for study of optimal size of bone marrow donor registry

1992 National Institute for Allergy and Infectious Diseases, Special Review Committee

1992 - 1994 U.S. General Accounting Office, Advisor for study of access to bone marrow transplantation

1993 - 1999 Eastern Cooperative Oncology Group, Bone Marrow Transplant Core Committee

1993 - 1999 National Marrow Donor Program, Board of Directors

1994 National Cancer Institute, Special Review Committee

1994 - 1995 American Society for Clinical Oncology, Expert Panel on Stem Cell Transplantation

1995 - 2000 National Cancer Institute, Subcommittee H, Clinical Cancer Investigations Review Committee

1995 - 1996 National Marrow Donor Program, Awards Committee, 1995-1996

1996 - 1998 National Cancer Institute, Common Toxicity Criteria for Bone Marrow Transplantation Working Group

1996 Health Resources & Services Administration, U.S. Department of Health & Human Services, Ad Hoc Review Committee for Solid Organ Transplantation Scientific Registry

1996 - 1999 Endpoint Evaluation Committee for randomized trial of GVHD prophylaxis, Fujisawa USA

1996 - 1998 National Marrow Donor Program, Cord Blood Stem Cell Advisory Panel

1997 - 1999 National Marrow Donor Program, Nominating Committee (Chair, 1999)

1997 - 1999 Blue Quality Centers for Transplant, Expert Institutional Criteria Development Panel

1997 - 2000 National Heart, Lung and Blood Institute, Data and Safety Monitoring Board, Cord Blood Transplantation Study

1997 Health Resources & Services Administration, Bone Marrow Transplant Policy Forum, Chair, Transplant Indications Subcommittee

1998 - 2000 Consultant for IB-367 Oral Mucositis Program, INTRABIOTICS

1998 - 2000 Member, Bone Marrow Transplant Advisory Board, Schering AG

1998 - Present United Network for Organ Sharing, Scientific Tumor Advisory Committee

1998 - 2004 National Marrow Donor Program, Research and Publications Committee

1999 - 2002 American Society of Blood and Marrow Transplantation, Steering Committee for Evidence-Based Reviews

1999 - 2000 ABX-CBL Program Advisory Committee, Abgenix, Inc., 1999-2000

1999 - 2000 National Marrow Donor Program, Ad Hoc Committee on Business Opportunities

1999 National Marrow Donor Program, Transplant Center-Specific Analysis Panel

1999 National Heart, Lung and Blood Institute, Ad Hoc Cord Blood Advisory Committee

1999 Phase III Study Investigator's Committee, Laboratoires Fournier

1999 - 2000 National Cancer Institute/National Heart, Lung & Blood Institute, Invited Participant for a Workshop on Clinical Trials in Transplantation (Chair, Alternative Donors Subcommittee)

1999 Member, Non-Hodgkins Lymphoma Advisory Board, Bristol-Myers Squibb Oncology

2000 - 2001 Medical Advisor, AmCell Corporation

2000 ACIT Scientific Advisory Board, Cerus Corporation

2000 - 2004 National Marrow Donor Program, Board of Directors

2000 - 2004 National Marrow Donor Program, International Affairs Committee

2000 - 2002 American Society for Clinical Oncology, BMT Subcommittee of the Program Committee, 2000-2002

2000 - 2001 National Institute of Allergy & Infectious Diseases, Immune Tolerance Network

2001 - 2003 Medical Advisory, Allianz - LifeTrac Bone Marrow Transplant Advisory Panel

2003 American Society for Clinical Oncology, Adult Leukemia, Lymphoma & Transplantation Subcommittee of the Program Committee

2003 National Institute for Allergy and Infectious Diseases, Special Emphasis Panel Member

2003 - 2005 Consultant for Indolent NHL: An Observational Registry Study of patients with Indolent B-cell

NHL, Genentech
2003 Consultant for IV Busulfex, ESP Pharma, 2003
2004 Institutes of Medicine/Board on Health Sciences Policy, Committee on Establishing a National Cord Blood Stem Cell Bank Program
2005 - 2006 DKMS America Bone Marrow Donor Registry, Board of Directors
2006 - 2010 Food and Drug Administration, Center for Biologics Evaluation and Research, Consultant, Center for Biologics Evaluation and Research
2006 - 2009 Consultant for OptumHealth on Assessing Center-Specific Outcomes
2007 - 2008 Integrated Research and Treatment Center for Transplantation (IFB-Tx), University of Hannover, International Advisory Board, 2008-present
2007 - 2009 U.S. Transplantation Section Head for Faculty of 1000 Medicine
2007 Consultant, Endo Pharmaceuticals Inc Advisory Board
2008 National Cancer Institute/National Heart, Lung & Blood Institute, Enhanced Translational Research and Clinical Trials for Cellular Therapies Working Group
2008 - 2009 Consultant, Otsuka Pharmaceutical Development and Commercialization Advisory Board
2009 - 2011 Leukemia & Lymphoma Society, Medical & Scientific Affairs Committee
2010 - 2011 Food and Drug Administration, Center for Biologics Evaluation and Research, Cellular, Tissue and Gene Therapies Advisory Committee
2010 - 2013 European Group for Blood and Marrow Transplantation, Board of Counsellors
2011 National Heart, Lung and Blood Institute, Invited Participant Workshop on Data Coordinating Centers
2013 - 2017 Anthony Nolan Scientific and Clinical Impact Advisory Board
2013 - 2016 Nominating Committee, American Society of Hematology
2015 - 2016 Member, Steering Committee, National Cancer Institute
2016 - 2017 Member, Education Program Advisory Panel, American Society of Hematology
2016 - Present Member, Clinical Research Training Institute Advisory Board, American Society of Hematology (ASH)
2017 - 2018 Member, MDS Clinical Research Consortium Advisory Board, Aplastic Anemia and MDS International Foundation
2021 - Present NHLBI Expert Panel

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Peer Review

Title:	BMT Clinical Research Network Data Coordinating Center
Source:	NIH: NHLBI (lead) and National Cancer Institute (NCI)
Role:	Principal Investigator
Dates:	2017 - 2024
Direct Funds:	$45,795,816
Title:	Cure Sickle Cell
Source:	National Institutes of Health (NIH): National Heart, Lung and Blood Institute (NHLBI)
Role:	Co-Principal Investigator
PI:	Mary Epen
Dates:	2018 - 2023
Direct Funds:	$12,800,000
Title:	Student-Centered Pipeline to Advance Research in Cancer Careers (SPARCC) for Underrepresented Minority Students
Source:	NIH: NCI
Role:	Co-Investigator
PI:	J Rader

Dates: 2018 - 2023
Direct Funds: $970,574

Title: A Data Resource for Analyzing Blood and Marrow Transplants
Source: NIH: NCI (lead), NHLBI, NHLBI, National Institute for Allergy and Infectious Disease (NIAID)
Role: Co-Investigator
PI: Bronwen Shaw
Dates: 2018 - 2023
Direct Funds: $16,495,815

Title: BMT Clinical Research Network Data Coordinating Center (Administrative Supplement: HIV Protocol)
Source: NIH: NCI
Role: Principal Investigator
Dates: 2019 - 2022
Direct Funds: $4,099,938

Prior

Peer Review

Title: A Collaborative Bone Marrow Transplant Program
Source: National Institutes of Health and the National Cancer Institute
Role: Principal Investigator
Dates: 1991 - 1994
Direct Funds: $2,106,400

Title: Competitive supplement to "A Collaborative Bone Marrow Transplant Program"", "Autotransplants for Breast Cancer"
Source: National Institutes of Health and the National Cancer Institute
Role: Principal Investigator
Dates: 1992 - 1994
Direct Funds: $256,469

Title: Cancer Following Bone Marrow Transplantation
Source: National Institutes of Health and the National Cancer Institute
Role: Principal Investigator
Dates: 1992 - 1995
Direct Funds: $315,685

Title: Database of Autotransplants for Breast Cancer
Source: U.S. Army, Department of Defense
Role: Principal Investigator
Dates: 1994 - 1998
Direct Funds: $1,220,000

Title:	A Collaborative Bone Marrow Transplant Program
Source:	National Institutes of Health (NCI, NHLBI, NIAID)
Role:	Principal Investigator
Dates:	1994 - 1999
Direct Funds:	$4,473,355

Title:	Cancer Following Bone Marrow Transplantation
Source:	National Institutes of Health and the National Cancer Institute
Role:	Principal Investigator
Dates:	1995 - 2000
Direct Funds:	$259,747

Title:	A Data Resource for Analyzing Blood and Marrow Transplant
Source:	National Institutes of Health and the National Cancer Institute
Role:	Principal Investigator
Dates:	1998 - 2003
Direct Funds:	$7,023,478

Title:	Quality of Life and Relationships after BMT
Source:	National Institutes of Health and the National Cancer Institute, Subcontract with the University of Florida
Role:	Co-Investigator
PI:	John Wingard
Dates:	1999 - 2002
Direct Funds:	$458,617

Title:	13th International Histocompatibility Working Group
Source:	National Institutes of Health and the National Institute of Allergy and Infectious Diseases, Subcontract with Fred Hutchinson Cancer Research Center
Role:	Co-Investigator
PI:	John Hansen
Dates:	2000 - 2005
Direct Funds:	$280,056

Title:	BMT Clinical Research Network Data Coordinating Center, National Institutes of Health, National Heart, Lung, and Blood Institute, U01HL6929
Source:	Center, National Institutes of Health, National Heart, Lung, and Blood Institute
Role:	Principal Investigator
Dates:	2001 - 2011
Direct Funds:	$61,629,078

Title:	A Data Resource for Analyzing Blood and Marrow Transplants
Source:	National Institutes of Health and the National Cancer Institute
Role:	Principal Investigator
Dates:	2003 - 2008
Direct Funds:	$9,432,060

Title:	A Public System for Electronic Exchange of Clinical Network Data: A Collaborative Effort of the International Bone Marrow Transplant Registry and the National Marrow Donor Program
Source:	National Institutes of Health and the National Heart, Lung and Blood Institute, Subcontract with the National Marrow Donor Program
Role:	Co-Investigator
PI:	Dennis Confer
Dates:	2004 - 2007
Direct Funds:	$318,617

Title:	Hematopoietic Stem Cell Transplantation
Source:	National Institutes of Health and the National Institute of Allergy and Infectious Diseases, Subcontract with the Fred Hutchinson Cancer Research Center
Role:	Co-Investigator
PI:	Effie Petersdorf
Dates:	2005 - 2010
Direct Funds:	$60,863

Title:	Stem Cell Therapeutic Outcomes Database
Source:	Health Resources and Services Administration
Role:	(Project Director, 2006-2008) (Research Director, 2008-2012)
Dates:	2006 - 2012
Direct Funds:	$17,480,329

Title:	A Data Resource for Analyzing Blood and Marrow Transplants
Source:	National Institutes of Health and the National Cancer Institute
Role:	Principal Investigator
Dates:	2008 - 2013
Direct Funds:	$12,881,026

Title:	A Data Resource for Analyzing Blood and Marrow Transplants (ARRA Supplement)
Source:	National Institutes of Health and the National Cancer Institute
Role:	Principal Investigator

Dates:	2009 - 2011
Direct Funds:	$384,061
Title:	RDSafe: A Multi-Institutional Study of HSC Donor Safety and Quality Life
Source:	National Institutes of Health and the National Heart, Lung and Blood Institute, Subcontract with the University of Utah
Role:	Co-Investigator
PI:	Michael Pulsipher
Dates:	2009 - 2014
Direct Funds:	$77,431
Title:	BMT Clinical Research Network Data Coordinating Center
Source:	National Institutes of Health, National Heart, Lung and Blood Institute (NIH, NHLBI)
Role:	Principal Investigator
Dates:	2011 - 2017
Direct Funds:	$57,916,053
Title:	Easy-to-Read Informed Consent (ETRIC) for HCT Clinical Trials (BMT CTN Supplement)
Source:	National Institutes of Health, National Heart, Lung and Blood Institute (NIH, NHLBI)
Role:	Principal Investigator
Dates:	2012 - 2016
Direct Funds:	$354,517
Title:	Stem Cell Therapeutic Outcomes Database
Source:	Health Resources and Services Administration
Role:	Research Director
Dates:	2012 - 2017
Direct Funds:	$16,725,822
Title:	A Data Resource for Analyzing Blood and Marrow Transplants
Source:	National Institutes of Health and the National Cancer Institute (NIH, NCI)
Role:	Principal Investigator
Dates:	2013 - 2018
Direct Funds:	$12,718,812

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

Local

Current Trends in Allogeneic Bone Marrow Transplant, Grand Rounds Program, St. Michael's Hospital, Milwaukee, WI, 10/1992

Bone Marrow Transplant Treatment Update, American Cancer Society Breast Cancer Forum, Milwaukee, WI, 04/1995

In Pursuit of Promotion: Organizing Yourself Effectively Through the CV and Educator's Portfolio, Women's

Faculty Council Meeting, Medical College of Wisconsin, Milwaukee, WI, 05/1995
Increased Use and Outcomes of Bone Marrow Transplants to Treat Cancer, Midwestern Medical Directors' Association Spring Meeting, Milwaukee, WI, 05/1995
Bone Marrow Transplants for Patients with Hematologic Malignancies, CME presentation at Community Memorial Hospital, Milwaukee, WI, 08/1995
The Use of a Registry to Assess Transplant Outcome, Pediatrics Department Faculty Research Seminar, Medical College of Wisconsin, Milwaukee, WI, 02/1996
An Overview of the IBMTR/ABMTR, Cancer Center Advisory Board Meeting, Milwaukee, WI, 02/1997
Clinical Update on Bone Marrow Transplants, Asthma & Allergy Center at Medical College of Wisconsin, Milwaukee, WI, 03/1997
The IBMTR - An International Research Effort in Marrow Transplants, Medical College of Wisconsin, Milwaukee, WI, 05/1997
The ABC's of Bone Marrow Transplant, Division of Biostatistics Seminar, Medical College of Wisconsin, Milwaukee, WI, 09/1997
The Expanding Role of Bone Marrow Transplantation, Eighteenth Annual Alumni Clinic Day at the Medical College of Wisconsin, Milwaukee, WI, 05/1998
Current Issues in Bone Marrow Transplantation - An Overview, Wisconsin Cancer Council, Brookfield, WI, 10/1999
Basics of BMT. IBMTR/ABMTR, Data Management Meeting, Milwaukee, WI, 09/2002
Graft Versus Host Disease: Overview, Indications and Results, Roche Laboratories Preceptorship, High Dose Therapy and Transplantation, Milwaukee, WI, 10/2003
Update in Transplantation. The Cerletty Retirement, Reunion and Recognition Weekend, Milwaukee, WI, 08/2004
Neoplastic Diseases and Related Disorders, Core Education Session, Medical College of Wisconsin, Milwaukee, WI, 02/2006
Research and Utilization of Large Databases., Fellow Research Lecture, Department of Medicine, Froedtert Memorial Lutheran Hospital, Milwaukee, WI, 03/2006
Schwartz Rounds. Palliative Care Program, Medical College of Wisconsin, Milwaukee WI, 11/2008
Physician as Patient, Palliative Care Core Lectures, Medical College of Wisconsin, Milwaukee, WI, 01/2009
In My Own Shoes: A Doctor's Breast Cancer Journey, Women in Science Luncheon, Milwaukee, WI, 09/2010
Designing Successful Clinical Trials: A Clinician's Perspective, Department of Biostatistics Seminar, Milwaukee, WI, 11/2010
HLA in the Real World. Life Technologies, IWIN Lunch and Learn, Brown Deer, WI, 12/2010
Center for International Blood and Marrow Transplant Research: Sharing knowledge...Sharing hope, Women in Science Luncheon, Milwaukee, WI, 10/2011
Conditioning regimen intensity, MS Biostats Workshop, Milwaukee, WI, 11/2011
CIBMTR-An opportunity for outcomes and health services research, CTSI-Cancer Center Workshop, Medical College of Wisconsin, Milwaukee, WI, 12/2011
My Life as a Physician, Alpha Omega Alpha, Milwaukee, WI, 02/2013
Use of an outcomes registry for clinical research, Clinical and Translational Science Research Seminar, Milwaukee, WI, 09/2013
Third Annual Controversies in Hematologic Malignancies Symposium, Milwaukee, WI, 03/2014
4th Annual Controversies in Heme Malignancies Symposium, Milwaukee, WI, 03/2015
International Conference on Survival Analysis in Memory of John P. Klein, Medical College of Wisconsin, 06/2015
Pediatric Foundation Grant Writing Course, Medical College of Wisconsin, 10/2015
Improving the Outcomes of Blood and Marrow Transplantation through a Patient Outcomes Registry, Fourth Annual Department of Medicine Retreat, Milwaukee, Wisconsin, 03/2018
Donor Sources, Fellow Core Curriculum, 04/2018
Welcome Introduction to CIBMTR, New Data Managers Virtual Onboarding, CIBMTR, Milwaukee, WI, 09/2020

Regional

Bone Marrow Transplants from Unrelated Donors, Media Research Seminar, Madison, WI, 10/1991
Increasing Use of Bone Marrow Transplant in the Treatment of Leukemia, American Cancer Society, Wisconsin Division Annual Meeting Representative Assembly, Pewaukee, WI, 10/1992

Comparison of Allogeneic Bone Marrow Transplantation and Chemotherapy for Treatment of ALL: Results from the IBMTR and POG, Sixth Annual Meeting of American Society of Pediatric Hematology and Oncology, Chicago, IL, 10/1993

Panel discussion of Cord Blood Banking, Regulatory Issues and Potential Interaction and Cooperation with the National Marrow Donor Program and International Bone Marrow Transplant Registry, International Conference Workshop on Cord Blood T, Indianapolis, IN, 11/1993

Bone Marrow Transplant: Curative Results, American Cancer Society National Excalibur Meeting, Milwaukee/Madison, WI, 08/1994

GAO Study: An International Comparison of Bone Marrow Transplantation, National Marrow Donor Program Council Meeting, Minneapolis, MN, 10/1994

Outcome of High-Dose Chemotherapy with Autologous Stem Cell Support for Breast Cancer and Multiple Myeloma as Reported to ABMTR-NA, Blue Cross Blue Shield's Technology Evaluation Centers Forum on High- Dose Chemotherapy with Autologous Stem Cell Support to Treat Breast Cancer or Multiple Myeloma, Chicago, IL, 02/1996

Statistical Challenges in Analyzing Transplant Outcome, Marshfield Clinic Grand Rounds, Marshfield, WI, 05/1996

Trends in Blood and Marrow Transplantation, Marshfield Clinic Grand Rounds, Marshfield, WI, 05/1996

Bone Marrow Transplant, Delevan Lions Club, Delevan, WI, 08/1996

Clinical Experience with Cord Blood and the International Cord Blood Transplantation Registry-Open Table Discussions, International Symposium & Workshop on Cord Blood Transplantation, Indianapolis, IN, 03/1997

Alternative Sources for Allogeneic Stem Cells: Peripheral and Umbilical Cord Blood, Robert H. Lurie Cancer Center of Northwestern University, Grand Rounds, Chicago, IL, 01/1998

Intro to IBMTR, IBMTR/ABMTR Meeting on Autoimmune Diseases, Chicago, IL, 09/1998

Current Trends in Hematopoietic Stem Cell Transplantation, Grand Rounds at Loyola University, Chicago, IL, 04/1999

Current Indications for Transplantation, Northwestern Memorial Hospital, Chicago, IL, 10/2000

Participant in a Collaborative Discussion Panel on Fanconi Anemia Bone Marrow Transplantation, Fanconi Anemia Research Fund, Inc. Conference, Chicago, IL, 04/2001

Overview of Randomized Studies, National Marrow Donor Program's Annual Council Meeting, Minneapolis, MN, 11/2003

Overview of the CIBMTR and The Blood and Marrow Transplant Clinical Trials Network, Transplant Center Grand Rounds, Mayo Clinic, Rochester, MN, 08/2005

Basics of HSCT, Clinical Research Professionals Data Management Fall Conference, Minneapolis, MN, 11/2005

What's New with the CIBMTR?, Clinical Research Professionals Data Management Fall Conference, Minneapolis, MN, 11/2005

Spotlight On the CIBMTR- What Network Members Need to Know, National Marrow Donor Program Council Meeting, Minneapolis, MN, 11/2005

Spotlight on the CIBMTR - What Network Members Need to Know, National Marrow Donor Program Council Meeting, Minneapolis, MN, 11/2007

How Should We Collect Cells for Donation: Issues for Donors, Recipients and their Doctors, National Marrow Donor Program Annual Council Meeting, Minneapolis, MN, 11/2008

Recipients and their Doctors, National Marrow Donor Program Annual Council Meeting, Minneapolis ,MN, 11/2008

CIBMTR Looking Back from 2008 Forward to 2009 and Beyond, Center for International Blood and Marrow Transplant Research Clinical Research Professionals Data Management Conference, Minneapolis, MN, 11/2008

Everything About ANC Recovery/Engraftment, Fall CIBMTR/NMDP Clinical Research Professionals' Data Management (CRP/DM) Conference, Minneapolis, MN, 11/2009

CIBMTR 5th Anniversary - Accomplishments and Future (presented with Dennis Confer), Fall CIBMTR/NMDP Clinical Research Professionals' Data Management (CRP/DM) Conference, Minneapolis, MN, 11/2009

Observational Studies, CIBMTR Clinical Research Professionals/Data Management Conference, Minneapolis, MN, 10/2010

State of the CIBMTR, NMDP Council Meeting, Minneapolis, MN, 10/2010

Optimizing Allogeneic Transplantation-Choosing the Best Stem Cell Source, Emory University School of

Medicine, Atlanta, GA, 01/2012

Hematopoietic Stem Cell Transplantation – A Good Therapy for Older Patients with AML and MDS?, Fourth Annual Advances in Hematology and Oncology Fall Symposium, Green Bay, WI, 10/2015

Allogeneic BMT 2017: Everyone Has a Donor, The Carbone Cancer Center of the University of Wisconsin Hospital and Clinics Grand Rounds, Madison, WI, 03/2016

Allogeneic BMT in 2015: Universal Donor Availability, The Robert H. Lurie Comprehensive Cancer Center Grand Rounds Lecturer, Chicago, IL, 06/2016 - Present

Hematopoietic Cell Transplantation in 2017: Everyone Has a Donor, The 4th Annual Karl G. Blume Memorial Lecture Medical Grand Rounds, Stanford, CA, 04/2017 - Present

Real World Data in Blood and Marrow Transplantation, Milwaukee Academy of Medicine, Milwaukee, WI, 10/2018

Clinical Trials in Transplantation and Cellular Therapy, Children's Hospital of Philadelphia, Philadelphia, PA, 02/2020

National

Clinical Evidence for Graft-versus-Leukemia Effect in Human Bone Marrow Transplantation, UCLA Symposium on Bone Marrow Transplantation, Tamarron, CO, 03/1988

Results of Bone Marrow Transplantation Using Related Donors Other than HLA-Identical Siblings, Workshop on Alternative Donors, International Society for Experimental Hematology, Houston, TX, 08/1988

Graft-versus-Leukemia Effects in CML, Leukaemia Research Fund International Workshop on Chronic Myelogenous Leukemia, Cape Cod, MA, 10/1989

Graft-versus-Leukemia Effects of Bone Marrow Transplantation for AML, UCLA Symposium on AML, Lake Lanier, GA, 11/1989

Comparison of Allogeneic Bone Marrow Transplantation and Intensive Chemotherapy for Adults with ALL in First Remission, UCLA Symposium on Bone Marrow Transplantation, Keystone, CO, 01/1990

Results of Second Transplants and Donor Complications, NMDP Open Forum for Second Transplants, St. Petersburg, FL, 03/1990

Use of a Registry to Evaluate Results of Bone Marrow Transplantation, Pediatric Oncology Group Meetings, Orlando, FL, 04/1990

Moderator, Workshop on Bone Marrow Transplantation from Alternative Donors, Seattle,WA, 08/1990

Does dose intensification increase cures in ALL?, Keystone Symposium on Curing Leukemia, Edgartown, MA, 12/1990

Bone Marrow Transplants for Leukemia, University of Texas, M.D. Anderson Cancer Center, Houston, TX, 05/1991

Idiopathic Interstitial Pneumonia Following Bone Marrow Transplantation, NHLBI Workshop, Bethesda, MD, 09/1991

Unrelated Donor versus Related Donor Bone Marrow Transplantation, National Marrow Donor Program, Annual Council Meeting, Minneapolis, MN, 10/1991

Unrelated Donor Transplants; Graft-versus-Leukemia Effects, First Annual Meeting of IBMTR Participating Teams, Providence, RI, 07/1992

The Status of Bone Marrow Transplantation for Hematologic Diseases, Leukemia Society of America, Washington, DC, 09/1992

Can Autotransplants be Better than Chemotherapy?, First Annual NAAMBTR Symposium, Keystone, CO, 12/1992

Bone Marrow Transplants from Unrelated Donors, Bone Marrow Transplantation in the 90's -- Controversies & Consensus Symposium, Tampa, FL, 02/1993

State of the Art: Bone Marrow Transplantation, 35th Annual Meeting of the American Society of Hematology, St. Louis, MO, 12/1993

Allo/Auto Bone Marrow Transplants for Acute Leukemia, Keystone Symposium, Keystone, CO, 01/1994

Incidence of New Malignancies in Recipients of Allogeneic Marrow Transplants Based on IBMTR Data, Keystone Symposium, Keystone, CO, 01/1994

Advances And Controversies in Bone Marrow Transplantation, Keystone Symposium, Keystone, CO, 01/1994

Allogeneic Transplantation for Acute Leukemia, Providence Symposium - Allogeneic Bone Marrow Transplantation: Current Status, Providence, RI, 04/1994

Health Outcomes: An International Comparison, Subcommittee on Health, Committee on Ways and Means,

US House of Representatives, Washington, DC, 04/1994

Using a Registry to Assess Technology, Institute of Medicine Forum on Drug Development, Washington, DC, 05/1994

Session Chair, Bone Marrow Transplantation Clinical: Prevention of Complications session, American Society of Hematology 36th Annual Meeting, Nashville, TN, 12/1994

Outcomes Assessment in BMT, First Annual Meeting of the American Society of Blood & Marrow Transplantation, Keystone, CO, 01/1995

International Bone Marrow Transplant Registry Data, High Dose Chemotherapy with Stem Cell Support for Breast Cancer, Bethesda, MD, 03/1995

Use of Autologous and Allogeneic Marrow Transplantation: An Overview from the ABMTR/IBMTR, Future Directions in Stem Cell Transplantation Symposium, Northern New Jersey Cancer Center at Hackensack Medical Center, Teaneck, NJ, 05/1995

Use of Autologous and Allogeneic Marrow Transplantation: An Overview from the ABMTR/IBMTR, Medical Grand Rounds at Roswell Park Cancer Institute, Buffalo, NY, 10/1995

The Role of High-Dose Therapy in Cancer Treatment: An Overview, 2nd Annual Northern New Jersey Cancer Center Research Symposium - Experimental & Clinical Approaches in Oncology: Approaching the 21st Century, Teaneck, NJ, 05/1996

Differences in Therapy and Survival for Autologous versus Allogeneic BMT: Implications for Second Cancer Risk, Cancer Following Bone Marrow Transplantation, Rockville, MD, 05/1996

Effect of Prior Interferon Therapy on Outcome of HLA-Identical Sibling Bone Marrow Transplants for Chronic Myelogenous Leukemia (CML) In First Chronic Phase, 25TH Meeting of the International Society for Experimental Hematology, New York, NY, 08/1996

A Review of International Bone Marrow Transplant Registry Outcomes, 105th American Academy of Insurance Medicine, Kansas City, MO, 09/1996

Potential Role of the IBMTR/ABMTR in Evaluating Use of BMT Therapies, 2nd Annual Meeting of the American Society for Blood and Marrow Transplantation (ASBMT), San Diego, CA, 10/1996

Effect of Prior Interferon Therapy on Outcome of HLA-Identical Sibling BMT for CML in First Chronic Phase, 38th Annual Meeting & Exposition of the American Society of Hematology, Orlando, FL, 12/1996

Outcome of Autotransplants for Advanced Ovarian Cancer, 33rd Annual Meeting of the American Society of Clinical Oncology, Denver, CO, 05/1997

Workgroup Facilitator on Clinical Indicators for Transplantation, National Policy Forum on Marrow Donation and Transplantation, Washington, DC, 06/1997

Introduction to BMT, Lisofylline Product Team US Strategy Session, Newark, NJ, 08/1997

Bone Marrow Transplantation for Aplastic Anemia, Aplastic Anemia Foundation of America, Inc. Patient Conference, Philadelphia, PA, 08/1997

Transplantation Biology. Meet The Experts, 39th Annual Meeting of the American Society of Hematology, San Diego, CA, 12/1997

Invited Participant to Discuss the Design of an Optimal System for Conducting Clinical Trials in the United States for the Benefit of All Current and Future Cancer Patients, Washington, DC, 07/1998

Outcomes of Transplantation Using Marrow vs. Blood-Derived Hematopoietic Stem Cells, Eleventh Annual National Marrow Donor Program Council Meeting, Minneapolis, MN, 09/1998

Current Trends in Hematopoietic Stem Cell Transplantation: New Stem Cell Sources, Harvard Medical School, Boston, MA, 01/1999

Current Trends in Blood and Marrow Transplantation, Medicine Grand Rounds at Scott and White Hospital, Temple, TX, 01/1999

Outline of Data Collected and Analyzed by the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry and Data Coordination with the National Marrow Donor Program, The Federal Interagency Work Group on Hematopoietic Stem Cell Transplantation, Bethesda, MD, 04/1999

Using the Resources of IBMTR/ABMTR and NMDP, Federal Interagency Work Group on Hematopoietic Stem Cell Transplantation, Washington, DC, 04/1999

Trends in Blood and Marrow Transplantation, Fred Hutchinson Cancer Research Center, Seattle, WA, 06/1999

What are Clinical Questions that Require a Network?, National Heart Lung & Blood Institute/National Cancer Institute Meeting to Discuss Hematopoietic Network, Bethesda, MD, 08/1999

The American Transplant Registry for Autoimmune Transplants, Worcester Translational Research

Conference - Stem and Immune Cell Therapy for the Treatment of Autoimmune Disease, Worcester, MA, 09/1999

Increasing use of Blood and Marrow Transplantation, Internal Medicine Grand Rounds, University of South Florida,Tampa, FL, 02/2000

Alternative Graft Sources for Allogeneic Transplants, Moffitt Grand Rounds, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL, 02/2000

Treatment of Acute Leukemia and BMT, 2nd Annual West Texas Oncology Symposium, Lubbock, TX, 06/2000

Comparison of related BMT and UCBT, Unrelated Allogeneic Cord Blood Banking and Transplant Forum, Bethesda, MD, 08/2000

Overall Use and Success of Allogeneic Stem Cell Transplantation, William Guy Forbeck Research Foundation XVIth Annual Forum on Allogeneic Stem Cell Transplantation, Hilton Head Island, SC, 11/2000

Chair of the BMT/Cytokines Session, Unrelated Allogeneic Cord Blood Banking and Transplant Forum, San Francisco, CA, 05/2001

Is Autologous Bone Marrow Transplantation Indicated for High-Risk Aggressive NHL?, 2001 Pan Pacific Lymphoma Conference, Maui, HI, 06/2001

Current Status and New Developments in Allogeneic Transplantation for Chronic Myelogenous Leukemia (CML), 1st International Congress of the Myeloproliferative Diseases and Myelodysplastic Syndrome, New York, NY, 10/2001

Regulatory Aspects of Stem Cell Transplants for Autoimmune Diseases, Hematopoietic Stem Cell Therapy in Autoimmune Diseases, Duarte, CA, 10/2001

Hematopoietic Stem Cell Transplants for Hematologic Malignancies, 4th Annual Richard D. Frisbee III Symposium - Current Trends in Stem Cell Transplantation, New Haven, CT, 11/2001

BMT Basics and the Registries., BMT Tandem Meetings, Keystone, CO, 01/2003

New Directions in Stem Cell Transplantation: A Perspective from the IBMTR/ABMTR, Tandem BMT Meetings, Keystone, CO, 02/2003

Benchmarking: A Perspective from the IBMTR/ABMTR, Tandem BMT Meetings, Keystone, CO, 02/2003

IBMTR and NMDP Registry: How It Runs, Safeguarding Adult and Pediatric Stem Cell Donors: Basic Science, Clinical & Ethical Issues, Washington, DC, 09/2004

CIBMTR - Purpose of the Newly Established Center & Role in Cellular Therapy Research, Second Chances: Symposium on Blood and Marrow Transplantation, Washington, DC, 11/2004

Comparisons of Outcomes: Unrelated Marrow vs. Unrelated Cord Blood Donor Transplants: CIBMTR Data, Cord Blood in Transplantation, Science to Practical Applications. 46th Annual Meeting of the American Society of Hematology, Corporate Friday Symposium, 12/2004

Advances in Allogeneic Transplantation: A Focus on Research to Improve Patient Outcomes, AABB Annual Meeting & TXPO, Seattle, WA, 10/2005

Donor and Patient Safety, 47th Annual Meeting and Exposition of the American Society of Hematology, Atlanta, GA, 12/2005

Stem Cell Donor Evaluation and Safety, Transfusion Medicine: Joint ASH and AABB Education Session, 2005

The Experiences of the CIBMTR" at Symposium 1 entitled "Registration System of Transplantation, 11th Congress of the Asia Pacific Bone Marrow Transplantation, Nagoya, Japan, 10/2006

Evolution of Clinical Research in HCT. Mortimer M. Bortin Lecture, 2007 BMT Tandem Meetings, Keystone, CO, 02/2007

Forms Harmonization Update/Bill Young Stem Cell Transplant Outcomes Database Program, Clinical Research Professionals Data Management Conference at the 2007 Tandem BMT Meetings, Keystone, CO, 02/2007

The Relationship Between the Stem Cell Transplant Outcomes Database and Other CIBMTR Programs, 2007 Tandem BMT Meetings, Keystone, CO, 02/2007

Chair, Designing Clinical Trials in HCT: Case Studies, 2007 BMT Tandem Meetings, Keystone, CO, 02/2007

Trial Design, Late Effects & Quality of Life, Regimen-Related Toxicity. The Future of Clinical Research in HCT: Reports from the 2007 State of the Science Symposium, 49th Annual Meeting of the American Society of Hematology, Atlanta, GA, 12/2007

Factors that Influence Unrelated-Donor HCT Outcomes. Friday Satellite Symposia, 50th Annual American Society of Hematology Meeting, San Francisco, CA, 12/2008

Chronic Myeloid Leukemia - Clinical Trials II, 50th Annual American Society of Hematology Meeting, San

Francisco, CA, 12/2008

Looking to the Future: Translating Research to Data - the CIBMTR Experience, AABB Board of Directors Strategic Planning Session, Bethesda, MD, 01/2009

BMT CTN and CIBMTR: National Networks for Multicenter HCT Research, National Cancer Advisory Board, Bethesda, MD, 02/2009

What's the Relationship - CIBMTR, NMDP, BMT CTN, SCTOD, 2009 Tandem BMT Meetings, Tampa, FL, 02/2009

BMT CTN Overview-Accomplishments (with Shelly Carter), 2009 Tandem BMT Meetings, Tampa, FL, 02/2009

Patients Who Start Preparative Regimen, but Are Not Infused, 2009 BMT Tandem Meetings, Tampa, FL, 02/2009

HLA-Matching for BMT - How Far Must We Go?, Medical Grand Rounds, Memorial Sloan-Kettering Cancer Center, New York, NY, 04/2009

Designing Clinical Trials. Meet-The-Experts, 51st Annual Meeting and Exposition of the American Society of Hematology, New Orleans, LA, 12/2009

Obstacles to Successful Hematopoietic Stem Cell Transplantation, Yale Cancer Center Grand Rounds for the Joseph R. and Nancy Bove Visiting Professorship, New Haven, NY, 01/2010

BMT CTN Update, 2010 Tandem BMT Meetings, Orlando, FL, 02/2010

The Future of BMT CTN, 2010 Tandem BMT Meetings, Orlando, FL, 02/2010

Moderator, Bone Marrow Transplantation Session., Acute Leukemia forum 2010: Advances and Controversies in the Biology and Therapy of Acute leukemia and Myelodysplasia, San Francisco, CA, 04/2010

CME Director, Management of Advanced Non-Hodgkin Lymphomas, 52nd Annual Meeting of the American Society of Hematology, Orlando, FL, 12/2010

Transplantation with Alternative Donors, Aplastic Anemia Session at the 52nd Annual Meeting of the American Society of Hematology, Orlando, FL, 12/2010

Neutrophil Recovery: The First Step in Post-Transplant Recovery, 2011 Tandem BMT Meetings, Honolulu, HI, 02/2011

BMT CTN Update, 2011 Tandem BMT Meetings, Honolulu, HI, 02/2011

The Warning Signs of a Problematic Mentoring Relationship and How to Fix It, 53rd Annual Meeting of the American Society of Hematology, San Diego, CA, 12/2011

BMT CTN Update, 2012 Tandem BMT Meetings, San Diego, CA, 02/2012

Does Matched Unrelated Donor Transplantation Have the Same Outcome as Match Sibling Transplantation in Unselected Patients?, Acute Leukemia Form 2012, San Francisco, CA, 04/2012

Optimizing Transplant Outcomes: Graft Selection, NHLBI NIH Hematology Clinical Conference, Bethesda, MD, 10/2012

Advances in Reduced Intensity Hematopoietic Stem Cell Transplants in MDS, MDS Foundation Satellite Symposium at 2013 ASH Meeting, Atlanta, GA, 12/2012

BMT CTN Update, 2013 Tandem BMT Meetings, Salt Lake City, UT, 02/2013

Welcome Address, 2013 Tandem BMT Meetings, Salt Lake City, UT, 02/2013

What Young (and not so Young) Investigators Should Know, 2013 Tandem BMT Meetings, Salt Lake City, UT, 02/2013

Barriers to Successful Hematopoietic Stem Cell Transplantation, 2nd Annual Controversies of Hematologic Malignancies Symposium, Milwaukee, WI, 03/2013

Delete Blood Cancer Presentation, DKMS Delete Blood Cancer Gala 2013, New York, NY, 05/2013

Advancing Hematopoietic Stem Cell Transplantation through Observational Research and Prospective Trials: CIBMTR and BMT CTN, NHLBI Biomedical Lecture Series, Bethesda, MD, 11/2013

Why We Do What We Do, Clinical Research Professionals/Data Management Conference at 2014 BMT Tandem Meetings, Grapevine, TX, 02/2014

Welcome Address, BMT CTN Coordinators Meeting at 2014 Tandem BMT Meetings, Grapevine, TX, 02/2014

16th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy, Philadelphia, PA, 09/2014

Welcome Address, BMT CTN Coordinators Meeting at 2015 Tandem BMT Meetings, San Francisco, CA, 02/2015

Meet the Professor, 2015 Tandem BMT Meeting, San Francisco, CA, 02/2015

Issues in Data Integration and Sharing for Novel Therapies, Expanding Opportunities for Collaboration and

Information Exchange Session, Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Workshop, Washington, DC, 02/2016

Welcome Address, 2016 BMT Tandem Meetings, Honolulu, HI, 02/2016

Moderator, Bone Marrow Transplantation Session, Acute Leukemia Forum 2016: Advances and Controversies in the Biology and Therapy of Acute Leukemia and Myelodysplasia, Newport Beach, CA, 03/2016

Transplant for Myelodysplastic Syndromes: Who, When, and Which Conditioning Regimen Presentation, Annual Meeting of the American Society of Hematology, San Diego, CA, 12/2016

Welcome Address, 2017 BMT Tandem Meetings, Orlando, FL, 02/2017

Outcomes Analyses in Engineered T Cell Therapies, American Society for Blood and Marrow Transplantation: Value Assessment in Engineered T Cell Therapies, Boston, MA, 05/2017

Choice of donor for allogeneic HCT, The Mexican Meeting of HSC Transplant, Guadalajara, Mexico, 11/2017

The Role of CIBMTR in HCT Research, The Mexican Meeting of HSC Transplant, Guadalajara, Mexico, 11/2017

A Year in Review-Or, What Your Data Makes Possible, 2018 BMT Tandem Meetings, Salt Lake City, UT, 02/2018

Welcome Address, 2018 BMT Tandem Meetings, Salt Lake City, UT, 02/2018

25 Years of Progress in the Science and Clinical Art of Hemapoietic Stem Cell Transplantation and Cellular Therapy, The ASBMT Presidential Symposium, 2018 BMT Tandem Meetings, Salt Lake City, UT, 02/2018

Symposium at Fred Hutchinson Cancer Research Center to Honor John Hanson, Seattle, Washington, 07/2018

Considerations in Planning Effective Clinical Trials, 61st Annual Meeting of the American Society of Hematology, Orlando, FL, 12/2019

Use of Registries to Guide Therapeutic Decisions, Presidential Symposium, 61st Annual Meeting of the American Society of Hematology, Orlando, FL, 12/2019

Looking Back and Looking Forward: Blueprint for Collaborative International Studies in BMT and CT, Transplant and Cellular Therapy Meetings, Orlando, FL, 02/2020

Changing Landscape of Treatment in Acute Myeloid Leukemia (Educational Session Chair and Speaker), American Society of Clinical Oncology Annual Meeting, Virtual, 08/2020

Your partners for life: CIBMTR and BMT-CTN, Virtual 2020 ASTCT Leadership Course, Chicago, IL, 11/05/2020

International

Moderator, Workshop on problems in diagnosis and grading of chronic GVHD. International Society for Experimental Hematology, Tokyo, Japan, 08/1987

Impact of radiation dose upon outcome of bone marrow transplantation. Perspectives of Bone Marrow Transplantation in Neoplastic Diseases, Augsburg, West Germany, 09/1988

Outcome of allogeneic marrow transplants from related donors other than HLA-identical siblings. European Bone Marrow Transplant Meeting, Badgastein, Austria, 02/1989

Bone marrow transplantation for leukemia: Mechanisms of cure. Hammersmith Hospital, London, 07/1989

Bone marrow transplantation for leukemia: A review. University of Muenster, Muenster, West Germany, 08/1989

Bone marrow transplantation versus conventional therapy for acute lymphoblastic leukemia. Ontario Cancer Institute, Toronto, Canada, 06/1991

Unrelated donor bone marrow transplants. Jose Carreras International Leukaemia Foundation, Santander, Spain, 07/1991

Role of the North American Autologous Bone Marrow Transplant Registry. International Conference on Autologous Progenitor Cell Transplantation, Buenos Aires, Argentina, 10/1994

Postremission Therapy: The Role of Bone Marrow Transplantation (IBMTR Results). Acute Leukemias VI: Prognostic Factors and Treatment Strategies, Muenster, Germany, 03/1995

IBMTR Results. Joint International Workshop on Foetal and Neonatal Hematopoiesis, Paris, France, 04/1995

Allogeneic, Unrelated and Autologous BMT in Adult ALL. 9th Symposium on Molecular Biology of Hematopoiesis, Genoa, Italy, 06/1995

Hydroxyurea and Interferon Alpha vs Allogeneic BMT in CML. Workshop on CML and Interferon, Weinheim, Germany, 06/1995

IBMTR Update. 4th Annual IBMTR Participants' Meeting, Düsseldorf, Germany, 08/1995
Challenges in using observational data to compare transplant and non-transplant treatment. 22nd Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, 03/1996
The role of registries in assessing efficacy of blood and marrow transplantation. 22nd Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, 03/1996
Solid tumors developing after allogeneic bone marrow transplantation. 22nd Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, 03/1996
Use of blood and marrow transplantation in cancer treatment: an overview from the IBMTR/ABMTR. Advances in Haematology, London, UK, 06/1996
Results of related and unrelated donor transplants for leukemia. Consensus Conference on Unrelated Donor Bone Marrow Transplantation, Edinburgh, UK, 10/1996
History and Overview of the IBMTR/ABMTR. I Encuentro Sobre Transplante De Medula "sea Y Hemopatias Malignas - Curitiba 97, Curitiba, Brazil, 03/1997
ALL: chemotherapy x auto x allo BMT. Which is the best treatment? I Encuentro Sobre Transplante De Medula "sea Y Hemopatias Malignas - Curitiba 97, Curitiba, Brazil, 03/1997
BMT in SAA - IBMTR data. I Encuentro Sobre Transplante De Medula "sea Y Hemopatias Malignas - Curitiba 97, Curitiba, Brazil, 03/1997
Advantages of participation in the IBMTR/ABMTR. I Encuentro Sobre Transplante De Medula "sea Y Hemopatias Malignas - Curitiba 97, Curitiba, Brazil, 03/1997
IBMTR data. I Encuentro Sobre Transplante De Medula "sea Y Hemopatias Malignas - Curitiba 97, Curitiba, Brazil, 03/1997
Breast cancer - ABMTR data. I Encuentro Sobre Transplante De Medula "sea Y Hemopatias Malignas - Curitiba 97, Curitiba, Brazil, 03/1997
Use of registry data in statistical analysis of bone marrow transplantation results. Kanto Bone Marrow Transplantation Seminar, Tokyo, Japan, 03/1998
Autologous transplantation. Osaka Hematopoietic Stem Cell Transplantation Seminar, Osaka, Japan, 03/1998
Increasing use of hematopoietic stem cell transplantation: lessons from the International Bone Marrow Transplant Registry. 60th Meeting of the Japanese Society of Hematology, Osaka, Japan, 03/1998
Status of blood and marrow transplantation. Transplantation in Hematology and Oncology at the University of Münster, Münster, Germany, 05/1998
Alternative stem cell sources for allogeneic transplantation. XIX Symposium of the International Association for Comparative Research on Leukemia and Related Disorders, Mannheim, Germany, 05/1998
Use and results of allogeneic and autologous transplants. Concerns: VII. International Workshop CML and IFN, Wachenburg/Mannheim, Germany, 06/1998
Myeloablative therapy: outcomes and trends. Expert Planning Session for development of IB-367 for INTRABIOTICS Pharmaceuticals, Inc, Milan, Italy, 07/1998
Changing patterns and future trends in allo- and autografts. Fludara Workshop on bone Marrow and Peripheral Stem Cell Transplantation, Berlin, Germany, 09/1998
Data Collection. International Meeting, Haemopoietic Stem Cell Therapy in Autoimmune Diseases, Basel, Switzerland, 10/1998
Collaborative studies in blood and marrow transplantation. 25th Annual Meeting of the European Group for Blood and Marrow Transplantation and 15th Meeting of the Nurses Group, Hamburg, Germany, 03/1999
Future of NST: Where do we go from here? International Workshop on Non-myeloablative Stem Cell Transplantation, St. Lucia, West Indies, 01/2000
Comparison of HLA-identical cord blood and bone marrow transplants in children. European School of Haematology, International Conference on Haemopoietic Stem cell Biology and Transplantation, Paris, France, 04/2000
Related donor transplants for chronic myelogenous leukemia (CML) and Chair for Session 3 "Allogeneic transplantation (family donor)". 3rd International Conference "The Jubilee Meeting on Chronic Myeloid Leukemia", Bologna, Italy, 06/2000
Problems for long term transplant survivors and Chair of the EBMTR/IBMTR session. European Haematology Association - EHA 5th Congress Meeting, Birmingham, UK, 06/2000
Obstacles to successful transplant outcome: perspectives from a large observational database. 28th World Congress of ISH 2000, Toronto, Canada, 08/2000
Definition of Relapse. ESH Conference on CML, Rapallo, Italy, 09/2000
Results of sibling donor transplants. ESH Conference on CML, Rapallo, Italy, 09/2000

The IBMTR/ABMTR: Overview and Future Directions. The CBMTG Transplant Registry and Clinical Trials Network Forum, Toronto, Canada, 10/2000

Transplants for Acute Leukemia. VIII Uruguayan Congress on Hematology, Montevideo, Uruguay, 10/2000

Transplants for CML. VIII Uruguayan Congress on Hematology, Montevideo, Uruguay, 10/2000

US Data collection. Haemopoietic Stem Cell Therapy in Autoimmune Diseases, Basel, Switzerland, 10/2000

Hematopoietic Stem Cell Transplantation for Lymphoma & Multiple Myeloma. VIII Uruguayan Congress on Hematology, Montevideo, Uruguay, 10/2000

Panel member for Joint Session discussion of questionnaire to estimate QOL. 27th Annual Meeting of the European Group for Blood and Marrow Transplantation, Maastricht, The Netherlands, 03/2001

Co-Chair of Plenary Session entitled "Reduced conditioning regimens: the future of allogeneic stem cell transplantation. 27th Annual Meeting of the European Group for Blood and Marrow Transplantation, Maastricht, The Netherlands, 03/2001

Co-Chair of the "Ongoing randomized and cooperative studies" session. 10th International Workshop on CML, Heidelberg, Germany, 05/2001

What is the future of allografting treatment concepts? 10th International Workshop on CML, Heidelberg, Germany, 05/2001

Chair of Joint Session: EBMT/IBMTR International Session: How to deal with new technology; peripheral blood stem cells in allotransplantation. 28th Annual Meeting of the European Group for Blood and Marrow Transplantation and 18th Meeting of the Nurses Group, Montreux, Switzerland, 03/2002

Comparison of unrelated cord blood and bone marrow transplants for children with leukemia. A collaborative study of the New York Blood Center and the International Bone Marrow Transplant Registry. International Workshop on Scientific and Management Aspects of Cord Blood Banking and Transplantation, Barcelona, Spain, 11/2002

Unrelated bone marrow donors. ESH-EUROCORD Meeting, Paris, France, 02/2003

Co-Chair, Joint Session EBMT-IBMTR. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation, Istanbul, Turkey, 07/2003

Current experience in the multiple myeloma auto/allo project. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation, Istanbul, Turkey, 07/2003

Summary and perspective. 29th Annual Meeting of the European Group for Blood and Marrow Transplantation, Istanbul, Turkey, 07/2003

Transplants as a Model of Immune Therapy. European Society of Hematology International Conference on CML in Rapallo, Italy, 09/2003

Results from IBMTR in adults. Fourth International Workshop on Haploidentical Transplants in Naples, Italy, 07/2004

A Decision Analysis of Allogeneic Bone Marrow Transplantation in Myelodysplastic Syndromes. 8th Congress of the Brazilian Society of Bone Marrow Transplantation, Curitiba, Brazil, 08/2004

How to Improve the Results of Stem Cell Transplantation in Adult AML. 8th Congress of the Brazilian Society of Bone Marrow Transplantation, Curitiba, Brazil, 08/2004

What is the Importance of the Latin American Registry for the Development of Stem Cell Transplantation Science? 8th Congress of the Brazilian Society of Bone Marrow Transplantation, Curitiba, Brazil, 08/2004

Co-Chair, Joint Session 3: EBMT/WMDA/ISCT: Regulatory Issues. 31st Annual Meeting of the European Group for Blood and Marrow Transplantation, Prague, Czech Republic, 03/2005

A Matched Pair Analysis Comparing IV Versus Oral Busulfan. Satellite Symposium, Pierre Fabre Oncologie in collaboration with Fresenius BioTech GmbH. 31st Annual Meeting of the European Group for Blood and Marrow Transplantation, Prague, Czech Republic, 03/2005

Co-Chair, Joint Session 2: EBMT/CIBMTR: Stem Cell Transplantation for Non-Malignant Disorders. 31st Annual Meeting of the European Group for Blood and Marrow Transplantation, Prague, Czech Republic, 03/2005

US Institute of Medicine Report on Establishing a National Cord Blood Stem Cell Bank Program. Establishing a National Cord Blood Bank System for Canada. Canadian Hematology Society Annual Scientific Meeting, Toronto, Ontario, Canada, 06/2005

Transplants of cord blood or marrow from unrelated donors in adults with leukemia. Establishing a National Cord Blood Bank System for Canada. Canadian Hematology Society Annual Scientific Meeting, Toronto, Ontario, Canada, 06/2005

Summary of CIBMTR/EBMT Studies of HLA-identical Sibling BM vs. PB Transplantation. 32nd Annual Meeting of the European Group for Blood and Marrow Transplantation, Hamburg, Germany, 03/2006

Long-term Sequelae of Unrelated HSCT (Marrow and PBSC): Is Chronic GvHD Increased? CIBMTR/NMDP Experience. Joint Session EBMT/WMDA: Challenges in Unrelated Donor Transplants, 32nd Annual Meeting of the European Group for Blood and Marrow Transplantation, Hamburg, Germany, 03/2006

New Treatment Options for GVHD. World Marrow Donor Association, 6th International Donor Registry Conference and Working Group Meetings, Cape Town, South Africa, 05/2006

Co-Chair, Regulation/SEAR/Donor Follow-up Session. World Marrow Donor Association, 6th International Donor Registry Conference and Working Group Meetings, Cape Town, South Africa, 05/2006

Co-Chair Session I: Chronic Cutaneous GVHD: Scoring and Treatment Response with and Without ECP. Assessing the Potential Role of Photopheresis in Hematopoietic Stem Cell Transplant, Evian, France, 09/2006

The Experiences of the CIBMTR" at Symposium 1 entitled "Registration System of Transplantation." 11th Congress of the Asia Pacific Bone Marrow Transplantation, Nagoya, Japan, 10/2006

Alfredo Pavlovsky Award Lecture - Unrelated Bone Marrow Transplantation. XXXI World Congress of the International Society of Hematology, Punta del Este, Uruguay, 03/2007

Co-Chair, Joint Session EBMT/WMDA: Long-term Follow-up after Haematopoietic Stem Cell Donation. 33rd Annual Meeting of the European Group for Blood and Marrow Transplantation, Lyon, France, 03/2007

The Likelihood of HCT in the United States. 33rd Annual Meeting of the European Group for Blood and Marrow Transplantation, Lyon, France, 03/2007

Co-Chair, Joint Session EBMT/CIBMTR. 33rd Annual Meeting of the European Group for Blood and Marrow Transplantation, Lyon, France, 03/2007

Autologous Bone Marrow Transplantation in Follicular Lymphoma. XXXI World Congress of the International Society of Hematology, Punta del Este, Uruguay, 03/2007

Chair, Autologous Bone Marrow Transplantation Session. XXXI World Congress of the International Society of Hematology, Punta del Este, Uruguay, 03/2007

CIBMTR Algorithm for Donor Selections. First Cord Blood Transplant European Conference, Rome, Italy, 05/2007

Structure of Data Collection. ESH, EUROCORD, NETCORD, EBMT, UT MD Anderson Cancer Center Conference on Biology and Clinical Applications of Cord Blood Cells, Paris, France, 10/2007

Comparisons of Cord Blood and Bone Marrow Transplantation. ESH, EUROCORD, NETCORD, EBMT, UT MD Anderson Cancer Center Conference on Biology and Clinical Applications of Cord Blood Cells, Paris, France, 10/2007

CIBMTR. International Congress on Bone Marrow and Stem Cell Transplantation, Riyadh, Kingdom of Saudi Arabia, 11/2007

CIBMTR. Donor Center and Transplant Center Seminar, National Marrow Donor Program Council Meeting, Minneapolis, MN, 11/2007

New Era of Registry System in HSCT. 30th Annual Meeting of the Japan Society of Hematopoietic Cell Transplantation (JSHCT), Osaka, Japan, 02/2008

Round Table Discussion Participant. 30th Annual Meeting of the Japan Society of Hematopoietic Cell Transplantation (JSHCT), Osaka, Japan, 02/2008

Co-Chair Joint Session Worldwide Network for Blood and Marrow Transplantation (WBMT). 34th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), Florence, Italy, 03/2008

Shirley Nolan Memorial Lecture. 7th International Donor Registries Conference and Working Group Meetings, Bern, Switzerland, 04/2008

Chair, Joint Session WBMT (EBMT, CIBMTR, APBMT, WMDA). 35th Annual Meeting of the European Group for Blood and Marrow Transplantation, Göteborg, Sweden, 04/2009

Center-specific Outcomes Analyses in Hematopoietic Stem Cell Transplantation: The United States Approach. 8th Nagoya International Blood and Marrow Transplantation Symposium, Nagoya, Japan, 04/2009

Factors that Influence Outcome after Unrelated HSCT. XIII Brazilian Society of Bone Marrow Transplantation Meeting, Curitiba, Brazil, 08/2009

Impact on Age on HCT Outcome. Workshop 8: Allografting Older Patients. 37th Annual Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, 03/2010

Designing and Implementing Effective Multicenter Trials in BMT - A Clinician's Perspective. Co-Chair, Statistical Symposium on Methodological Issues in Experimental as Well as Observational Studies, Fundamental to the Quality of Scientific Research within the EBMT Organization. 37th Annual

Meeting of the European Group for Blood and Marrow Transplantation, Vienna, Austria, 03/2010
CIBMTR Registry. World Cord Blood Congress, Marseille, France, 11/2010
Source of stem cells, Leukemia and Lymphoma - East and West are Together, Coratia, 09/2011
Reduced intensity conditioning transplants for AML/MDS, Haematology of Australia and New Zealand Asia Pacific BMT Group, Australia, 10/2011
Donor choice for Allo-transplants for haematological malignancies., Haematology of Australia and New Zealand Asia Pacific BMT Group, Australia, 10/2011
The future of observational research in stem cell transplantation, 38th Annual EBMT 2012, Geneva, Switzerland, 04/2012
The role of outcomes registries in advancing hematopoietic stem cell transplantation (HCT): Examples from the Center for International Blood and Marrow Transplant Research (CIBMTR), International Donor Registries Conference 2012, Sydney, Australia, 05/2012
The history of CIBMTR and the role of outcomes registries in HCT Research, Blood and Marrow Transplant Workshop, Hangzhou, China, 11/2012
The history of CIBMTR and the role of outcomes registries in HCT research, Chinese Hematology Conference, Fujian, China, 11/2012
Improving Access and Outcomes: The Role of Collaborative Clinical Research, Swiss Blood Stem Cells 25th Anniversary Celebration, Bern, Switzerland, 11/2013
EBMT 40th Anniversary Meeting, Milan, Italy, 03/30/2014 - 04/02/2014
International Society for Cellular Therapy (ISCT) 2014 Meeting, Le Palais des Congres de Paris, Paris France, 04/23/2014 - 04/27/2014
John's Royal College Day, London, UK, 05/2014
3rd WBMT Workshop in partnership with the WHO, Cape Town, South Africa, 11/2014
41st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Istanbul, Turkey, 03/2015
Horowitz MM, SBTMO/LABMT/CIBMTR - Latin America Collaboration with the CIBMTR, XIX Congress of the Brazilian Bone Marrow Transplantation Society (SBTMO), Foz do Iguaçu – Parana - Brazil, 08/2015
Horowitz MM, Current State of Transplantation and Future Perspectives, XIX Congress of the Brazilian Bone Marrow Transplantation Society (SBTMO), Foz do Iguaçu – Parana ? Brazil, 08/2015
Logan B, Pasquini MC, Eapen M, Horowitz MM, Rocha V, What Do We Need to Know about Stem Cell Transplantation, XIX Congress of the Brazilian Bone Marrow Transplantation Society (SBTMO), Foz do Iguaçu – Parana – Brazil, 08/2015
Horowitz MM, Getting All AML Patients to Transplant, 47th Advances in Haematology Course 2015, London, UK, 10/2015
Horowitz MM, The US Clinical Trials Network, 2015 Anthony Nolan Clinical Meeting, London, UK, 10/2015
Allogeneic Hematopoietic Stem Cell Transplantation 2016: Everyone had a donor, Korean Society of Blood and Marrow Transplantation (KSBMT) 20th Summer Scientific Meeting, Pusan, Korea, 08/2016 - Present
Data from the Registry: Epidemiology and Biology of Relapse Session, 3rd International Workshop on Biology, Prevention and Treatment of Relapse after Stem Cell Transplantation, Hamburg, Germany, 11/2016 - Present
The Importance of Outcome Databases, The 4th Worldwide Network for Blood and Marrow (WBMT) Workshop and Symposium, Riyadh, Saudi Arabia, 01/2017 - Present
The Importance of Outcome Databases, The 4th Worldwide Network for Blood and Marrow (WBMT) Workshop and Symposium, Riyadh, Saudi Arabia, 01/2017
Hematopoietic Stem Cell Transplantation: Where Have We Been and Where Are We Going?, Canadian Blood and Marrow Transplant Annual Meeting, Ottowa, Ontario Canada, 06/2018
Behind the Scenes, Ahead of the Curve: Collaboration for the Future, Virtual 2020 SBTMO Annual Meeting, Rio de Janeiro, Brazil, 10/27/2020

COMMITTEE SERVICE:

Medical College of Wisconsin

1987 - 1988 Member, Liaison Committee on Medical Education
1988 - 1992 Member, Health Information Technology Center Steering Committee

1989 - 1990 Member, Search Committee for Clinical BMT Director
1991 - 1995 Ad Hoc Committee for Rank and Tenure Guidelines
1992 - 2006 Health Policy Institute Faculty Council
1994 - 2000 Cancer Center Steering Committee
1994 - 1995 Chair, Bone Marrow Transplantation Search Committee
1995 - 1996 Liaison, Blood Research Institute Committee
1999 - 2001 Cancer Center Research Advisory Group
2000 - 2010 Cancer Center Search Committee
2000 - 2002 Faculty Mentor Program
2000 - 2001 Strategic Issues Group - Role of Information Technology
2008 - 2009 Chair, Search Committee, Population Health
2009 - 2013 Biospecimen Resource Steering Committee
2010 - 2013 Clinical Trials Office Planning Committee
2010 Research Task Force for Leveraging NIH's Research Agenda
2011 - 2013 Chair, VanDeuren Chair Search Committee
2011 - 2014 Member, Cancer Center Internal Scientific Advisory Board
2012 - 2015 MCP Compensation Committee
2012 - Present Member, Cancer Center Executive Committee, Department of Medicine, Froedtert & MCW
2013 Member, Biostatistics Director Search Committee, Institute for Health and Society, Biostatistics
2013 Member, Research Focus Cancer Workgroup
2016 - Present Member, Executive Committee of the Faculty, Radiation Thereap Search Committee
2016 Member, Cancer Center Executive Committee, Department of Medicine, Froedtert & MCW
2017 - Present Member, Society for Research Excellence
2018 Data Science Task Force
2019 - 2020 Chair, Data Science Working Group
2020 - Present Cancer Center Research Council

Hospital

1984 - 1985 Member, Resident Evaluation Committee, Froedtert Hospital
1984 - 1986 Member, Annual Report Committee, Department of Medicine, Froedtert Hospital
1985 - 1987 Chair, Curriculum Task Force, Froedtert Hospital
1985 - 1987 Director, Employee Health Services for Milwaukee County, Froedtert Hospital
1986 - 1987 Member, Faculty Advisory Committee for Ambulatory Care
1986 - 1987 Member, Human Research Review Committee/Milwaukee County Medical Complex
1986 - 1987 Member, Medical Assistance Utilization Review Committee
1986 - 1987 Director, General Medical Clinics, Milwaukee County Medical Complex
1986 Member, Dean's Advisory Committee for Student Health
1986 - 1987 Member, Ambulatory Services Committee, Froedtert Hospital
1991 - 1992 Cancer Center Computer Committee
2009 - Present Research Leadership Council
2010 - Present Cancer Center Leadership Group
2010 - 2017 Member, Cancer Service Line Steering Committee, Froedtert & MCW
2013 - Present MCP Compensation Work Group
2013 - Present Faculty Research Committee

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:

Postdoctoral Students

Philip Rowling, MD, Medical College of Wisconsin, 1992 - 1998 Mentor
Fausto R Loberiza, Jr, MD, MS, Medical College of Wisconsin, 1998 - 2003 Mentor
J. Douglas Rizzo, MD, MS, Medical College of Wisconsin, 1999 - 2004 Mentor
Christopher N. Bredeson, MD, MSc, Medical College of Wisconsin, 2000 - 2005 Mentor
Mary Eapen, MBBS, MS, Medical College of Wisconsin, 2000 - 2004 Mentor
Parameswaran Hari, MD, MS, Medical College of Wisconsin, 2004 - 2008 Mentor
Marcelo C. Pasquini, MD, MS, Medical College of Wisconsin, 2005 - 2008 Mentor
Marcie Tomblyn, MD, MS, Medical College of Wisconsin, 2005 - 2009 Mentor
Thomas Joshua, MS, Medical College of Wisconsin, 2005 - 2008 Mentor

Vanderson Rocha, MD, PhD, Medical College of Wisconsin, 2007 - 2008 Mentor
Wael Saber, MD, BcH, MPH, Medical College of Wisconsin, 2009 - Present Mentor
Lauren Wiebe, MD, Medical College of Wisconsin, 2010 - 2012 Mentor
Li-Shu Wang, MS, PhD, Medical College of Wisconsin, 2011 - 2012 Mentor
Yachiyo Kuwatsuka, MD, PhD, Medical College of Wisconsin, 2011 - 2012 Mentor
Jeanne Palmer, MD, Medical College of Wisconsin, 2012 - Present Mentor

Clinical/Research Fellows

Jakob Passweg, MD, MS, Medical College of Wisconsin, 1994 - 1996 Mentor

Faculty

Bronwen Shaw, MD, PhD, Medical College of Wisconsin, 2004 - Present
Lisa Baumann-Kreuziger, MD, Medical College of Wisconsin, 2013 - 2018

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Herzig RH, Bortin MM, Barrett AJ, Blume KG, Gluckman E, **Horowitz MM**, Jacobsen SJ, Marmont A, Masaoka T, Prentice HG. Bone-marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission. Lancet. 1987 Apr 04;1(8536):786-9.
2. **Horowitz MM**, Byrd JC, Gruchow HW. Attitudes of faculty members, residents, students, and community physicians toward health promotion. J Med Educ. 1987 Nov;62(11):931-4.
3. Bortin MM, **Horowitz MM**, Gale RP. Current status of bone marrow transplantation in humans: report from the International Bone Marrow Transplant Registry. Nat Immun Cell Growth Regul. 1988;7(5-6):334-50.
4. Atkinson K, **Horowitz MM**, Biggs JC, Gale RP, Rimm AA, Bortin MM. The clinical diagnosis of acute graft-versus-host disease: a diversity of views amongst marrow transplant centers. Bone Marrow Transplant. 1988 Jan;3(1):5-10.
5. **Horowitz MM**, Ershler WB, McKinney WP, Battiola RJ. Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann Intern Med. 1988 Feb;108(2):185-9.
6. Goldman JM, Gale RP, **Horowitz MM**, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988 Jun;108(6):806-14.
7. Bortin MM, Atkinson K, van Bekkum DW, Biggs JC, Dicke KA, Gale RP, Gluckman E, Good RA, Hoffmann RG, **Horowitz MM**. Factors influencing the risk of acute and chronic graft-versus-host disease in humans: a preliminary report from the IBMTR. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:222-4.
8. Barrett AJ, **Horowitz MM**, McCarthy DM, Kanfer E, Bortin MM. Bone marrow transplantation for acute lymphoblastic leukaemia in first and second remission. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:247-9.
9. McKinney WP, **Horowitz MM**, Battiola RJ. Susceptibility of hospital-based health care personnel to varicella-zoster virus infections. Am J Infect Control. 1989 Feb;17(1):26-30.
10. Ringdén O, **Horowitz MM**. Graft-versus-leukemia reactions in humans. The Advisory Committee of the International Bone Marrow Transplant Registry. Transplant Proc. 1989 Feb;21(1 Pt 3):2989-92.
11. Champlin RE, **Horowitz MM**, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP, Gluckman E, Good RA, Rimm AA, Rozman C. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood. 1989 Feb;73(2):606-13.
12. **Horowitz MM**, Gale RP, Barrett AJ, Biggs JC, Camitta BM, Dicke KA, Gluckman E, Good RA, Herzig RH, Lee MB, Marmont AM, Masaoka T, Ramsay NKC, Rimm AA, Speck B, Zwaan FE, Bortin MM Effect of methotrexate on relapse after bone-marrow transplantation for acute lymphoblastic leukaemia. International Bone Marrow Transplant Registry. Lancet. 1989 Mar 11;1(8637):535-7
13. Weiner RS, **Horowitz MM**, Gale RP, Dicke KA, van Bekkum DW, Masaoka T, Ramsay NK, Rimm AA, Rozman C, Bortin MM. Risk factors for interstitial pneumonia following bone marrow transplantation for severe aplastic anaemia. Br J Haematol. 1989 Apr;71(4):535-43.
14. Atkinson K, **Horowitz MM**, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow

transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1989 May;4(3):247-54.
15. Gale RP, **Horowitz MM**, Biggs JC, Blume KA, Herzig RH, Kersey JH, Marmont AM, Masaoka T, Speck B, Rimm AA, Weiner RS, Zwaan FE, Bortin MM Transplant or chemotherapy in acute myelogenous leukaemia. International Bone Marrow Transplant Registry. Lancet. 1989 May 20;1(8647):1119-22
16. Bortin MM, Ringdén O, **Horowitz MM**, Rozman C, Weiner RS, Rimm AA. Temporal relationships between the major complications of bone marrow transplantation for leukemia. Bone Marrow Transplant. 1989 Jul;4(4):339-44.
17. Clift R, Goldman J, Gratwohl A, **Horowitz M**. Proposals for standardized reporting of results of bone marrow transplantation for leukaemia. Bone Marrow Transplant. 1989 Jul;4(4):445-8.
18. Barrett AJ, **Horowitz MM**, Gale RP, Biggs JC, Camitta BM, Dicke KA, Gluckman E, Good RA, Herzig RH, Lee MB. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood. 1989 Aug 01;74(2):862-71.
19. Gale RP, **Horowitz MM**, Bortin MM. IBMTR analysis of bone marrow transplants in acute leukaemia. Advisory Committee of the International Bone Marrow Transplant Registry (IBMTR). Bone Marrow Transplant. 1989 Dec;4 Suppl 3:83-4.
20. **Horowitz MM**, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990 Feb 01;75(3):555-62.
21. Atkinson K, **Horowitz MM**, Gale RP, van Bekkum DW, Gluckman E, Good RA, Jacobsen N, Kolb HJ, Rimm AA, Ringdén O. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood. 1990 Jun 15;75(12):2459-64.
22. Gale RP, **Horowitz MM**. Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1990 Jul;6 Suppl 1:94-7.
23. **Horowitz MM**, Bortin MM, Gale RP Allogeneic bone marrow trans-planta-tion: a review. Turk J Med Sci. 1990 Oct 1; 14(1990):513-541.
24. Rimm AA, Barr JT, **Horowitz MM**, Bortin MM. Use of a clinical data registry to evaluate medical technologies. Experience from the International Bone Marrow Transplant Registry. Int J Technol Assess Health Care. 1991;7(2):182-93.
25. Bortin MM, **Horowitz MM**, Mrsic M, Rimm AA, Sobocinski KA. Progress in bone marrow transplantation for leukemia: a preliminary report from the Advisory Committee of the International Bone Marrow Transplant Registry. Transplant Proc. 1991 Feb;23(1 Pt 1):61-2.
26. McKinney WP, Russler SK, **Horowitz MM**, Battiola RJ, Lee MB. Duration of response to intramuscular versus low dose intradermal hepatitis B booster immunization. Infect Control Hosp Epidemiol. 1991 Apr;12(4):226-30.
27. Gale RP, **Horowitz MM**, Butturini A. Autotransplants in acute leukaemia. Br J Haematol. 1991 May;78(1):135-7.
28. Ash RC, **Horowitz MM**, Gale RP, van Bekkum DW, Casper JT, Gordon-Smith EC, Henslee PJ, Kolb HJ, Lowenberg B, Masaoka T. Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion. Bone Marrow Transplant. 1991 Jun;7(6):443-52.
29. Keating A, **Horowitz MM**. Evaluating new therapy for acute myeloid leukemia. Semin Hematol. 1991 Jul;28(3 Suppl 4):70-1.
30. Gale RP, Butturini A, **Horowitz MM**. Does more intensive therapy increase cures in acute leukemia? Semin Hematol. 1991 Jul;28(3 Suppl 4):93-4.
31. **Horowitz MM**, Messerer D, Hoelzer D, Gale RP, Neiss A, Atkinson K, Barrett AJ, Büchner T, Freund M, Heil G. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med. 1991 Jul 01;115(1):13-8.
32. Marmont AM, **Horowitz MM**, Gale RP, Sobocinski K, Ash RC, van Bekkum DW, Champlin RE, Dicke KA, Goldman JM, Good RA. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991 Oct 15;78(8):2120-30.
33. Bortin MM, Barrett AJ, **Horowitz MM**, Gale RP, Sobocinski KA, Rimm AA. Progress in allogeneic bone marrow transplantation for acute lymphoblastic leukemia in the 1980's: a report from the IBMTR. The International Bone Marrow Transplant Registry. Leukemia. 1992;6 Suppl 2:196-7.
34. Barrett AJ, **Horowitz MM**. Transplants in ALL. Bone Marrow Transplant. 1992;10 Suppl 1:30-6.
35. Kolb HJ, Guenther W, Duell T, Socie G, Schaeffer E, Holler E, Schumm M, **Horowitz MM**, Gale RP,

Fliedner TM. Cancer after bone marrow transplantation. IBMTR and EBMT/EULEP Study Group on Late Effects. Bone Marrow Transplant. 1992;10 Suppl 1:135-8.
36. Sobocinski KA, **Horowitz MM**, Rimm AA, Bortin MM. Current status of allogeneic bone marrow transplantation. Biomed Pharmacother. 1992;46(2-3):57-69.
37. Atkinson KA, **Horowitz MM**, Sobocinski KA, Rimm AA, Bortin MM, Gale RP. Therapy decisions in leukemia. Bone Marrow Transplant. 1992 Jan;9(1):5-10.
38. Gluckman E, **Horowitz MM**, Champlin RE, Hows JM, Bacigalupo A, Biggs JC, Camitta BM, Gale RP, Gordon-Smith EC, Marmont AM. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. Blood. 1992 Jan 01;79(1):269-75.
39. Bortin MM, **Horowitz MM**, Rimm AA. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey. Ann Intern Med. 1992 Mar 15;116(6):505-12.
40. Mrsíc M, **Horowitz MM**, Atkinson K, Biggs JC, Champlin RE, Ehninger G, Gajewski JL, Gale RP, Herzig RH, Prentice HG. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant. 1992 Apr;9(4):269-75.
41. **Horowitz MM**, Przepiorka D, Champlin RE, Gale RP, Gratwohl A, Herzig RH, Prentice HG, Rimm AA, Ringdén O, Bortin MM. Should HLA-identical sibling bone marrow transplants for leukemia be restricted to large centers? Blood. 1992 May 15;79(10):2771-4.
42. Barrett AJ, **Horowitz MM**, Ash RC, Atkinson K, Gale RP, Goldman JM, Henslee-Downey PJ, Herzig RH, Speck B, Zwaan FE. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 1992 Jun 01;79(11):3067-70.
43. Gale RP, **Horowitz MM**, Butturini A, Barrett AJ, Kolb HJ. What determines who develops graft-versus-host disease: the graft or the host (or both)? Bone Marrow Transplant. 1992 Aug;10(2):99-102.
44. Bortin MM, **Horowitz MM**, Rimm AA. Progress report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1992 Aug;10(2):113-22.
45. Bortin MM, **Horowitz MM**, Gale RP, Barrett AJ, Champlin RE, Dicke KA, Gluckman E, Kolb HJ, Marmont AM, Mrsic M. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA. 1992 Aug 05;268(5):607-12.
46. Biggs JC, **Horowitz MM**, Gale RP, Ash RC, Atkinson K, Helbig W, Jacobsen N, Phillips GL, Rimm AA, Ringdén O. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood. 1992 Aug 15;80(4):1090-3.
47. Gale RP, **Horowitz MM**. Alternative donor transplants for leukemia. Scientific Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1993;11 Suppl 1:66-7.
48. Gale RP, **Horowitz MM**. Predicting results of alternative donor transplants for thalassemia using a chronic myelogenous leukemia model. Bone Marrow Transplant. 1993;12 Suppl 1:82-3.
49. Krance R, Heslop HE, Mahmoud H, Ribeiro R, Douglass E, Hurwitz C, Santana V, Kun L, **Horowitz MM**, Brenner MK. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors. Bone Marrow Transplant. 1993 Jan;11(1):33-6.
50. **Horowitz MM**, Bortin MM. Results of bone marrow transplants from human leukocyte antigen-identical sibling donors for treatment of childhood leukemias. A report from the International Bone Marrow Transplant Registry. Am J Pediatr Hematol Oncol. 1993 Feb;15(1):56-64.
51. Ringdén O, **Horowitz MM**, Sondel P, Gale RP, Biggs JC, Champlin RE, Deeg HJ, Dicke K, Masaoka T, Powles RL. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood. 1993 Feb 15;81(4):1094-101.
52. Drobyski WR, Dunne WM, Burd EM, Knox KK, Ash RC, **Horowitz MM**, Flomenberg N, Carrigan DR. Human herpesvirus-6 (HHV-6) infection in allogeneic bone marrow transplant recipients: evidence of a marrow-suppressive role for HHV-6 in vivo. J Infect Dis. 1993 Mar;167(3):735-9.
53. **Horowitz MM**. The role of the International Bone Marrow Transplant Registry in assessing clinical efficacy. Leukemia. 1993 Jul;7(7):1106.
54. Ringdén O, **Horowitz MM**, Gale RP, Biggs JC, Gajewski J, Rimm AA, Speck B, Veum-Stone JA, de Witte T, Bortin MM. Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA. 1993 Jul 07;270(1):57-60.
55. Bortin MM, **Horowitz MM**, Rowlings PA, Rimm AA, Sobocinski KA, Zhang MJ, Gale RP. 1993 progress report from the International Bone Marrow Transplant Registry. Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1993 Aug;12(2):97-104.

56. Goldman JM, Szydlo R, **Horowitz MM**, Gale RP, Ash RC, Atkinson K, Dicke KA, Gluckman E, Herzig RH, Marmont A. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood. 1993 Oct 01;82(7):2235-8.
57. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, **Horowitz MM**. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993 Oct 15;82(8):2310-8.
58. Sobocinski KA, **Horowitz MM**, Rowlings PA, Zhang MJ, Nugent ML, Passweg JR, Armitage JO, Gale RP, Bortin MM. Bone marrow transplantation--1994: a report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. J Hematother. 1994;3(2):95-102.
59. Rowlings PA, Gale RP, **Horowitz MM**, Bortin MM. Bone marrow transplantation in leukemia. J Hematother. 1994;3(3):235-8.
60. Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmak GV, McAuliffe T, Camitta B, **Horowitz MM**, Bunin N. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis. 1994 Apr;169(4):775-81.
61. Drobyski WR, Ash RC, Casper JT, McAuliffe T, **Horowitz MM**, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994 Apr 01;83(7):1980-7.
62. Gale RP, **Horowitz MM**, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringdén O, Stone JA, Bortin MM. Identical-twin bone marrow transplants for leukemia. Ann Intern Med. 1994 Apr 15;120(8):646-52.
63. Dabrowska DM, Sun GW, **Horowitz MM** Cox regression in a Markov renewal model: an application to the analysis of bone marrow transplant data. J Am Stat Assoc. 1994 Sep 1; 89(427):867-877
64. Messerer D, Neiss A, **Horowitz MM**, Hoelzer D, Gale RP. Comparison of chemotherapy and bone marrow transplants using two independent clinical databases. J Clin Epidemiol. 1994 Oct;47(10):1119-26.
65. Silberman G, Crosse MG, Peterson EA, Weston RC, **Horowitz MM**, Appelbaum FR, Cheson BD. Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med. 1994 Oct 20;331(16):1063-7.
66. Barrett AJ, **Horowitz MM**, Pollock BH, Zhang MJ, Bortin MM, Buchanan GR, Camitta BM, Ochs J, Graham-Pole J, Rowlings PA. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. N Engl J Med. 1994 Nov 10;331(19):1253-8.
67. Mugishima H, Gale RP, Rowlings PA, **Horowitz MM**, Marmont AM, McCann SR, Sobocinski KA, Bortin MM. Bone marrow transplantation for Diamond-Blackfan anemia. Bone Marrow Transplant. 1995 Jan;15(1):55-8.
68. Gale RP, Goldman JM, **Horowitz MM**, Silberman G, Crosse MG, Peterson EA, Weston RC. Bone-marrow transplantation for leukaemia. Lancet. 1995 May 13;345(8959):1235.
69. Barquinero J, Witherspoon R, Sanders J, **Horowitz MM**, Montuoro A, Patton DF, Bacigalupo A, Abecasis MM, Miale T, Rozman C. Allogeneic marrow grafts from donors with congenital chromosomal abnormalities in marrow cells. Br J Haematol. 1995 Jul;90(3):595-601.
70. Gale RP, **Horowitz MM**, Weiner RS, Ash RC, Atkinson K, Babu R, Dicke KA, Klein JP, Lowenberg B, Reiffers J. Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission. Bone Marrow Transplant. 1995 Aug;16(2):203-8.
71. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR, Ash RC, **Horowitz MM**, Camitta B, Lawton C. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant. 1995 Aug;16(2):271-5.
72. Zhang MJ, Hoelzer D, **Horowitz MM**, Gale RP, Messerer D, Klein JP, Löffler H, Sobocinski KA, Thiel E, Weisdorf DJ. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. Ann Intern Med. 1995 Sep 15;123(6):428-31.
73. Gluckman E, Auerbach AD, **Horowitz MM**, Sobocinski KA, Ash RC, Bortin MM, Butturini A, Camitta BM, Champlin RE, Friedrich W, Good RA, Gordon-Smith EC, Harris RE, Klein JP, Ortega JJ, Pasquini R, Ramsay NK, Speck B, Vowels MR, Zhang MJ, Gale RP. Bone marrow transplantation for Fanconi anemia. Blood. 1995 Oct 01;86(7):2856-62.

74. Hessner MJ, Endean DJ, Casper JT, **Horowitz MM**, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood. 1995 Nov 15;86(10):3987-96.
75. Gale RP, **Horowitz MM**, Rees JK, Gray RG, Oken MM, Estey EH, Kim KM, Zhang MJ, Ash RC, Atkinson K, Champlin RE, Dicke KA, Gajewski JL, Goldman JM, Helbig W, Henslee-Downey PS, Hinterberger W, Jacobsen N, Keating A, Klein JP, Marmont AM, Prentice HG, Reiffers J, Rimm AA, Bortin MM. Chemotherapy versus transplants for acute myelogenous leukemia in second remission. Leukemia. 1996 Jan;10(1):13-9.
76. Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA, Ash RC, Champlin RE, Henslee-Downey PJ, Herzig RH, Hinterberger W, Klein JP, Prentice HG, Reiffers J, Zwaan FE, **Horowitz MM**. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant. 1996 Jan;17(1):75-80.
77. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP, Lazarus HM, McCarthy PL Jr, Pavlovsky S, Peterson FB, Rowlings PA, Russell JA, Silver SM, Vose JM, Wiernik PH, Bortin MM, **Horowitz MM**. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol. 1996 Feb;14(2):572-8.
78. **Horowitz MM**, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1996 May;17 Suppl 3:S5-6.
79. Gale RP, Büchner T, Zhang MJ, Heinecke A, Champlin RE, Dicke KA, Gluckman E, Good RA, Gratwohl A, Herzig RH, Keating A, Klein JP, Marmont AM, Prentice HG, Rowlings PA, Sobocinski KA, Speck B, Weiner RS, **Horowitz MM**. HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission. Leukemia. 1996 Nov;10(11):1687-91.
80. Hinterberger W, Rowlings PA, Hinterberger-Fischer M, Gibson J, Jacobsen N, Klein JP, Kolb HJ, Stevens DA, **Horowitz MM**, Gale RP. Results of transplanting bone marrow from genetically identical twins into patients with aplastic anemia. Ann Intern Med. 1997 Jan 15;126(2):116-22.
81. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socíe G, Travis LB, **Horowitz MM**, Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeni JF Jr, Boice JD Jr. Solid cancers after bone marrow transplantation. N Engl J Med. 1997 Mar 27;336(13):897-904.
82. Szydlo R, Goldman JM, Klein JP, Gale RP, Ash RC, Bach FH, Bradley BA, Casper JT, Flomenberg N, Gajewski JL, Gluckman E, Henslee-Downey PJ, Hows JM, Jacobsen N, Kolb HJ, Lowenberg B, Masaoka T, Rowlings PA, Sondel PM, van Bekkum DW, van Rood JJ, Vowels MR, Zhang MJ, **Horowitz MM**. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol. 1997 May;15(5):1767-77.
83. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL Jr, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, **Horowitz MM**. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997 May;15(5):1870-9.
84. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ, Cahn JY, Calderwood S, Gratwohl A, Socié G, Abecasis MM, Sobocinski KA, Zhang MJ, **Horowitz MM**. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997 Jun;97(4):855-64.
85. Passweg JR, Socié G, Hinterberger W, Bacigalupo A, Biggs JC, Camitta BM, Champlin RE, Gale RP, Gluckman E, Gordon-Smith EC, Hows JM, Klein JP, Nugent ML, Pasquini R, Rowlings PA, Speck B, Tichelli A, Zhang MJ, **Horowitz MM**, Bortin MM. Bone marrow transplantation for severe aplastic anemia: has outcome improved? Blood. 1997 Jul 15;90(2):858-64.
86. Zhang MJ, Baccarani M, Gale RP, McGlave PB, Atkinson K, Champlin RE, Dicke KA, Giralt S, Gluckman E, Goldman JM, Klein JP, Herzig RH, Masaoka T, O'Reilly RJ, Rozman C, Rowlings PA, Sobocinski KA, Speck B, Zwaan FE, **Horowitz MM**. Survival of patients with chronic myelogenous leukaemia relapsing after bone marrow transplantation: comparison with patients receiving conventional chemotherapy. Br J Haematol. 1997 Oct;99(1):23-9.
87. Chen CS, Seidel K, Armitage JO, Fay JW, Appelbaum FR, **Horowitz MM**, Shpall EJ, Weiden PL, Antman KS, Champlin RE, Kersey JH, Sullivan KM. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 1997 Dec;3(6):331-40.

88. Lawton CA, Cohen EP, Murray KJ, Derus SW, Casper JT, Drobyski WR, **Horowitz MM**, Moulder JE. Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. Bone Marrow Transplant. 1997 Dec;20(12):1069-74.
89. Lee SJ, Kuntz KM, **Horowitz MM**, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med. 1997 Dec 15;127(12):1080-8.
90. Passweg JR, Tiberghien P, Cahn JY, Vowels MR, Camitta BM, Gale RP, Herzig RH, Hoelzer D, **Horowitz MM**, Ifrah N, Klein JP, Marks DI, Ramsay NK, Rowlings PA, Weisdorf DJ, Zhang MJ, Barrett AJ. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. Bone Marrow Transplant. 1998 Jan;21(2):153-8.
91. Passweg JR, Rowlings PA, **Horowitz MM**. Related donor bone marrow transplantation for chronic myelogenous leukemia. Hematol Oncol Clin North Am. 1998 Feb;12(1):81-92.
92. Gale RP, Hehlmann R, Zhang MJ, Hasford J, Goldman JM, Heimpel H, Hochhaus A, Klein JP, Kolb HJ, McGlave PB, Passweg JR, Rowlings PA, Sobocinski KA, **Horowitz MM**. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group. Blood. 1998 Mar 01;91(5):1810-9.
93. Waters TM, Bennett CL, Pajeau TS, Sobocinski KA, Klein JP, Rowlings PA, **Horowitz MM**. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know? Bone Marrow Transplant. 1998 Apr;21(7):641-50.
94. Passweg JR, Rowlings PA, Atkinson KA, Barrett AJ, Gale RP, Gratwohl A, Jacobsen N, Klein JP, Ljungman P, Russell JA, Schaefer UW, Sobocinski KA, Vossen JM, Zhang MJ, **Horowitz MM**. Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant. 1998 Jun;21(12):1231-8.
95. Sullivan KM, Anasetti C, **Horowitz M**, Rowlings PA, Petersdorf EW, Martin PJ, Clift RA, Walters MC, Gooley T, Sierra J, Anderson JE, Bjerke J, Siadak M, Flowers ME, Nash RA, Sanders JE, Appelbaum FR, Storb R, Hansen JA. Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry. Ann N Y Acad Sci. 1998 Jun 30;850:312-24.
96. Oh H, Gale RP, Zhang MJ, Passweg JR, Ino T, Murakami H, Ohno R, Rowlings PA, Sobocinski KA, Tanimoto M, Tomonaga M, Weisdorf DJ, **Horowitz MM**. Chemotherapy vs HLA-identical sibling bone marrow transplants for adults with acute lymphoblastic leukemia in first remission. Bone Marrow Transplant. 1998 Aug;22(3):253-7.
97. Lee SJ, Anasetti C, **Horowitz MM**, Antin JH. Initial therapy for chronic myelogenous leukemia: playing the odds. J Clin Oncol. 1998 Sep;16(9):2897-903.
98. van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, Chaekal OK, Gale RP, Klein JP, Lazarus HM, McCarthy PL Jr, Raemaekers JM, Reiffers J, Phillips GL, Schattenberg AV, Verdonck LF, Vose JM, **Horowitz MM**. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998 Sep 01;92(5):1832-6.
99. Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, **Horowitz MM**, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission. Leuk Res. 1998 Nov;22(11):973-81.
100. Hale G, Zhang MJ, Bunjes D, Prentice HG, Spence D, **Horowitz MM**, Barrett AJ, Waldmann H. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood. 1998 Dec 15;92(12):4581-90.
101. **Horowitz MM**, Przepiorka D, Bartels P, Buell DN, Zhang MJ, Fitzsimmons WE, Erdman J, Huang C, Hodosh E, Maher R, Wingard JR. Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. Biol Blood Marrow Transplant. 1999;5(3):180-6.
102. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ, Gajewski JL, Gale RP, Keating A, Klein JP, Miller CB, Phillips GL, Reece DE, Sobocinski KA, van Besien K, **Horowitz MM**. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 1999 Feb;17(2):534-45.
103. Saso R, Marsh J, Cevreska L, Szer J, Gale RP, Rowlings PA, Passweg JR, Nugent ML, Luzzatto L, **Horowitz MM**, Gordon-Smith EC. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1999 Feb;104(2):392-6.
104. Andersen PK, **Horowitz MM**, Klein JP, Socie G, Stone JV, Zhang MJ. Modelling covariate adjusted

mortality relative to a standard population. Stat Med. 1999 Jun 30;18(12):1529-40.
105. Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, **Horowitz MM**, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leuk Res. 1999 Aug;23(8):709-18.
106. McCarthy P, Hurd D, Rowlings P, Crump M, Gale R, Lazarus H, Vaughan W, Weinberger B, Wiemann M, Freytes C, Cirenza E, Antman K. Autotransplants in men with breast cancer. ABMTR Breast Cancer Working Committee. Autologous Blood and Marrow Transplant Registry. Bone Marrow Transplant. 1999 Aug;24(4):365-8.
107. Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, **Horowitz MM**, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in chronic myelogenous leukemia in chronic phase. Leuk Res. 1999 Sep;23(9):817-26.
108. Rowlings PA, Curtis RE, Passweg JR, Deeg HJ, Socié G, Travis LB, Kingma DW, Jaffe ES, Sobocinski KA, **Horowitz MM**. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. J Clin Oncol. 1999 Oct;17(10):3122-7.
109. Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, Jaffe ES, Sale GE, **Horowitz MM**, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr, Deeg HJ. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999 Oct 01;94(7):2208-16.
110. Rowlings PA, Williams SF, Antman KH, Fields KK, Fay JW, Reed E, Pelz CJ, Klein JP, Sobocinski KA, Kennedy MJ, Freytes CO, McCarthy PL Jr, Herzig RH, Stadtmauer EA, Lazarus HM, Pecora AL, Bitran JD, Wolff SN, Gale RP, Armitage JO, Vaughan WP, Spitzer G, **Horowitz MM**. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA. 1999 Oct 13;282(14):1335-43.
111. Davies SM, Ramsay NK, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY, Camitta BM, Gale RP, Giralt S, Heilmann C, Henslee-Downey PJ, Herzig RH, Hutchinson R, Keating A, Lazarus HM, Milone GA, Neudorf S, Perez WS, Powles RL, Prentice HG, Schiller G, Socié G, Vowels M, Wiley J, Yeager A, **Horowitz MM**. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol. 2000 Jan;18(2):340-7.
112. Socié G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB, Sullivan KM, Rowlings PA, Kingma DW, Banks PM, Travis WD, Witherspoon RP, Sanders J, Jaffe ES, **Horowitz MM**. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol. 2000 Jan;18(2):348-57.
113. **Horowitz MM**. Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. Semin Hematol. 2000 Jan;37(1):30-42.
114. Giralt S, Szydlo R, Goldman JM, Veum-Stone J, Biggs JC, Herzig RH, Klein JP, McGlave PB, Schiller G, Gale RP, Rowlings PA, **Horowitz MM**. Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. Blood. 2000 Jan 15;95(2):410-5.
115. Champlin RE, Schmitz N, **Horowitz MM**, Chapuis B, Chopra R, Cornelissen JJ, Gale RP, Goldman JM, Loberiza FR Jr, Hertenstein B, Klein JP, Montserrat E, Zhang MJ, Ringdén O, Tomany SC, Rowlings PA, Van Hoef ME, Gratwohl A. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood. 2000 Jun 15;95(12):3702-9.
116. Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringdén O, Slavin S, Sobocinski KA, Speck B, Weiner RS, **Horowitz MM**. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood. 2000 Jun 15;95(12):3996-4003.
117. Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, **Horowitz MM**, Gluckman E. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000 Jun 22;342(25):1846-54.
118. Tallman MS, Rowlings PA, Milone G, Zhang MJ, Perez WS, Weisdorf D, Keating A, Gale RP, Geller RB,

Laughlin MJ, Lazarus HM, Luger SM, McCarthy PL, Rowe JM, Saez RA, Vowels MR, **Horowitz MM**. Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood. 2000 Aug 15;96(4):1254-8.

119. Collins RH Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, Barrett J, Johnson M, Kirk A, **Horowitz M**, Parker P. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000 Sep;26(5):511-6.
120. Stiff PJ, Veum-Stone J, Lazarus HM, Ayash L, Edwards JR, Keating A, Klein JP, Oblon DJ, Shea TC, Thomé S, **Horowitz MM**. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an autologous blood and marrow transplant registry report. Ann Intern Med. 2000 Oct 03;133(7):504-15.
121. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, Pavlovsky S, Keating A, Yanes B, van Besien K, Armitage JO, **Horowitz MM**, Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2001 Jan 15;19(2):406-13.
122. Lazarus HM, Loberiza FR Jr, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, **Horowitz MM**. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant. 2001 Feb;27(4):387-96.
123. Filipovich AH, Stone JV, Tomany SC, Ireland M, Kollman C, Pelz CJ, Casper JT, Cowan MJ, Edwards JR, Fasth A, Gale RP, Junker A, Kamani NR, Loechelt BJ, Pietryga DW, Ringdén O, Vowels M, Hegland J, Williams AV, Klein JP, Sobocinski KA, Rowlings PA, **Horowitz MM**. Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. Blood. 2001 Mar 15;97(6):1598-603.
124. Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, **Horowitz MM**, IBMTR Statistical Center of the International Bone Marrow Transplant Registry, Medical College of Wisconcin, Milwaukee, WI, USA, EBMT, Kiel, Germany. Peripheral blood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant. 2001 Apr;27(7):689-92.
125. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, **Horowitz M**. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001 Apr 15;19(8):2201-5.
126. **Horowitz MM**, Loberiza FR, Bredeson CN, Rizzo JD, Nugent ML. Transplant registries: guiding clinical decisions and improving outcomes. Oncology (Williston Park). 2001 May;15(5):649-59; discussion 663-4, 666.
127. Keiding N, Klein JP, **Horowitz MM**. Multi-state models and outcome prediction in bone marrow transplantation. Stat Med. 2001 Jun 30;20(12):1871-85.
128. Miller CB, Rowlings PA, Zhang MJ, Jones RJ, Piantadosi S, Keating A, Armitage JO, Calderwood S, Harris RE, Klein JP, Lazarus HM, Linker CA, Sobocinski KA, Weisdorf D, **Horowitz MM**. The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia. Exp Hematol. 2001 Nov;29(11):1336-46.
129. Lee SJ, Klein JP, Anasetti C, Antin JH, Loberiza FR, Bolwell BJ, LeMaistre CF, Litzow MR, Marks D, Waller EK, Matlack M, Giralt S, **Horowitz MM**. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood. 2001 Dec 01;98(12):3205-11.
130. Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, Antin JH, **Horowitz MM**, Akpek G, Flowers ME, Couriel D, Martin PJ. A survey of diagnosis, management, and grading of chronic GVHD. Biol Blood Marrow Transplant. 2002;8(1):32-9.
131. Weisdorf D, Bishop M, Dharan B, Bolwell B, Cahn JY, Cairo M, Giralt S, Klein J, Lazarus H, Litzow M, Marks D, McCarthy P, Miller C, Milone G, Russell J, Schultz KR, Sierra J, Wiernik P, Keating A, Loberiza F, Kollman C, **Horowitz M**. Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. Biol Blood Marrow Transplant. 2002;8(4):213-20.

132. Rizzo JD, Elias AD, Stiff PJ, Lazarus HM, Zhang MJ, Oblon DJ, Pecora AL, Hale GA, **Horowitz MM**. Autologous stem cell transplantation for small cell lung cancer. Biol Blood Marrow Transplant. 2002;8(5):273-80.
133. Martin PJ, Antin JH, Weisdorf DJ, Paton V, **Horowitz MM**. Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(6):295-302.
134. Bredeson CN, Forman SJ, **Horowitz MM**, Openshaw H, Pavletic SZ, Wulffraat N Conference synopsis: hematopoietic stem cell therapy in autoimmune diseases, October 2001. Biol Blood Marrow Transplant. 2002;8(8):407-11
135. Bellm LA, Cunningham G, Durnell L, Eilers J, Epstein JB, Fleming T, Fuchs HJ, Haskins MN, **Horowitz MM**, Martin PJ, McGuire DB, Mullane K, Oster G. Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Invest. 2002;20(5-6):793-800.
136. Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Leis J, Holmes HE, Johnson M, **Horowitz M**, Collins RH Jr. Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. J Clin Oncol. 2002 Jan 15;20(2):405-12.
137. Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson IC, Lazarus HM, McCarthy PL Jr, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, **Horowitz MM**. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2002 Feb 01;20(3):743-50.
138. van Rood JJ, Loberiza FR Jr, Zhang MJ, Oudshoorn M, Claas F, Cairo MS, Champlin RE, Gale RP, Ringdén O, Hows JM, **Horowitz MH**. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002 Mar 01;99(5):1572-7.
139. Loberiza FR Jr, Rizzo JD, Bredeson CN, Antin JH, **Horowitz MM**, Weeks JC, Lee SJ. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol. 2002 Apr 15;20(8):2118-26.
140. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, **Horowitz MM**. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood. 2002 Jul 15;100(2):406-14.
141. Goldman JM, **Horowitz MM**. The international bone marrow transplant registry. Int J Hematol. 2002 Aug;76 Suppl 1:393-7.
142. Sierra J, Pérez WS, Rozman C, Carreras E, Klein JP, Rizzo JD, Davies SM, Lazarus HM, Bredeson CN, Marks DI, Canals C, Boogaerts MA, Goldman J, Champlin RE, Keating A, Weisdorf DJ, de Witte TM, **Horowitz MM**. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002 Sep 15;100(6):1997-2004.
143. Litzow MR, Pérez WS, Klein JP, Bolwell BJ, Camitta B, Copelan EA, Gale RP, Giralt SA, Keating A, Lazarus HM, Marks DI, McCarthy PL, Miller CB, Milone G, Prentice HG, Russell JA, Schultz KR, Trigg ME, Weisdorf DJ, **Horowitz MM**. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. Br J Haematol. 2002 Dec;119(4):1115-24.
144. Mehta P, Pollock BH, Nugent M, **Horowitz M**, Wingard JR. Access to stem cell transplantation: do women fare as well as men? Am J Hematol. 2003 Feb;72(2):99-102.
145. Loberiza FR Jr, Serna DS, **Horowitz MM**, Rizzo JD. Transplant center characteristics and clinical outcomes after hematopoietic stem cell transplantation: what do we know? Bone Marrow Transplant. 2003 Mar;31(6):417-21.
146. Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, López-Guillermo A, Gisselbrecht C, Guilhot F, Vose JM, van Biesen K, Rizzo JD, Weisenburger DD, Isaacson P, **Horowitz MM**, Goldstone AH, Lazarus HM, Schmitz N. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol. 2003 Mar;120(5):793-800.
147. Metayer C, Curtis RE, Vose J, Sobocinski KA, **Horowitz MM**, Bhatia S, Fay JW, Freytes CO, Goldstein

SC, Herzig RH, Keating A, Miller CB, Nevill TJ, Pecora AL, Rizzo JD, Williams SF, Li CY, Travis LB, Weisdorf DJ. Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study. Blood. 2003 Mar 01;101(5):2015-23.

148. Levine JE, Harris RE, Loberiza FR Jr, Armitage JO, Vose JM, Van Besien K, Lazarus HM, **Horowitz MM**, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ, Lymphoma Study Writing Committee, International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. Blood. 2003 Apr 01;101(7):2476-82.
149. Ringdén O, Barrett AJ, Zhang MJ, Loberiza FR, Bolwell BJ, Cairo MS, Gale RP, Hale GA, Litzow MR, Martino R, Russell JA, Tiberghien P, Urbano-Ispizua A, **Horowitz MM**. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol. 2003 Jun;121(6):874-85.
150. Rizzo JD, Williams S, Wu JT, Pecora AL, Lazarus HM, Bolwell B, Fields KK, Gale RP, Elfenbein G, **Horowitz MM**, Antman KH. Syngeneic hematopoietic stem cell transplantation for women with metastatic breast cancer. Bone Marrow Transplant. 2003 Jul;32(2):151-5.
151. Akpek G, Lee SJ, Flowers ME, Pavletic SZ, Arora M, Lee S, Piantadosi S, Guthrie KA, Lynch JC, Takatu A, **Horowitz MM**, Antin JH, Weisdorf DJ, Martin PJ, Vogelsang GB. Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study. Blood. 2003 Aug 01;102(3):802-9.
152. Bierman PJ, Sweetenham JW, Loberiza FR Jr, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, **Horowitz M**, Goldstone A, Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003 Oct 15;21(20):3744-53.
153. Serna DS, Lee SJ, Zhang MJ, Baker kS, Eapen M, **Horowitz MM**, Klein JP, Rizzo JD, Loberiza FR Jr. Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada. J Clin Oncol. 2003 Oct 15;21(20):3754-60.
154. Khoury H, Trinkaus K, Zhang MJ, Adkins D, Brown R, Vij R, Goodnough LT, Ma MK, McLeod HL, Shenoy S, **Horowitz M**, Dipersio JF. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant. 2003 Nov;9(11):714-21.
155. van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, Freytes CO, Gibson J, **Horowitz MM**, Inwards DJ, Marks DI, Martino R, Maziarz RT, Molina A, Pavlovsky S, Pecora AL, Schouten HC, Shea TC, Lazarus HM, Rizzo JD, Vose JM. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood. 2003 Nov 15;102(10):3521-9.
156. Vose JM, Rizzo DJ, Tao-Wu J, Armitage JO, Bashey A, Burns LJ, Christiansen NP, Freytes CO, Gale RP, Gibson J, Giralt SA, Herzig RH, Lemaistre CF, McCarthy PL Jr, Nimer SD, Petersen FB, Schenkein DP, Wiernik PH, Wiley JM, Loberiza FR, Lazarus HM, van Biesen K, **Horowitz MM**. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. Biol Blood Marrow Transplant. 2004 Feb;10(2):116-27.
157. Passweg JR, Walker I, Sobocinski KA, Klein JP, **Horowitz MM**, Giralt SA, Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol. 2004 Jun;125(5):613-20.
158. Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Pérez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, **Horowitz MM**. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004 Jul 15;104(2):579-85.
159. Godder K, Eapen M, Laver JH, Zhang MJ, Camitta BM, Wayne AS, Gale RP, Doyle JJ, Yu LC, Chen AR, Garvin JH Jr, Sandler ES, Yeager AM, Edwards JR, **Horowitz MM**. Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis. J Clin Oncol. 2004 Sep 15;22(18):3798-804.
160. Eapen M, Giralt SA, **Horowitz MM**, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta

BM, Champlin RE, Ringdén O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, deLima M. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004 Oct;34(8):721-7.

161. Flomenberg N, Baxter-Lowe LA, Confer D, Fernandez-Vina M, Filipovich A, **Horowitz M**, Hurley C, Kollman C, Anasetti C, Noreen H, Begovich A, Hildebrand W, Petersdorf E, Schmeckpeper B, Setterholm M, Trachtenberg E, Williams T, Yunis E, Weisdorf D. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood. 2004 Oct 01;104(7):1923-30.
162. Lee SJ, Joffe S, Kim HT, Socie G, Gilman AL, Wingard JR, **Horowitz MM**, Cella D, Syrjala KL. Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. Blood. 2004 Oct 01;104(7):2194-200.
163. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, Stevens C, Barker JN, Gale RP, Lazarus HM, Marks DI, van Rood JJ, Scaradavou A, **Horowitz MM**. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004 Nov 25;351(22):2265-75.
164. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, **Horowitz MM**, Klumpp TR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus HM, van Besien K, Lymphoma Working Committee of the International Bone Marrow Transplant Registry. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. Blood. 2004 Dec 01;104(12):3797-803.
165. Eapen M, **Horowitz MM**, Klein JP, Champlin RE, Loberiza FR Jr, Ringdén O, Wagner JE. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol. 2004 Dec 15;22(24):4872-80.
166. Andrykowski MA, Bishop MM, Hahn EA, Cella DF, Beaumont JL, Brady MJ, **Horowitz MM**, Sobocinski KA, Rizzo JD, Wingard JR. Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. J Clin Oncol. 2005 Jan 20;23(3):599-608.
167. Oh H, Loberiza FR Jr, Zhang MJ, Ringdén O, Akiyama H, Asai T, Miyawaki S, Okamoto S, **Horowitz MM**, Antin JH, Bashey A, Bird JM, Carabasi MH, Fay JW, Gale RP, Giller RH, Goldman JM, Hale GA, Harris RE, Henslee-Downey J, Kolb HJ, Litzow MR, McCarthy PL, Neudorf SM, Serna DS, Socié G, Tiberghien P, Barrett AJ. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005 Feb 15;105(4):1408-16.
168. Loberiza FR Jr, Zhang MJ, Lee SJ, Klein JP, LeMaistre CF, Serna DS, Eapen M, Bredeson CN, **Horowitz MM**, Rizzo JD. Association of transplant center and physician factors on mortality after hematopoietic stem cell transplantation in the United States. Blood. 2005 Apr 01;105(7):2979-87.
169. Gale RP, **Horowitz MM**, Talpaz M, Scheinberg DA, Molldrem J, Li Z, Baccarani M, Goldman JM, Tura S. Immune therapy of chronic myelogenous leukemia. Leuk Res. 2005 May;29(5):583-6.
170. Curtis RE, Metayer C, Rizzo JD, Socié G, Sobocinski KA, Flowers ME, Travis WD, Travis LB, **Horowitz MM**, Deeg HJ. Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005 May 15;105(10):3802-11. PMCID: PMC1895092
171. Hsu KC, Keever-Taylor CA, Wilton A, Pinto C, Heller G, Arkun K, O'Reilly RJ, **Horowitz MM**, Dupont B. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood. 2005 Jun 15;105(12):4878-84. PMCID: PMC1894998
172. Santo Tomas LH, Loberiza FR Jr, Klein JP, Layde PM, Lipchik RJ, Rizzo JD, Bredeson CN, **Horowitz MM**. Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. Chest. 2005 Jul;128(1):153-61.
173. Ho VT, Cutler C, Carter S, Martin P, Adams R, **Horowitz M**, Ferrara J, Soiffer R, Giralt S. Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Aug;11(8):571-5.
174. Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, Leblond V, Ifrah N, Jouet JP, Loberiza F, Ringden O, Barrett AJ, **Horowitz MM**, Socié G, Société Française de Greffe de Moëlle et Thérapie

Cellulaire, Dana Farber Cancer Institute, International Bone Marrow Transplant Registry. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005 Aug 15;106(4):1495-500. PMCID: PMC1895210

175. Baker KS, Loberiza FR Jr, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA, Camitta BM, Garcia JJ, Ho WG, Liesveld JL, Maharaj D, Marks DI, Schultz KR, Wiernik P, Zander AR, **Horowitz MM**, Keating A, Weisdorf DJ. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol. 2005 Oct 01;23(28):7032-42.
176. Seebach JD, Stussi G, Passweg JR, Loberiza FR Jr, Gajewski JL, Keating A, Goerner M, Rowlings PA, Tiberghien P, Elfenbein GJ, Gale RP, van Rood JJ, Reddy V, Gluckman E, Bolwell BJ, Klumpp TR, **Horowitz MM**, Ringdén O, Barrett AJ, GVHD Working Committee of Center for International Blood and Marrow Transplant Research. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant. 2005 Dec;11(12):1006-13.
177. Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher MA, Ortega JJ, Scaradavou A, **Horowitz MM**, Wagner JE. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol. 2006 Jan 01;24(1):145-51.
178. Tallman MS, Pérez WS, Lazarus HM, Gale RP, Maziarz RT, Rowe JM, Marks DI, Cahn JY, Bashey A, Bishop MR, Christiansen N, Frankel SR, García JJ, Ilhan O, Laughlin MJ, Liesveld J, Linker C, Litzow MR, Luger S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang MJ, Keating A, Weisdorf DJ, **Horowitz MM**. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2006 Feb;12(2):204-16.
179. Khoury HJ, Loberiza FR Jr, Ringdén O, Barrett AJ, Bolwell BJ, Cahn JY, Champlin RE, Gale RP, Hale GA, Urbano-Ispizua A, Martino R, McCarthy PL, Tiberghien P, Verdonck LF, **Horowitz MM**. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood. 2006 Feb 15;107(4):1712-6. PMCID: PMC1895414
180. Lazarus HM, Pérez WS, Klein JP, Kollman C, Bate-Boyle B, Bredeson CN, Gale RP, Geller RB, Keating A, Litzow MR, Marks DI, Miller CB, Douglas Rizzo J, Spitzer TR, Weisdorf DJ, Zhang MJ, **Horowitz MM**. Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. Br J Haematol. 2006 Mar;132(6):755-69.
181. Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Gooley T, Ruffner K, Nemecek E, Sickle E, Durack L, Carreras J, **Horowitz MM**, Press OW, Gopal AK, Martin PJ, Bernstein ID, Matthews DC. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006 Mar 01;107(5):2184-91. PMCID: PMC1895719
182. Marks DI, Forman SJ, Blume KG, Pérez WS, Weisdorf DJ, Keating A, Gale RP, Cairo MS, Copelan EA, Horan JT, Lazarus HM, Litzow MR, McCarthy PL, Schultz KR, Smith DD, Trigg ME, Zhang MJ, **Horowitz MM**. A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant. 2006 Apr;12(4):438-53.
183. Passweg JR, Pérez WS, Eapen M, Camitta BM, Gluckman E, Hinterberger W, Hows JM, Marsh JC, Pasquini R, Schrezenmeier H, Socié G, Zhang MJ, Bredeson C. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant. 2006 Apr;37(7):641-9.
184. Loren AW, Bunin GR, Boudreau C, Champlin RE, Cnaan A, **Horowitz MM**, Loberiza FR, Porter DL. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 Jul;12(7):758-69.
185. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, **Horowitz M**, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006 Sep 15;108(6):1809-20.

186. Schmitz N, Eapen M, **Horowitz MM**, Zhang MJ, Klein JP, Rizzo JD, Loberiza FR, Gratwohl A, Champlin RE, International Bone Marrow Transplant Registry, European Group for Blood and Marrow Transplantation. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood. 2006 Dec 15;108(13):4288-90. PMCID: PMC1895450
187. Weisdorf D, Carter S, Confer D, Ferrara J, **Horowitz M**. Blood and marrow transplant clinical trials network (BMT CTN): addressing unanswered questions. Biol Blood Marrow Transplant. 2007 Mar;13(3):257-62; discussion 255-6.
188. Petersdorf EW, Gooley T, Malkki M, **Horowitz M**, International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens. 2007 Apr;69 Suppl 1:25-30.
189. Malkki M, Gooley T, **Horowitz M**, Petersdorf EW, IHWG HCT Component. MHC class I, II, and III microsatellite marker matching and survival in unrelated donor hematopoietic cell transplantation. Tissue Antigens. 2007 Apr;69 Suppl 1:46-9.
190. Malkki M, Gooley T, Dubois V, **Horowitz M**, Petersdorf EW. Immune response gene polymorphisms in unrelated donor hematopoietic cell transplantation. Tissue Antigens. 2007 Apr;69 Suppl 1:50-3.
191. Bishop MM, Beaumont JL, Hahn EA, Cella D, Andrykowski MA, Brady MJ, **Horowitz MM**, Sobocinski KA, Rizzo JD, Wingard JR. Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls. J Clin Oncol. 2007 Apr 10;25(11):1403-11.
192. Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, Bredeson CN, Eapen M, **Horowitz MM**. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007 May 15;109(10):4582-5. PMCID: PMC1885491
193. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, Sobocinski KA, **Horowitz MM**, Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007 Jun;137(5):461-7.
194. Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, **Horowitz MM**, Klein JP, Weisdorf DJ. Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. Blood. 2007 Jun 01;109(11):5058-61. PMCID: PMC1885526
195. Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, Loberiza FR, Champlin RE, Klein JP, **Horowitz MM**, Wagner JE. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007 Jun 09;369(9577):1947-54.
196. Malkki M, Gooley TA, **Horowitz MM**, Absi L, Christiansen FT, Cornelissen JJ, Dormoy A, Dubois V, Gagne K, Gluckman E, Haagenson MD, Oudshoorn M, Spellman S, Petersdorf EW, International Histocompatibility Working Group in Transplantation. Mapping MHC-resident transplantation determinants. Biol Blood Marrow Transplant. 2007 Aug;13(8):986-95. PMCID: PMC3182140
197. Ferrara JL, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, **Horowitz M**. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. Biol Blood Marrow Transplant. 2007 Nov;13(11):1268-85.
198. Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, Wingard JR, Rowley SD, Stroncek D, Gee AP, **Horowitz MM**, Anasetti C. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant. 2007 Dec;13(12):1461-8. PMCID: PMC2267869
199. Shaw BE, Gooley TA, Malkki M, Madrigal JA, Begovich AB, **Horowitz MM**, Gratwohl A, Ringdén O, Marsh SG, Petersdorf EW. The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation. Blood. 2007 Dec 15;110(13):4560-6.
200. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, Fernandez-Vina M, Flomenberg N, **Horowitz M**, Hurley CK, Noreen H, Oudshoorn M, Petersdorf E, Setterholm M, Spellman S, Weisdorf D, Williams TM, Anasetti C. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood. 2007 Dec 15;110(13):4576-83.
201. Logan B, Leifer E, Bredeson C, **Horowitz M**, Ewell M, Carter S, Geller N. Use of biological assignment in

hematopoietic stem cell transplantation clinical trials. Clin Trials. 2008;5(6):607-16. PMCID: PMC2671015

202. Schlenk RF, Pasquini MC, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, **Horowitz MM**, Ganser A, CIBMTR Acute Leukemia Working Committee. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant. 2008 Feb;14(2):187-96. PMCID: PMC2531160
203. Nietfeld JJ, Pasquini MC, Logan BR, Verter F, **Horowitz MM**. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008 Mar;14(3):316-22. PMCID: PMC2531159
204. Howard DH, Meltzer D, Kollman C, Maiers M, Logan B, Gragert L, Setterholm M, **Horowitz MM**. Use of cost-effectiveness analysis to determine inventory size for a national cord blood bank. Med Decis Making. 2008;28(2):243-53.
205. Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn JY, Lazarus HM, Litzow MR, Marks DI, Wiernik PH, McCarthy PL, Russell JA, Miller CB, Sierra J, Milone G, Keating A, Loberiza FR Jr, Giralt S, **Horowitz MM**, Weisdorf DJ. Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008 Apr;41(7):635-42. PMCID: PMC2587442
206. Weisdorf D, Spellman S, Haagenson M, **Horowitz M**, Lee S, Anasetti C, Setterholm M, Drexler R, Maiers M, King R, Confer D, Klein J. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58. PMCID: PMC2668157
207. Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, Drobyski W, Wang D, Pavletic S, Ringden O, **Horowitz MM**, Collins R Jr. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant. 2008 Aug;42(3):201-5.
208. Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K, Brown C, Chaudhry MA, **Horowitz MM**, Kurian S, Quinlan D, Muehlenbien CE, Russell JA, Savoie L, Rizzo JD, Stewart DA. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant. 2008 Sep;14(9):993-1003. PMCID: PMC3321981
209. Duquesnoy R, Spellman S, Haagenson M, Wang T, **Horowitz MM**, Oudshoorn M. HLAMatchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors. Biol Blood Marrow Transplant. 2008 Sep;14(9):1064-1071. PMCID: PMC2572684
210. Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M, Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter J, Keating A, Marks DI, McCarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B, Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ, Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten HC, Zander AR, **Horowitz MM**, Maziarz RT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood. 2008 Oct 15;112(8):3500-7. PMCID: PMC2954751
211. Lazarus HM, Carreras J, Boudreau C, Loberiza FR Jr, Armitage JO, Bolwell BJ, Freytes CO, Gale RP, Gibson J, Hale GA, Inwards DJ, LeMaistre CF, Maharaj D, Marks DI, Miller AM, Pavlovsky S, Schouten HC, van Besien K, Vose JM, Bitran JD, Khouri IF, McCarthy PL, Yu H, Rowlings P, Serna DS, **Horowitz MM**, Rizzo JD, Center For International Blood & Marrow Transplant Research (CIBMTR). Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2008 Dec;14(12):1323-33. PMCID: PMC2638759
212. Dehn J, Arora M, Spellman S, Setterholm M, **Horowitz M**, Confer D, Weisdorf D. Unrelated donor hematopoietic cell transplantation: factors associated with a better HLA match. Biol Blood Marrow Transplant. 2008 Dec;14(12):1334-40. PMCID: PMC3319684
213. Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, **Horowitz M**, Antin JH, Soiffer R. Sirolimus is associated with

veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 01;112(12):4425-31. PMCID: PMC2597119

214. Aljurf MD, Zaidi SZ, El Solh H, Hussain F, Ghavamzadeh A, Mahmoud HK, Shamsi T, Othman TB, Sarhan MM, Dennison D, Ibrahim A, Benchekroun S, Chaudhri N, Labar B, **Horowitz M**, Niederwieser D, Gratwohl A. Special issues related to hematopoietic SCT in the Eastern Mediterranean region and the first regional activity report. Bone Marrow Transplant. 2009 Jan;43(1):1-12. PMCID: PMC3351791
215. Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers ME, Friedman DL, **Horowitz MM**, Wingard JR, Deeg HJ. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009 Jan 29;113(5):1175-83. PMCID: PMC2635083
216. Giralt S, Ballen K, Rizzo D, Bacigalupo A, **Horowitz M**, Pasquini M, Sandmaier B. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009 Mar;15(3):367-9. PMCID: PMC3110087
217. Ringdén O, Pavletic SZ, Anasetti C, Barrett AJ, Wang T, Wang D, Antin JH, Di Bartolomeo P, Bolwell BJ, Bredeson C, Cairo MS, Gale RP, Gupta V, Hahn T, Hale GA, Halter J, Jagasia M, Litzow MR, Locatelli F, Marks DI, McCarthy PL, Cowan MJ, Petersdorf EW, Russell JA, Schiller GJ, Schouten H, Spellman S, Verdonck LF, Wingard JR, **Horowitz MM**, Arora M. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood. 2009 Mar 26;113(13):3110-8. PMCID: PMC2662650
218. Arora M, Weisdorf DJ, Spellman SR, Haagenson MD, Klein JP, Hurley CK, Selby GB, Antin JH, Kernan NA, Kollman C, Nademanee A, McGlave P, **Horowitz MM**, Petersdorf EW. HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia. J Clin Oncol. 2009 Apr 01;27(10):1644-52. PMCID: PMC2668970
219. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, Leitman SF, Anderlini P, Haagenson MD, Kurian S, Klein JP, **Horowitz MM**, Confer DL. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood. 2009 Apr 09;113(15):3604-11. PMCID: PMC2668845
220. Lazarus HM, Kan F, Tarima S, Champlin RE, Confer DL, Frey N, Gee AP, Wagner JE, **Horowitz MM**, Eapen M. Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant. Biol Blood Marrow Transplant. 2009 May;15(5):589-96. PMCID: PMC2688780
221. Landgren O, Gilbert ES, Rizzo JD, Socié G, Banks PM, Sobocinski KA, **Horowitz MM**, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood. 2009 May 14;113(20):4992-5001. PMCID: PMC2686146
222. Ratanatharathorn V, Logan B, Wang D, **Horowitz M**, Uberti JP, Ringden O, Gale RP, Khoury H, Arora M, Spellman S, Cutler C, Antin J, Bornhaüser M, Hale G, Verdonck L, Cairo M, Gupta V, Pavletic S, Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA. Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. Br J Haematol. 2009 Jun;145(6):816-24. PMCID: PMC3355660
223. Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE, Pollack MS, Storek J, Thompson JC, Tiberghien P, Young JA, Ribaud P, **Horowitz MM**, Keating A. Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009 Jul;15(7):864-71. PMCID: PMC2881828
224. Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N, Pasquini M, Goldstein SC, Ho VT, Hayes-Lattin B, Wingard JR, **Horowitz MM**, Levine JE, Blood and Marrow Transplant Clinical Trials Network. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood. 2009 Jul 16;114(3):511-7. PMCID: PMC2713466
225. Baxter-Lowe LA, Maiers M, Spellman SR, Haagenson MD, Wang T, Fernandez-Vina M, Marsh SG, **Horowitz M**, Hurley CK. HLA-A disparities illustrate challenges for ranking the impact of HLA mismatches on bone marrow transplant outcomes in the United States. Biol Blood Marrow Transplant. 2009 Aug;15(8):971-81. PMCID: PMC2747529
226. Pulsipher MA, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP, **Horowitz MM**, Miller JP,

King RJ, Confer DL. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood. 2009 Sep 24;114(13):2606-16. PMCID: PMC2756121

227. Pamphilon D, Siddiq S, Brunskill S, Dorée C, Hyde C, **Horowitz M**, Stanworth S. Stem cell donation--what advice can be given to the donor? Br J Haematol. 2009 Oct;147(1):71-6. PMCID: PMC3409390
228. Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH, Bolwell B, Cahn JY, Cervantes F, Copelan E, Gale R, Gratwohl A, Khoury HJ, McCarthy P, Marks DI, Szer J, Woolfrey A, Cortes-Franco J, **Horowitz MM**, Arora M, Chronic Leukemia Working Committee. Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. Biol Blood Marrow Transplant. 2009 Nov;15(11):1475-8. PMCID: PMC2929002
229. Gajewski JL, LeMaistre CF, Silver SM, Lill MC, Selby GB, **Horowitz MM**, Rizzo JD, Heslop HE, Anasetti C, Maziarz RT. Impending challenges in the hematopoietic stem cell transplantation physician workforce. Biol Blood Marrow Transplant. 2009 Dec;15(12):1493-501.
230. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, Apperley J, Slavin S, Pasquini M, Sandmaier BM, Barrett J, Blaise D, Lowski R, **Horowitz M**. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009 Dec;15(12):1628-33. PMCID: PMC2861656
231. **Horowitz MM**. High-resolution typing for unrelated donor transplantation: how far do we go? Best Pract Res Clin Haematol. 2009 Dec;22(4):537-41. PMCID: PMC2904986
232. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, **Horowitz M**, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10;27(35):6041-51. PMCID: PMC4979100
233. Eapen M, **Horowitz MM**. Alternative donor transplantation for aplastic anemia. Hematology Am Soc Hematol Educ Program. 2010;2010:43-6.
234. Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kröger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, **Horowitz MM**, Giralt SA, Arora M. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010 Mar;16(3):358-67. PMCID: PMC2908949
235. Kalaycio ME, Kukreja M, Woolfrey AE, Szer J, Cortes J, Maziarz RT, Bolwell BJ, Buser A, Copelan E, Gale RP, Gupta V, Maharaj D, Marks DI, Pavletic SZ, **Horowitz MM**, Arora M. Allogeneic hematopoietic cell transplant for prolymphocytic leukemia. Biol Blood Marrow Transplant. 2010 Apr;16(4):543-7. PMCID: PMC2839005
236. Gajewski JL, Lill M, **Horowitz M**, Maziarz RT. Response to Letter from Demetrios S. Theodoropoulos, MD, DSc. Biol Blood Marrow Transplant. 2010 Apr;16(4):561-2.
237. Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M, **Horowitz MM**, Rizzo JD. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010 Apr 10;28(11):1888-95. PMCID: PMC2860369
238. Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M, Frauendorfer K, Niederwieser D, **Horowitz M**, Kodera Y, Worldwide Network of Blood and Marrow Transplantation. Hematopoietic stem cell transplantation: a global perspective. JAMA. 2010 Apr 28;303(16):1617-24. PMCID: PMC3219875
239. Hurley CK, Foeken L, **Horowitz M**, Lindberg B, McGregor M, Sacchi N, WMDA Accreditation and Regulatory Committees. Standards, regulations and accreditation for registries involved in the worldwide exchange of hematopoietic stem cell donors and products. Bone Marrow Transplant. 2010 May;45(5):819-24.
240. Shaughnessy PJ, Bolwell BJ, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Durrant S, Ilhan O, Parenti D, Gallo J, Foss F, Apperley J, Zhang MJ, **Horowitz MM**, Abhyankar S. Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2010 Jun;45(6):1068-76. PMCID: PMC3376382
241. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, Gee

AP, Isola L, Laughlin MJ, Marks DI, Nabhan S, Ruggeri A, Soiffer R, **Horowitz MM**, Gluckman E, Wagner JE, Center for International Blood and Marrow Transplant Research, Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation), National Cord Blood Program of the New York Blood Center. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010 Jul;11(7):653-60. PMCID: PMC3163510

242. Joshua TV, Rizzo JD, Zhang MJ, Hari PN, Kurian S, Pasquini M, Majhail NS, Lee SJ, **Horowitz MM**. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer. 2010 Jul 15;116(14):3469-76. PMCID: PMC3153958
243. Wingard JR, Huang IC, Sobocinski KA, Andrykowski MA, Cella D, Rizzo JD, Brady M, **Horowitz MM**, Bishop MM. Factors associated with self-reported physical and mental health after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010 Dec;16(12):1682-92. PMCID: PMC2975785
244. King RJ, Confer DL, Greinix HT, Halter J, **Horowitz M**, Schmidt AH, Costeas P, Shaw B, Egeland T, Ethics and Clinical Working Groups of World Marrow Donor Association. Unrelated hematopoietic stem cell donors as research subjects. Bone Marrow Transplant. 2011 Jan;46(1):10-3.
245. Cohen YC, Scaradavou A, Stevens CE, Rubinstein P, Gluckman E, Rocha V, **Horowitz MM**, Eapen M, Nagler A, Shpall EJ, Laughlin MJ, Daniely Y, Pacheco D, Barishev R, Olmer L, Freedman LS. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplant. 2011 Jan;46(1):70-6. PMCID: PMC3366187
246. Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, **Horowitz MM**, Bolwell B, Wingard JR, Socie G. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011 Jan 06;117(1):316-22. PMCID: PMC3037753
247. Horwitz EM, **Horowitz MM**, DiFronzo NL, Kohn DB, Heslop HE, Blood and Marrow Transplant Clinical Trials Network, State of the Science Cell and Gene Therapy Committee. Guidance for developing phase II cell therapy trial proposals for consideration by the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow Transplant. 2011 Feb;17(2):192-6. PMCID: PMC3387575
248. Giralt SA, **Horowitz M**, Weisdorf D, Cutler C. Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. J Clin Oncol. 2011 Feb 10;29(5):566-72. PMCID: PMC4874212
249. Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P, Calado R, Kojima S, Eapen M, Harris R, Scheinberg P, Savage S, Maciejewski JP, Tiu RV, DiFronzo N, **Horowitz MM**, Antin JH. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant. 2011 Mar;17(3):291-9. PMCID: PMC3053041
250. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, **Horowitz MM**, Bolwell B, Rizzo JD, Socié G. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011 Jun 01;29(16):2230-9. PMCID: PMC3107742
251. Arora M, Klein JP, Weisdorf DJ, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola L, Jacobsohn DA, Jagasia M, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman S, Wingard JR, **Horowitz MM**, Pavletic SZ. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood. 2011 Jun 16;117(24):6714-20. PMCID: PMC3123030
252. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, Devine S, Isola L, Lazarus HM, Marks DI, Porter DL, Waller EK, **Horowitz MM**, Eapen M. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011 Jun 23;117(25):6963-70. PMCID: PMC3128486
253. Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, **Horowitz MM**, Vose JM, Negrin RS, Laport GG. Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. Biol Blood Marrow Transplant. 2011 Jul;17(7):1051-7. PMCID: PMC3114272
254. Ahmed SO, Ghavamzadeh A, Zaidi SZ, Baldomero H, Pasquini MC, Hussain F, Alimoghaddam K, Almohareb F, Ayas M, Hamidieh A, Mahmoud HK, Elhaddad A, Ben Othman T, Abdelkefi A, Sarhan M, Abdel-Rahman F, Adil S, Alkindi S, Bazarbachi A, Benchekroun S, Niederwieser D, **Horowitz M**, Gratwohl A, El Solh H, Aljurf M. Trends of hematopoietic stem cell transplantation in the Eastern Mediterranean region, 1984-2007. Biol Blood Marrow Transplant. 2011 Sep;17(9):1352-61. PMCID:

PMC3371191
255. Eapen M, Le Rademacher J, Antin JH, Champlin RE, Carreras J, Fay J, Passweg JR, Tolar J, **Horowitz MM**, Marsh JC, Deeg HJ. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood. 2011 Sep 01;118(9):2618-21. PMCID: PMC3167362
256. Jacobsohn DA, Arora M, Klein JP, Hassebroek A, Flowers ME, Cutler CS, Urbano-Ispizua A, Bolwell BJ, Antin JH, Boyiadzis M, Cahn JY, Cairo MS, Herzig RH, Isola LM, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Gale RP, Schouten HC, Spellman SR, Weisdorf DJ, Wingard JR, **Horowitz MM**, Pavletic SZ. Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. Blood. 2011 Oct 20;118(16):4472-9. PMCID: PMC3204914
257. Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, **Horowitz MM**, Giralt S, Maloney DG, Blood Marrow Transplant Clinical Trials Network (BMT CTN). Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011 Dec;12(13):1195-203. PMCID: PMC3611089
258. Eapen M, Klein JP, Sanz GF, Spellman S, Ruggeri A, Anasetti C, Brown M, Champlin RE, Garcia-Lopez J, Hattersely G, Koegler G, Laughlin MJ, Michel G, Nabhan SK, Smith FO, **Horowitz MM**, Gluckman E, Rocha V, Eurocord-European Group for Blood and Marrow Transplantation, Netcord, Center for International Blood and Marrow Transplant Research. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011 Dec;12(13):1214-21. PMCID: PMC3245836
259. Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, **Horowitz MM**, Hahn T. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012 Jan 05;119(1):296-307. PMCID: PMC3251233
260. Denzen EM, Santibáñez ME, Moore H, Foley A, Gersten ID, Gurgol C, Majhail NS, Spellecy R, **Horowitz MM**, Murphy EA. Easy-to-read informed consent forms for hematopoietic cell transplantation clinical trials. Biol Blood Marrow Transplant. 2012 Feb;18(2):183-9. PMCID: PMC3242929
261. Fleischhauer K, Shaw BE, Gooley T, Malkki M, Bardy P, Bignon JD, Dubois V, **Horowitz MM**, Madrigal JA, Morishima Y, Oudshoorn M, Ringden O, Spellman S, Velardi A, Zino E, Petersdorf EW, International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol. 2012 Apr;13(4):366-74. PMCID: PMC3813000
262. Annen K, Friedman K, Eshoa C, **Horowitz M**, Gottschall J, Straus T. Two cases of transfusion-transmitted Anaplasma phagocytophilum. Am J Clin Pathol. 2012 Apr;137(4):562-5.
263. Saber W, Opie S, Rizzo JD, Zhang MJ, **Horowitz MM**, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood. 2012 Apr 26;119(17):3908-16. PMCID: PMC3350357
264. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, **Horowitz MM**, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1770-81. PMCID: PMC3744390
265. Majhail NS, Brazauskas R, Hassebroek A, Bredeson CN, Hahn T, Hale GA, **Horowitz MM**, Lazarus HM, Maziarz RT, Wood WA, Parsons SK, Joffe S, Rizzo JD, Lee SJ, Hayes-Lattin BM. Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia. Biol Blood Marrow Transplant. 2012 Jun;18(6):861-73. PMCID: PMC3288160
266. Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, **Horowitz MM**, Lee SJ. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2012 Jun;47(6):810-6. PMCID:

PMC3896981
267. Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM, Adams RH, Ewell M, Leifer ES, Gersten ID, Carter SL, **Horowitz MM**, Nakamura R, Pulsipher MA, Difronzo NL, Confer DL, Eapen M, Anderlini P. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant. 2012 Jul;18(7):1007-11. PMCID: PMC3677744
268. Petersdorf EW, Malkki M, Gooley TA, Spellman SR, Haagenson MD, **Horowitz MM**, Wang T. MHC-resident variation affects risks after unrelated donor hematopoietic cell transplantation. Sci Transl Med. 2012 Jul 25;4(144):144ra101. PMCID: PMC3633562
269. Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, **Horowitz MM**, Saber W. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant. 2012 Sep;18(9):1446-54. PMCID: PMC3499973
270. Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, **Horowitz MM**, Carter S, O'Reilly RJ, Soiffer RJ. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol. 2012 Sep 10;30(26):3194-201. PMCID: PMC3434978
271. Tomblyn M, Chen M, Kukreja M, Aljurf MD, Al Mohareb F, Bolwell BJ, Cahn JY, Carabasi MH, Gale RP, Gress RE, Gupta V, Hale GA, Ljungman P, Maziarz RT, Storek J, Wingard JR, Young JA, **Horowitz MM**, Ballen KK. No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation. Transpl Infect Dis. 2012 Oct;14(5):468-78. PMCID: PMC3481161
272. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, **Horowitz MM**, Confer DL, Blood and Marrow Transplant Clinical Trials Network. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012 Oct 18;367(16):1487-96. PMCID: PMC3816375
273. Weisdorf D, Zhang MJ, Arora M, **Horowitz MM**, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant. 2012 Nov;18(11):1727-33. PMCID: PMC3472079
274. Rocha V, Spellman S, Zhang MJ, Ruggeri A, Purtill D, Brady C, Baxter-Lowe LA, Baudoux E, Bergamaschi P, Chow R, Freed B, Koegler G, Kurtzberg J, Larghero J, Lecchi L, Nagler A, Navarrette C, Prasad V, Pouthier F, Price T, Ratanatharathorn V, van Rood JJ, **Horowitz MM**, Gluckman E, Eapen M, Eurocord-European Blood and Marrow Transplant Group and the Center for International Blood and Marrow Transplant Research. Effect of HLA-matching recipients to donor noninherited maternal antigens on outcomes after mismatched umbilical cord blood transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2012 Dec;18(12):1890-6. PMCID: PMC3826155
275. **Horowitz MM**. Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients? Best Pract Res Clin Haematol. 2012 Dec;25(4):483-6. PMCID: PMC6432637
276. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, **Horowitz M**, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13;367(24):2305-15. PMCID: PMC3805360
277. Halter JP, van Walraven SM, Worel N, Bengtsson M, Hägglund H, Nicoloso de Faveri G, Shaw BE, Schmidt AH, Fechter M, Madrigal A, Szer J, Aljurf MD, Weisdorf D, **Horowitz MM**, Greinix H, Niederwieser D, Gratwohl A, Kodera Y, Confer D. Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). Bone Marrow Transplant. 2013 Feb;48(2):220-5.
278. Petersdorf EW, Malkki M, **Horowitz MM**, Spellman SR, Haagenson MD, Wang T. Mapping MHC

haplotype effects in unrelated donor hematopoietic cell transplantation. Blood. 2013 Mar 07;121(10):1896-905. PMCID: PMC3591807

279. Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, **Horowitz M**, Fisher R, Tomblyn M. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013 May 01;31(13):1662-8. PMCID: PMC3635682
280. Fernández-Viña MA, Klein JP, Haagenson M, Spellman SR, Anasetti C, Noreen H, Baxter-Lowe LA, Cano P, Flomenberg N, Confer DL, **Horowitz MM**, Oudshoorn M, Petersdorf EW, Setterholm M, Champlin R, Lee SJ, de Lima M. Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3/4/5 associate with adverse outcomes in hematopoietic stem cell transplantation. Blood. 2013 May 30;121(22):4603-10. PMCID: PMC3668493
281. Koreth J, Pidala J, Perez WS, Deeg HJ, Garcia-Manero G, Malcovati L, Cazzola M, Park S, Itzykson R, Ades L, Fenaux P, Jadersten M, Hellstrom-Lindberg E, Gale RP, Beach CL, Lee SJ, **Horowitz MM**, Greenberg PL, Tallman MS, DiPersio JF, Bunjes D, Weisdorf DJ, Cutler C. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol. 2013 Jul 20;31(21):2662-70. PMCID: PMC3825320
282. Gratwohl A, Baldomero H, Gratwohl M, Aljurf M, Bouzas LF, **Horowitz M**, Kodera Y, Lipton J, Iida M, Pasquini MC, Passweg J, Szer J, Madrigal A, Frauendorfer K, Niederwieser D, Worldwide Network of Blood and Marrow Transplantation (WBMT). Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica. 2013 Aug;98(8):1282-90. PMCID: PMC3729910
283. Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, **Horowitz MM**, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2013 Sep;19(9):1368-73.
284. Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolaños-Meade J, Brown JM, Walsh TJ, **Horowitz MH**, Kurtzberg J, Marr KA, Wingard JR. Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. Am J Health Syst Pharm. 2013 Sep 01;70(17):1518-27. PMCID: PMC4019750
285. Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, **Horowitz MM**. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood. 2013 Sep 12;122(11):1974-82. PMCID: PMC3772501
286. Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, **Horowitz MM**, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05;122(24):3863-70. PMCID: PMC3854108
287. Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, Arcese W, Barker JN, Baxter-Lowe LA, Brown M, Fernandez-Vina MA, Freeman J, He W, Iori AP, **Horowitz MM**, Locatelli F, Marino S, Maiers M, Michel G, Sanz GF, Gluckman E, Rocha V, Center for International Blood and Marrow Transplant Research, Netcord, Eurocord, and the European Group for Blood and Marrow Transplantation. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014 Jan 02;123(1):133-40. PMCID: PMC3879902
288. Kuwatsuka Y, Atsuta Y, **Horowitz MM**, Inagaki J, Kanda J, Kato K, Koh K, Zhang MJ, Eapen M, Center for International Blood and Marrow Transplant Research (CIBMTR), and Donor/Source and GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations. Biol Blood Marrow Transplant. 2014 May;20(5):662-7. PMCID: PMC4071962

289. Yanik GA, **Horowitz MM**, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, Carter SL, Wu J, Wingard JR, Difronzo NL, Ferrara JL, Giralt S, Madtes DK, Drexler R, White ES, Cooke KR. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant. 2014 Jun;20(6):858-64. PMCID: PMC4128626
290. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, Rizzo JD, **Horowitz MM**, Saber W. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014 Jun 05;123(23):3664-71. PMCID: PMC4047501
291. Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, Rizzo JD, **Horowitz M**, Confer D, Maiers M. HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med. 2014 Jul 24;371(4):339-48. PMCID: PMC5965695
292. Cutler C, Logan B, Nakamura R, Johnston L, Choi S, Porter D, Hogan WJ, Pasquini M, MacMillan ML, Hsu JW, Waller EK, Grupp S, McCarthy P, Wu J, Hu ZH, Carter SL, **Horowitz MM**, Antin JH. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. Blood. 2014 Aug 21;124(8):1372-7. PMCID: PMC4141519
293. Jacobsen PB, Le-Rademacher J, Jim H, Syrjala K, Wingard JR, Logan B, Wu J, Majhail NS, Wood W, Rizzo JD, Geller NL, Kitko C, Faber E, Abidi MH, Slater S, **Horowitz MM**, Lee SJ. Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. Biol Blood Marrow Transplant. 2014 Oct;20(10):1530-6. PMCID: PMC4163109
294. Saber W, Le Rademacher J, Sekeres M, Logan B, Lewis M, Mendizabal A, Leifer E, Appelbaum FR, **Horowitz MM**, Nakamura R, Cutler CS. Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods. Biol Blood Marrow Transplant. 2014 Oct;20(10):1566-72. PMCID: PMC4169902
295. Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Viña M, Gratwohl A, Gupta V, Hanna R, **Horowitz MM**, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW, Prasad V, Robinson J, Saber W, Schultz KR, Shaw B, Storek J, Wood WA, Woolfrey AE, Anasetti C. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood. 2014 Oct 16;124(16):2596-606. PMCID: PMC4199961
296. Wagner JE Jr, Eapen M, Carter S, Wang Y, Schultz KR, Wall DA, Bunin N, Delaney C, Haut P, Margolis D, Peres E, Verneris MR, Walters M, **Horowitz MM**, Kurtzberg J, Blood and Marrow Transplant Clinical Trials Network. One-unit versus two-unit cord-blood transplantation for hematologic cancers. N Engl J Med. 2014 Oct 30;371(18):1685-94. PMCID: PMC4257059
297. Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, **Horowitz MM**, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014 Nov 20;124(22):3221-7; quiz 3335. PMCID: PMC4239331
298. Petersdorf EW, Gooley TA, Malkki M, Bacigalupo AP, Cesbron A, Du Toit E, Ehninger G, Egeland T, Fischer GF, Gervais T, Haagenson MD, **Horowitz MM**, Hsu K, Jindra P, Madrigal A, Oudshoorn M, Ringdén O, Schroeder ML, Spellman SR, Tiercy JM, Velardi A, Witt CS, O'Huigin C, Apps R, Carrington M, International Histocompatibility Working Group in Hematopoietic Cell Transplantation. HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation. Blood. 2014 Dec 18;124(26):3996-4003. PMCID: PMC4271183
299. Howard CA, Fernandez-Vina MA, Appelbaum FR, Confer DL, Devine SM, **Horowitz MM**, Mendizabal A, Laport GG, Pasquini MC, Spellman SR. Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant. 2015 Jan;21(1):4-7. PMCID: PMC4272893
300. Appelbaum FR, Anasetti C, Antin JH, Atkins H, Davies S, Devine S, Giralt S, Heslop H, Laport G, Lee SJ, Logan B, Pasquini M, Pulsipher M, Stadtmauer E, Wingard JR, **Horowitz MM**. Blood and marrow transplant clinical trials network state of the Science Symposium 2014. Biol Blood Marrow Transplant.

2015 Feb;21(2):202-24. PMCID: PMC4426907

301. Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, **Horowitz MM**, Pavletic SZ, Graft-vs-Host Disease Working Committee of the CIBMTR. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015 Feb;21(2):266-74. PMCID: PMC4326247
302. Eapen M, Logan BR, **Horowitz MM**, Zhong X, Perales MA, Lee SJ, Rocha V, Soiffer RJ, Champlin RE. Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J Clin Oncol. 2015 Feb 01;33(4):364-9. PMCID: PMC4302216
303. Gratwohl A, Pasquini MC, Aljurf M, Atsuta Y, Baldomero H, Foeken L, Gratwohl M, Bouzas LF, Confer D, Frauendorfer K, Gluckman E, Greinix H, **Horowitz M**, Iida M, Lipton J, Madrigal A, Mohty M, Noel L, Novitzky N, Nunez J, Oudshoorn M, Passweg J, van Rood J, Szer J, Blume K, Appelbaum FR, Kodera Y, Niederwieser D, Worldwide Network for Blood and Marrow Transplantation (WBMT). One million haemopoietic stem-cell transplants: a retrospective observational study. Lancet Haematol. 2015 Mar;2(3):e91-100.
304. Copelan EA, Avalos BR, Ahn KW, Zhu X, Gale RP, Grunwald MR, Hamadani M, Hamilton BK, Hale GA, Marks DI, Waller EK, Savani BN, Costa LJ, Ramanathan M, Cahn JY, Khoury HJ, Weisdorf DJ, Inamoto Y, Kamble RT, Schouten HC, Wirk B, Litzow MR, Aljurf MD, van Besien KW, Ustun C, Bolwell BJ, Bredeson CN, Fasan O, Ghosh N, **Horowitz MM**, Arora M, Szer J, Loren AW, Alyea EP, Cortes J, Maziarz RT, Kalaycio ME, Saber W. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. Biol Blood Marrow Transplant. 2015 Mar;21(3):552-8. PMCID: PMC4329042
305. Anderlini P, Wu J, Gersten I, Ewell M, Tolar J, Antin JH, Adams R, Arai S, Eames G, Horwitz ME, McCarty J, Nakamura R, Pulsipher MA, Rowley S, Leifer E, Carter SL, DiFronzo NL, **Horowitz MM**, Confer D, Deeg HJ, Eapen M. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation: a phase 1-2 dose de-escalation study. Lancet Haematol. 2015 Sep;2(9):e367-75. PMCID: PMC4861234
306. Khera N, Majhail NS, Brazauskas R, Wang Z, He N, Aljurf MD, Akpek G, Atsuta Y, Beattie S, Bredeson CN, Burns LJ, Dalal JD, Freytes CO, Gupta V, Inamoto Y, Lazarus HM, LeMaistre CF, Steinberg A, Szwajcer D, Wingard JR, Wirk B, Wood WA, Joffe S, Hahn TE, Loberiza FR, Anasetti C, **Horowitz MM**, Lee SJ. Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. Biol Blood Marrow Transplant. 2015 Oct;21(10):1815-22. PMCID: PMC4568172
307. Arora M, Hemmer MT, Ahn KW, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RP, Inamoto Y, Weisdorf DJ, Li P, Antin JH, Bolwell BJ, Boyiadzis M, Cahn JY, Cairo MS, Isola LM, Jacobsohn DA, Jagasia M, Klumpp TR, Petersdorf EW, Santarone S, Schouten HC, Wingard JR, Spellman SR, Pavletic SZ, Lee SJ, **Horowitz MM**, Flowers ME. Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. Biol Blood Marrow Transplant. 2015 Apr;21(4):640-5. PMCID: PMC4359642
308. Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, **Horowitz MM**, Linker C, Alyea EP. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10;33(35):4167-75. PMCID: PMC4658453
309. Petersdorf EW, Malkki M, O'hUigin C, Carrington M, Gooley T, Haagenson MD, **Horowitz MM**, Spellman SR, Wang T, Stevenson P. High HLA-DP Expression and Graft-versus-Host Disease. N Engl J Med. 2015 Aug 13;373(7):599-609. PMCID: PMC4560117

310. Boyiadzis M, Arora M, Klein JP, Hassebroek A, Hemmer M, Urbano-Ispizua A, Antin JH, Bolwell BJ, Cahn JY, Cairo MS, Cutler CS, Flowers ME, Gale RP, Herzig R, Isola LM, Jacobsohn DA, Jagasia MH, Klumpp TR, Lee SJ, Petersdorf EW, Santarone S, Spellman SR, Schouten HC, Verdonck LF, Wingard JR, Weisdorf DJ, **Horowitz MM**, Pavletic SZ. Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. Clin Cancer Res. 2015 May 01;21(9):2020-8. PMCID: PMC4411210
311. Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, Armand P, Antin JH, Chen J, Devine SM, Fowler DH, Luznik L, Nakamura R, O'Donnell PV, Perales MA, Pingali SR, Porter DL, Riches MR, Ringdén OT, Rocha V, Vij R, Weisdorf DJ, Champlin RE, **Horowitz MM**, Fuchs EJ, Eapen M. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20;126(8):1033-40. PMCID: PMC4543223
312. Graff TM, Singavi AK, Schmidt W, Eastwood D, Drobyski WR, **Horowitz M**, Palmer J, Pasquini M, Rizzo DJ, Saber W, Hari P, Fenske TS. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma. Bone Marrow Transplant. 2015 Jul;50(7):947-53. PMCID: PMC4490016
313. Wood WA, Le-Rademacher J, Syrjala KL, Jim H, Jacobsen PB, Knight JM, Abidi MH, Wingard JR, Majhail NS, Geller NL, Rizzo JD, Fei M, Wu J, **Horowitz MM**, Lee SJ. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). Cancer. 2016 Jan 01;122(1):91-8. PMCID: PMC4707096
314. Kollman C, Spellman SR, Zhang MJ, Hassebroek A, Anasetti C, Antin JH, Champlin RE, Confer DL, DiPersio JF, Fernandez-Viña M, Hartzman RJ, **Horowitz MM**, Hurley CK, Karanes C, Maiers M, Mueller CR, Perales MA, Setterholm M, Woolfrey AE, Yu N, Eapen M. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood. 2016 Jan 14;127(2):260-7. PMCID: PMC4713163
315. Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, Ho VT, **Horowitz MM**, Pasquini MC. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015 Aug;21(8):1479-87. PMCID: PMC4512746
316. Martin PJ, Lee SJ, Przepiorka D, **Horowitz MM**, Koreth J, Vogelsang GB, Walker I, Carpenter PA, Griffith LM, Akpek G, Mohty M, Wolff D, Pavletic SZ, Cutler CS. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biol Blood Marrow Transplant. 2015 Aug;21(8):1343-59. PMCID: PMC4506719
317. Young JH, Logan BR, Wu J, Wingard JR, Weisdorf DJ, Mudrick C, Knust K, **Horowitz MM**, Confer DL, Dubberke ER, Pergam SA, Marty FM, Strasfeld LM, Brown JWM, Langston AA, Schuster MG, Kaul DR, Martin SI, Anasetti C, Blood and Marrow Transplant Clinical Trials Network Trial 0201. Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. Biol Blood Marrow Transplant. 2016 Feb;22(2):359-370. PMCID: PMC4716871
318. Al Malki MM, **Horowitz M**, Handgretinger R, Leung W, Roy DC, Huang XJ, Fuchs E, Locatelli F, Blaise D, Mineishi S, Martelli M, Miller J, June C, Ai HS, Luznik L, Mavilio D, Lugli E, van den Brink MRM, Champlin RE, Ciurea SO. Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014. Biol Blood Marrow Transplant. 2016 Apr;22(4):594-604. PMCID: PMC7104805
319. Strouse C, Richardson P, Prentice G, Korman S, Hume R, Nejadnik B, **Horowitz MM**, Saber W. Defibrotide for Treatment of Severe Veno-Occlusive Disease in Pediatrics and Adults: An Exploratory Analysis Using Data from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2016 Jul;22(7):1306-1312. PMCID: PMC4914048
320. Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, Bouzas LF, Confer D, Greinix H, **Horowitz M**, Iida M, Lipton J, Mohty M, Novitzky N, Nunez J, Passweg J, Pasquini MC, Kodera Y, Apperley J, Seber A, Gratwohl A. Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. Bone Marrow Transplant. 2016 Jun;51(6):778-85. PMCID: PMC4889523
321. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, **Horowitz M**, Lazarus HM, Riches ML, Blood and Marrow Transplant Clinical Trials Network. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. Biol Blood Marrow

Transplant. 2016 Aug;22(8):1440-1448. PMCID: PMC4949103
322. Arora M, Lee SJ, Spellman SR, Weisdorf DJ, Guan W, Haagenson M, Wang T, **Horowitz MH**, Verneris MR, Fleischhauer K, Hsu K, Thyagarajan B. Validation Study Failed to Confirm an Association between Genetic Variants in the Base Excision Repair Pathway and Transplant-Related Mortality and Relapse after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Aug;22(8):1531-1532. PMCID: PMC5364725
323. Saber W, Zhang MJ, Steinert P, Chen M, **Horowitz MM**. The Impact of Palifermin Use on Hematopoietic Cell Transplant Outcomes in Children. Biol Blood Marrow Transplant. 2016 Aug;22(8):1460-1466. PMCID: PMC4949099
324. Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE Jr, Thompson J, **Horowitz MM**, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder R. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. Blood. 2016 Aug 25;128(8):1050-8. PMCID: PMC5000843
325. Lazaryan A, Wang T, Spellman SR, Wang HL, Pidala J, Nishihori T, Askar M, Olsson R, Oudshoorn M, Abdel-Azim H, Yong A, Gandhi M, Dandoy C, Savani B, Hale G, Page K, Bitan M, Reshef R, Drobyski W, Marsh SG, Schultz K, Müller CR, Fernandez-Viña MA, Verneris MR, **Horowitz MM**, Arora M, Weisdorf DJ, Lee SJ. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. Haematologica. 2016 Oct;101(10):1267-1274. PMCID: PMC5046657
326. Steering Committee Of The Blood And Marrow Transplant Clinical Trials Network. The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Oct;22(10):1747-1757. PMCID: PMC5027144
327. Wood WA, McGinn MK, Wilson D, Deal AM, Khera N, Shea TC, Devine SM, Appelbaum FR, **Horowitz MM**, Lee SJ. Practice Patterns and Preferences Among Hematopoietic Cell Transplantation Clinicians. Biol Blood Marrow Transplant. 2016 Nov;22(11):2092-2099. PMCID: PMC5067220
328. Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller EK, Maziarz RT, Wu J, Shaw BE, Confer D, **Horowitz MM**, Anasetti C. Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. JAMA Oncol. 2016 Dec 01;2(12):1583-1589. PMCID: PMC5145732
329. Epperla N, Pasquini M, Pierce K, Drobyski WR, Rizzo JD, **Horowitz MM**, Saber W, Zellner K, Ramirez S, Bartz K, Raj RV, Hari PN, Hamadani M. Salvage haploidentical hematopoietic cell transplantation for graft rejection following a prior haploidentical allograft. Bone Marrow Transplant. 2017 Jan;52(1):147-150.
330. Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, Confer DL, **Horowitz MM**, King RJ, Shaw BE, van Walraven SM, Wiener L, Packman W, Varni JW, Pulsipher MA. Health-Related Quality of Life among Pediatric Hematopoietic Stem Cell Donors. J Pediatr. 2016 Nov;178:164-170.e1. PMCID: PMC5085860
331. O'Donnell PV, Eapen M, **Horowitz MM**, Logan BR, DiGilio A, Brunstein C, Fuchs EJ, Flowers ME, Salit R, Raj K, Pagliuca A, Bradstock K, Granata A, Castagna L, Furst S, Blaise D. Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. Bone Marrow Transplant. 2016 Dec;51(12):1599-1601. PMCID: PMC5143194
332. Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA, Jim HSL, Wingard JR, **Horowitz MM**, Abidi MH, Fei M, Rawls L, Rizzo JD. Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. Biol Blood Marrow Transplant. 2016 Dec;22(12):2256-2263. PMCID: PMC5116244
333. Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, Brochstein J, Chaudhury S, Godder K, Haight AE, Kasow KA, Leung K, Andreansky M, Bhatia M, Dalal J, Haines H, Jaroscak J, Lazarus HM, Levine JE, Krishnamurti L, Margolis D, Megason GC, Yu LC, Pulsipher MA, Gersten I, DiFronzo N, **Horowitz MM**, Walters MC, Kamani N. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016 Nov 24;128(21):2561-2567. PMCID: PMC5123194

334. Switzer GE, Bruce J, Kiefer DM, Kobusingye H, Drexler R, Besser RM, Confer DL, **Horowitz MM**, King RJ, Shaw BE, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, Litzow MR, Pulsipher MA. Health-Related Quality of Life among Older Related Hematopoietic Stem Cell Donors (>60 Years) Is Equivalent to That of Younger Related Donors (18 to 60 Years): A Related Donor Safety Study. Biol Blood Marrow Transplant. 2017 Jan;23(1):165-171. PMCID: PMC5182103
335. Saber W, **Horowitz MM**. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens. Hematology Am Soc Hematol Educ Program. 2016 Dec 02;2016(1):478-484. PMCID: PMC6142436
336. Weisdorf DJ, Millard HR, **Horowitz MM**, Hyare PS, Champlin R, Ho V, Mielcarek M, Rezvani A, Stockerl-Goldstein K, Khoury HJ, De Lima M, Saber W, Sandmaier B, Zhang MJ, Eapen M. Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. Cancer. 2017 Jun 01;123(11):2025-2034. PMCID: PMC5445001
337. Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, **Horowitz MM**, Deeg HJ, Horwitz ME. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017 Apr 10;35(11):1154-1161. PMCID: PMC5455603
338. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, Fenske TS, Cumpston A, Bunner P, Craig M, **Horowitz MM**, Hamadani M. Recipient Immune Modulation with Atorvastatin for Acute Graft-versus-Host Disease Prophylaxis after Allogeneic Transplantation. Biol Blood Marrow Transplant. 2017 Aug;23(8):1295-1302.
339. Hojima Y, Tanaka M, Moriya H, Moriwaki C. [Kinin-inactivating enzymes from plants. 1. Partial purification of bradykinin-inactivating enzyme from potatoes]. Arerugi. 1971 Oct;20(10):755-62.
340. Lee SJ, Logan B, Westervelt P, Cutler C, Woolfrey A, Khan SP, Waller EK, Maziarz RT, Wu J, Shaw BE, Confer D, **Horowitz MM**, Anasetti C. Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. JAMA Oncol. 2016 Dec 01;2(12):1583-1589. PMCID: PMC5145732
341. Shenoy S, Eapen M, Panepinto JA, Logan BR, Wu J, Abraham A, Brochstein J, Chaudhury S, Godder K, Haight AE, Kasow KA, Leung K, Andreansky M, Bhatia M, Dalal J, Haines H, Jaroscak J, Lazarus HM, Levine JE, Krishnamurti L, Margolis D, Megason GC, Yu LC, Pulsipher MA, Gersten I, DiFronzo N, **Horowitz MM**, Walters MC, Kamani N. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016 Nov 24;128(21):2561-2567. PMCID: PMC5123194
342. Steering Committee Of The Blood And Marrow Transplant Clinical Trials Network. The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Oct;22(10):1747-1757. PMCID: PMC5027144
343. Knight JM, Syrjala KL, Majhail NS, Martens M, Le-Rademacher J, Logan BR, Lee SJ, Jacobsen PB, Wood WA, Jim HSL, Wingard JR, **Horowitz MM**, Abidi MH, Fei M, Rawls L, Rizzo JD. Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. Biol Blood Marrow Transplant. 2016 Dec;22(12):2256-2263. PMCID: PMC5116244
344. O'Donnell PV, Eapen M, **Horowitz MM**, Logan BR, DiGilio A, Brunstein C, Fuchs EJ, Flowers ME, Salit R, Raj K, Pagliuca A, Bradstock K, Granata A, Castagna L, Furst S, Blaise D. Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. Bone Marrow Transplant. 2016 Dec;51(12):1599-1601. PMCID: PMC5143194
345. Eapen M, Wang T, Veys PA, Boelens JJ, St Martin A, Spellman S, Bonfim CS, Brady C, Cant AJ, Dalle JH, Davies SM, Freeman J, Hsu KC, Fleischhauer K, Kenzey C, Kurtzberg J, Michel G, Orchard PJ, Paviglianiti A, Rocha V, Veneris MR, Volt F, Wynn R, Lee SJ, **Horowitz MM**, Gluckman E, Ruggeri A. Allele-level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analysis. Lancet Haematol. 2017 Jul;4(7):e325-e333. PMCID: PMC5699478
346. Eapen M, Kurtzberg J, Zhang MJ, Hattersely G, Fei M, Mendizabal A, Chan KW, De Oliveira S, Schultz KR, Wall D, **Horowitz MM**, Wagner JE. Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. Biol Blood Marrow

Transplant. 2017 Oct;23(10):1714-1721. PMCID: PMC5605440
347. Switzer GE, Bruce J, Pastorek G, Kiefer DM, Kobusingye H, Drexler R, Besser RAM, Confer DL, **Horowitz MM**, King RJ, Shaw BE, van Walraven SM, Wiener L, Packman W, Varni JW, Pulsipher MA. Parent versus child donor perceptions of the bone marrow donation experience. Bone Marrow Transplant. 2017 Sep;52(9):1338-1341. PMCID: PMC5933883
348. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, **Horowitz MM**, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep;4(9):e431-e442. PMCID: PMC5718627
349. Shaw BE, Brazauskas R, Millard HR, Fonstad R, Flynn KE, Abernethy A, Vogel J, Petroske C, Mattila D, Drexler R, Lee SJ, **Horowitz MM**, Rizzo JD. Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. Cancer. 2017 Dec 01;123(23):4687-4700. PMCID: PMC5693638
350. Hamadani M, **Horowitz MM**. Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All? J Oncol Pract. 2017 Dec;13(12):798-806. PMCID: PMC5728364
351. Kebriaei P, Anasetti C, Zhang MJ, Wang HL, Aldoss I, de Lima M, Khoury HJ, Sandmaier BM, **Horowitz MM**, Artz A, Bejanyan N, Ciurea S, Lazarus HM, Gale RP, Litzow M, Bredeson C, Seftel MD, Pulsipher MA, Boelens JJ, Alvarnas J, Champlin R, Forman S, Pullarkat V, Weisdorf D, Marks DI, Acute Leukemia Committee of the CIBMTR. Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2018 Apr;24(4):726-733. PMCID: PMC5902420
352. Qayed M, Wang T, Hemmer MT, Spellman S, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Aljurf M, Ayas M, Bitan M, Cairo M, Choi SW, Dandoy C, Delgado D, Gale RP, Hale G, Frangoul H, Kamble RT, Kharfan-Dabaja M, Lehman L, Levine J, MacMillan M, Marks DI, Nishihori T, Olsson RF, Hematti P, Ringden O, Saad A, Satwani P, Savani BN, Schultz KR, Seo S, Shenoy S, Waller EK, Yu L, **Horowitz MM**, Horan J. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant. 2018 Mar;24(3):521-528. PMCID: PMC5826854
353. Shaw BE, Syrjala KL, Onstad LE, Chow EJ, Flowers ME, Jim H, Baker KS, Buckley S, Fairclough DL, **Horowitz MM**, Lee SJ. PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer. 2018 Feb 15;124(4):841-849. PMCID: PMC5800994
354. Pasquini MC, Logan B, Jones RJ, Alousi AM, Appelbaum FR, Bolaños-Meade J, Flowers MED, Giralt S, **Horowitz MM**, Jacobsohn D, Koreth J, Levine JE, Luznik L, Maziarz R, Mendizabal A, Pavletic S, Perales MA, Porter D, Reshef R, Weisdorf D, Antin JH. Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials. Biol Blood Marrow Transplant. 2018 Jun;24(6):1274-1280. PMCID: PMC5993573
355. Shaw BE, Logan BR, Spellman SR, Marsh SGE, Robinson J, Pidala J, Hurley C, Barker J, Maiers M, Dehn J, Wang H, Haagenson M, Porter D, Petersdorf EW, Woolfrey A, **Horowitz MM**, Verneris M, Hsu KC, Fleischhauer K, Lee SJ. Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters Most. Biol Blood Marrow Transplant. 2018 May;24(5):1049-1056. PMCID: PMC5953795
356. Burns LJ, Abbetti B, Arnold SD, Bender J, Doughtie S, El-Jawahiri A, Gee G, Hahn T, **Horowitz MM**, Johnson S, Juckett M, Krishnamurit L, Kullberg S, LeMaistre CF, Loren A, Majhail NS, Murphy EA, Rizzo D, Roche-Green A, Saber W, Schatz BA, Schmit-Pokorny K, Shaw BE, Syrjala KL, Tierney DK, Ullrich C, Vanness DJ, Wood WA, Denzen EM. Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018 Jun;24(6):1111-1118. PMCID: PMC5993588
357. Turcotte LM, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Ahmed I, Beitinjaneh A, Buchbinder D, Byrne M, Callander N, Chao N, Choi SW, DeFilipp Z, Gadalla SM, Gale RP, Gergis U, Hashmi S, Hematti P, Holmberg L, Inamoto Y, Kamble RT, Lehmann L, MacMillan MA, McIver Z, Nishihori T, Norkin M, O'Brien T, Olsson RF, Reshef R, Saad

A, Savani BN, Schouten HC, Seo S, Solh M, Verdonck L, Vij R, Wirk B, Yared J, **Horowitz MM**, Knight JM, Verneris MR. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplant. 2018 Jul;53(7):932-937. PMCID: PMC6041147

358. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, **Horowitz MM**, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. Haematologica. 2018 Apr;103(4):717-727. PMCID: PMC5865423
359. Stiff PJ, Montesinos P, Peled T, Landau E, Goudsmid NR, Mandel J, Hasson N, Olesinski E, Glukhman E, Snyder DA, Cohen EG, Kidron OS, Bracha D, Harati D, Ben-Abu K, Freind E, Freedman LS, Cohen YC, Olmer L, Barishev R, Rocha V, Gluckman E, **Horowitz MM**, Eapen M, Nagler A, Sanz G. Cohort-Controlled Comparison of Umbilical Cord Blood Transplantation Using Carlecortemcel-L, a Single Progenitor-Enriched Cord Blood, to Double Cord Blood Unit Transplantation. Biol Blood Marrow Transplant. 2018 Jul;24(7):1463-1470. PMCID: PMC6045964
360. Atallah E, Schiffer CA, Weinfurt KP, Zhang MJ, Radich JP, Oehler VG, Pinilla-Ibarz J, Deininger MWN, Lin L, Larson RA, Mauro MJ, Moore JO, Ritchie EK, Shah NP, Silver RT, Wadleigh M, Cortes J, Thompson J, Guhl J, **Horowitz MM**, Flynn KE. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC Cancer. 2018 Apr 02;18(1):359. PMCID: PMC5879565
361. Spellecy R, Tarima S, Denzen E, Moore H, Abhyankar S, Dawson P, Foley A, Gersten I, Horwitz M, Idossa L, Joffe S, Kamani N, King R, Lazaryan A, Morris L, **Horowitz MM**, Majhail NS. Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. Biol Blood Marrow Transplant. 2018 Oct;24(10):2145-2151. PMCID: PMC6193865
362. Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, **Horowitz MM**, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD. Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. BMC Cancer. 2018 May 24;18(1):593. PMCID: PMC5968588
363. Carpenter PA, Logan BR, Lee SJ, Weisdorf DJ, Johnston L, Costa LJ, Kitko CL, Bolaños-Meade J, Sarantopoulos S, Alousi AM, Abhyankar S, Waller EK, Mendizabal A, Zhu J, O'Brien KA, Lazaryan A, Wu J, Nemecek ER, Pavletic SZ, Cutler CS, **Horowitz MM**, Arora M, BMT CTN.. A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. Haematologica. 2018 Nov;103(11):1915-1924. PMCID: PMC6278959
364. Strouse C, Zhang Y, Zhang MJ, DiGilio A, Pasquini M, **Horowitz MM**, Lee S, Ho V, Ramanathan M, Chinratanalab W, Loren A, Burns LJ, Artz A, Villa KF, Saber W. Risk Score for the Development of Veno-Occlusive Disease after Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transplant. 2018 Oct;24(10):2072-2080. PMCID: PMC6239945
365. Petersdorf EW, Stevenson P, Malkki M, Strong RK, Spellman SR, Haagenson MD, **Horowitz MM**, Gooley T, Wang T. Patient HLA Germline Variation and Transplant Survivorship. J Clin Oncol. 2018 Aug 20;36(24):2524-2531. PMCID: PMC6097831
366. Bhatt NS, Brazauskas R, Tecca HR, Vogel J, Mattila D, Lee SJ, **Horowitz MM**, Rizzo JD, Shaw BE. Female Sex is Associated With Poor Health-related Quality of Life in Children at 12 Months Post-Hematopoietic Cell Transplantation. J Pediatr Hematol Oncol. 2019 Apr;41(3):233-237. PMCID: PMC6301126
367. Khera N, Mau LW, Denzen EM, Meyer C, Houg K, Lee SJ, **Horowitz MM**, Burns LJ. Translation of Clinical Research into Practice: An Impact Assessment of the Results from the Blood and Marrow Transplant Clinical Trials Network Protocol 0201 on Unrelated Graft Source Utilization. Biol Blood Marrow Transplant. 2018 Nov;24(11):2204-2210. PMCID: PMC6242749
368. Pulsipher MA, Logan BR, Chitphakdithai P, Kiefer DM, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Bunin NJ, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR,

Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, **Horowitz MM**, Switzer GE, Shaw BE, Confer DL. Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. Biol Blood Marrow Transplant. 2019 Apr;25(4):699-711. PMCID: PMC6453753

369. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman OF, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Akard LP, Artz AS, Ball ED, Bayer RL, Bigelow C, Bolwell BJ, Broun ER, Delgado DC, Duckworth K, Dvorak CC, Hahn TE, Haight AE, Hari PN, Hayes-Lattin BM, Jacobsohn DA, Jakubowski AA, Kasow KA, Lazarus HM, Liesveld JL, Linenberger M, Litzow MR, Longo W, Magalhaes-Silverman M, McCarty JM, McGuirk JP, Mori S, Parameswaran V, Prasad VK, Rowley SD, Rybka WB, Sahdev I, Schriber JR, Selby GB, Shaughnessy PJ, Shenoy S, Spitzer T, Tse WT, Uberti JP, Vusirikala M, Waller EK, Weisdorf DJ, Yanik GA, Navarro WH, **Horowitz MM**, Switzer GE, Confer DL, Shaw BE. Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors. Haematologica. 2019 Apr;104(4):844-854. PMCID: PMC6442962
370. Jones RJ, **Horowitz MM**. Should an HLA-matched donor still be considered the perfect donor? Lancet Haematol. 2018 Sep;5(9):e388-e390.
371. Eapen M, Brazauskas R, Hemmer M, Perez WS, Steinert P, **Horowitz MM**, Deeg HJ. Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity. Blood Adv. 2018 Aug 28;2(16):2095-2103. PMCID: PMC6113615
372. Stadtmauer EA, Pasquini MC, Blackwell B, Hari P, Bashey A, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, **Horowitz MM**, Koreth J, Knust K, Landau H, Brunstein C, McCarthy P, Nelson C, Qazilbash MH, Shah N, Vesole DH, Vij R, Vogl DT, Giralt S, Somlo G, Krishnan A. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial. J Clin Oncol. 2019 Mar 01;37(7):589-597. PMCID: PMC6553842
373. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Ball ED, Bolwell BJ, Bunin NJ, Cheerva A, Delgado DC, Dvorak CC, Gillio AP, Hahn TE, Hale GA, Haight AE, Hayes-Lattin BM, Kasow KA, Linenberger M, Magalhaes-Silverman M, Mori S, Prasad VK, Quigg TC, Sahdev I, Schriber JR, Shenoy S, Tse WT, Yanik GA, Navarro WH, **Horowitz MM**, Confer DL, Shaw BE, Switzer GE. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. Biol Blood Marrow Transplant. 2019 May;25(5):955-964. PMCID: PMC6511296
374. Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, Alousi AM, Antin JH, Arai S, Bickett K, Chen YB, Damon LE, Efebera YA, Geller NL, Giralt SA, Hari P, Holtan SG, **Horowitz MM**, Jacobsohn DA, Jones RJ, Liesveld JL, Logan BR, MacMillan ML, Mielcarek M, Noel P, Pidala J, Porter DL, Pusic I, Sobecks R, Solomon SR, Weisdorf DJ, Wu J, Pasquini MC, Koreth J. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019 Mar;6(3):e132-e143. PMCID: PMC6503965
375. Atallah E, Logan B, Chen M, Cutler C, Deeg J, Jacoby M, Champlin R, Nishihori T, Confer D, Gajewski J, Farnia S, Greenberg P, Warlick E, Weisdorf D, Saber W, **Horowitz MM**, Rizzo JD. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study. JAMA Oncol. 2020 Apr 01;6(4):486-493. PMCID: PMC6990739
376. Pidala J, Hamadani M, Dawson P, Martens M, Alousi AM, Jagasia M, Efebera YA, Chhabra S, Pusic I, Holtan SG, Ferrara JLM, Levine JE, Mielcarek M, Anasetti C, Antin JH, Bolaños-Meade J, Howard A, Logan BR, Leifer ES, Pritchard TS, **Horowitz MM**, MacMillan ML. Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood. 2020 Jan 09;135(2):97-107. PMCID: PMC6952830
377. Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, **Horowitz MM**, Weisdorf D, Aljurf M. Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant. 2020 Apr;55(4):837.

378. Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, **Horowitz MM**, Weisdorf D, Aljurf M. Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant. 2020 Apr;55(4):698-707.
379. Ambinder RF, Wu J, Logan B, Durand CM, Shields R, Popat UR, Little RF, McMahon DK, Cyktor J, Mellors JW, Ayala E, Kaplan LD, Noy A, Jones RJ, Howard A, Forman SJ, Porter D, Arce-Lara C, Shaughnessy P, Sproat L, Hashmi SK, Mendizabal AM, **Horowitz MM**, Navarro WH, Alvarnas JC. Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial. Biol Blood Marrow Transplant. 2019 Nov;25(11):2160-2166. PMCID: PMC6907401
380. Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, **Horowitz MM**, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. Blood Adv. 2019 Mar 26;3(6):875-883. PMCID: PMC6436017
381. Levis MJ, Chen YB, Hamadani M, **Horowitz MM**, Jones RJ, Blood and Marrow Transplant Clinical Trials Network. FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? J Clin Oncol. 2019 Jul 01;37(19):1604-1607. PMCID: PMC6804888
382. Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas MF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y, Hildegard G, Szer J, **Horowitz MM**, Niederwieser D. Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. Biol Blood Marrow Transplant. 2019 Dec;25(12):2330-2337.
383. Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, **Horowitz MM**, Cole SW. Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. Blood Adv. 2020 Feb 11;4(3):467-476. PMCID: PMC7013267
384. Koenig K, Mims A, Levis MJ, **Horowitz MM**. The Changing Landscape of Treatment in Acute Myeloid Leukemia. Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-12.
385. Eapen M, Zhang MJ, Tang XY, Lee SJ, Fei MW, Wang HL, Hebert KM, Arora M, Chhabra S, Devine SM, Hamadani M, D'Souza A, Pasquini MC, Phelan R, Rizzo JD, Saber W, Shaw BE, Weisdorf DJ, **Horowitz MM**. Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2020 Jul;26(7):e161-e166. PMCID: PMC7206419
386. Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, Shaw BE, Weisdorf D, Devine SM, **Horowitz MM**. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant. 2020 Jul;26(7):1312-1317. PMCID: PMC7194895
387. Frigault MJ, Nikiforow S, Mansour MK, Hu ZH, **Horowitz MM**, Riches ML, Hematti P, Turtle CJ, Zhang MJ, Perales MA, Pasquini MC. Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19? Blood. 2020 Jul 02;136(1):137-139. PMCID: PMC7332891
388. Petersdorf EW, Stevenson P, Bengtsson M, De Santis D, Dubois V, Gooley T, **Horowitz M**, Hsu K, Madrigal JA, Malkki M, McKallor C, Morishima Y, Oudshoorn M, Spellman SR, Villard J, Carrington M. HLA-B leader and survivorship after HLA-mismatched unrelated donor transplantation. Blood. 2020 Jul 16;136(3):362-369. PMCID: PMC7365916
389. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, **Horowitz MM**. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant. 2020 Aug;26(8):e177-e182. PMCID: PMC7404814
390. Fuchs EJ, O'Donnell PV, Eapen M, Logan BR, Antin JH, Dawson P, Devine SM, **Horowitz MM**, Horwitz ME, Karanes C, Leifer E, Magenau JM, McGuirk JP, Morris LE, Rezvani AR, Jones RJ, Brunstein

CG. Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101). Blood. 2020 Aug 31.

391. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, **Horowitz MM**, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Oct;26(10):1876-1885. PMCID: PMC7571859
392. Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, **Horowitz MM**, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 2020 Nov 10;4(21):5414-5424. PMCID: PMC7656920
393. Algwaiz G, Aljurf M, Koh M, **Horowitz MM**, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, Perales MA, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR, Kharfan-Dabaja MA, Hamadani M, Majhail NS, Waghmare AA, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi SK, WBMT and the CIBMTR Health Services and International Studies Committee. Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020 Dec;26(12):2181-2189. PMCID: PMC7380217
394. Switzer GE, Bruce JG, Kiefer DM, Kobusingye H, Abebe KZ, Drexler R, Besser RM, Confer DL, **Horowitz MM**, King RJ, Shaw BE, Riches M, Hayes-Lattin B, Linenberger M, Bolwell B, Rowley SD, Litzow MR, Pulsipher MA. Health-Related Quality-of-Life Comparison of Adult Related and Unrelated HSC Donors: An RDSafe Study. Biol Blood Marrow Transplant. 2020 Dec;26(12):2365-2371. PMCID: PMC7686016
395. Fuchs EJ, O'Donnell PV, Eapen M, Logan B, Antin JH, Dawson P, Devine S, **Horowitz MM**, Horwitz ME, Karanes C, Leifer E, Magenau JM, McGuirk JP, Morris LE, Rezvani AR, Jones RJ, Brunstein CG. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. Blood. 2021 Jan 21;137(3):420-428. PMCID: PMC7819761
396. Farhadfar N, Burns LJ, Mupfudze T, Shaw BE, Bollard CM, Devine SM, **Horowitz MM**, Jones RJ, Murthy HS, Wingard JR, Lee SJ. Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. Transplant Cell Ther. 2021 Feb;27(2):183.e1-183.e7. PMCID: PMC7546661
397. Devine SM, **Horowitz MM**. Building a Fit for Purpose Clinical Trials Infrastructure to Accelerate the Assessment of Novel Hematopoietic Cell Transplantation Strategies and Cellular Immunotherapies. J Clin Oncol. 2021 Feb 10;39(5):534-544. PMCID: PMC8443822
398. Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, **Horowitz MM**, Deeg HJ, Horwitz ME. Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transplant Cell Ther. 2021 Jun;27(6):483.e1-483.e6. PMCID: PMC8217373
399. El Fakih R, Greinix H, Koh M, Shaw B, Mohty M, Al Nahedh M, Saber W, Kharfan-Dabaja MA, Perales MA, Savani BN, Majhail NS, Passweg JR, Sureda A, Ahmed SO, Gluckman E, Riches M, El-Jawahri A, Rondelli D, Srivastava A, Faulkner L, Atsuta Y, Ballen KK, Rasheed W, Okamoto S, Seber A, Chao N, Kröger N, Kodera Y, Szer J, Hashmi SK, **Horowitz MM**, Weisdorf D, Niederwieser D, Aljurf M. Worldwide Network for Blood and Marrow Transplantation (WBMT) Recommendations Regarding Essential Medications Required To Establish An Early Stage Hematopoietic Cell Transplantation Program. Transplant Cell Ther. 2021 Mar;27(3):267.e1-267.e5.
400. Hsu JW, Farhadfar N, Murthy H, Logan BR, Bo-Subait S, Frey N, Goldstein SC, **Horowitz MM**, Lazarus H, Schwanke JD, Shah NN, Spellman SR, Switzer GE, Devine SM, Shaw BE, Wingard JR. The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. Transplant Cell Ther. 2021 Jun;27(6):507-516. PMCID: PMC8217124
401. Seftel MD, Chitphakdithai P, Miller JP, Kobusingye H, Logan BR, Linenberger M, Artz AS, Haight AE,

Jacobsohn DA, Litzow MR, Magalhaes-Silverman M, Selby GB, Vusirikala M, **Horowitz MM**, Switzer GE, Confer DL, Shaw BE, Pulsipher MA. Serious Adverse Events in Related Donors: A Report from the Related Donor Safe Study. Transplant Cell Ther. 2021 Apr;27(4):352.e1-352.e5. PMCID: PMC8036235

402. Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, **Horowitz MM**, Bolaños-Meade J. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021 Jun 20;39(18):1971-1982. PMCID: PMC8260905
403. Heslop HE, Stadtmauer EA, Levine JE, Ballen KK, Chen YB, DeZern AE, Eapen M, Hamadani M, Hamilton BK, Hari P, Jones RJ, Logan BR, Kean LS, Leifer ES, Locke FL, Maziarz RT, Nemecek ER, Pasquini M, Phelan R, Riches ML, Shaw BE, Walters MC, Foley A, Devine SM, **Horowitz MM**. Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th Year. Transplant Cell Ther. 2021 Nov;27(11):885-907. PMCID: PMC8556300
404. Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh AA, Hashmi S, Ho A, **Horowitz MM**, Iida M, Jaimovich G, Karduss A, Kodera Y, Kröger N, Péffault de Latour R, Lee JW, Martínez-Rolón J, Pasquini MC, Passweg J, Paulson K, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Koh MBC, Aljurf M, Greinix H, Atsuta Y, Saber W. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. Haematologica. 2022 May 01;107(5):1045-1053. PMCID: PMC9052915
405. Warlick ED, Ustun C, Andreescu A, Bonagura AF, Brunner A, Chandra AB, Foran JM, Juckett MB, Kindwall-Keller TL, Klimek VM, Pease DF, Steensma DP, Waldman BM, **Horowitz MM**, Burns LJ, Khera N. Blood and Marrow Transplant Clinical Trials Network Study 1102 heralds a new era in hematopoietic cell transplantation in high-risk myelodysplastic syndromes: Challenges and opportunities in implementation. Cancer. 2021 Dec 01;127(23):4339-4347. PMCID: PMC8578257
406. Wingard JR, Alexander BD, Baden LR, Chen M, Sugrue MW, Leather HL, Caliendo AM, Clancy CJ, Denning DW, Marty FM, Nguyen MH, Wheat LJ, Logan BR, **Horowitz MM**, Marr KA. Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials? Open Forum Infect Dis. 2021 Oct;8(10):ofab441. PMCID: PMC8496761
407. Cusatis R, Flynn KE, Vasu S, Pidala J, Muffly L, Uberti J, Tamari R, Mattila D, Mussetter A, Bruzauskas R, Chen M, Leckrone E, Myers J, Mau LW, Rizzo JD, Saber W, **Horowitz M**, Lee SJ, Burns LJ, Shaw B. Adding Centralized Electronic Patient-Reported Outcome Data Collection to an Established International Clinical Outcomes Registry. Transplant Cell Ther. 2022 Feb;28(2):112.e1-112.e9. PMCID: PMC8915447
408. Mary Eapen, Joanne Kurtzberg, Mei-Jie Zhang, Gareth Hattersely, Mingwei Fei, Adam Mendizabal, Ka Wah Chan, Satiro De Oliveira, Kirk R Schultz, Donna Wall, Mary M Horowitz, John E Wagner . Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes Biol Blood Marrow Transplant. Eapen M, Kurtzberg J, Zhang MJ, Hattersely G, Fei M, Mendizabal A, Chan KW, De Oliveira S, Schultz KR, Wall D, **Horowitz MM**, Wagner JE. Umbilical Cord Blood Transplantation in Child.
409. Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, **Horowitz M**, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells Leukemia. January 2022;36(1):155-164.
410. Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, Geller N, Giralt S, Heslop HE, **Horowitz MM**, Jones RJ, Litzow MR, Mendizabal A, Muffly L, Nemecek ER, O'Donnell L, O'Reilly RJ, Palencia R, Schetelig J, Shune L, Solomon SR, Vasu S, Ho VT, Perales MA. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 Feb 01;40(4):356-368. PMCID: PMC8797487
411. O'Donnell PV, Brunstein CG, Fuchs EJ, Zhang MJ, Allbee-Johnson M, Antin JH, Leifer ES, Elmariah H, Grunwald MR, Hashmi H, **Horowitz MM**, Magenau JM, Majhail N, Milano F, Morris LE, Rezvani

AR, McGuirk JP, Jones RJ, Eapen M. Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. Transplant Cell Ther. 2022 Feb;28(2):109.e1-109.e8. PMCID: PMC8882346

412. Saber W, Steinert P, Zhang MJ, Chen M, Pope A, Keating A, Wingard JR, Ballen K, Stiff P, Perales MA, Forman S, Champlin R, Langston A, Rudebeck M, **Horowitz M**. A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. Transplant Cell Ther. 2021 Oct;27(10):837.e1-837.e10. PMCID: PMC8606163
413. Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, **Horowitz M**, Cutler C. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol. 2021 Oct 20;39(30):3328-3339. PMCID: PMC8791814
414. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, **Horowitz MM**. Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182] (Transplantation and Cellular Therapy (2020) 26/8(e177-e182) (S1083879120302251), (10.1016/j.bbmt.2020.04.013)) Transplantation and Cellular Therapy. 2021.
415. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, **Horowitz MM**, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation (2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005)) Transplantation and Cellular Therapy. 2021.
416. Atallah E, Schiffer CA, Radich JP, Weinfurt KP, Zhang MJ, Pinilla-Ibarz J, Kota V, Larson RA, Moore JO, Mauro MJ, Deininger MWN, Thompson JE, Oehler VG, Wadleigh M, Shah NP, Ritchie EK, Silver RT, Cortes J, Lin L, Visotcky A, Baim A, Harrell J, Helton B, **Horowitz M**, Flynn KE. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan 01;7(1):42-50. PMCID: PMC7662490
417. Annapragada A, Sikora A, Bollard C, Conejo-Garcia J, Cruz CR, Demehri S, Demetriou M, Demirdjian L, Fong L, **Horowitz M**, Hutson A, Kadash-Edmondson K, Kufe D, Lipkin S, Liu S, McCarthy C, Morgan M, Morris Z, Pan Y, Pasquini M, Schoenberger S, Van Allen E, Vilar E, Xing Y, Zha W, IOTN Consortium, Odunsi A. Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer. J Immunother Cancer. 2020 Jun;8(1). PMCID: PMC7304845
418. Petersdorf EW, Bengtsson M, De Santis D, Dubois V, Fleischhauer K, Gooley T, **Horowitz M**, Madrigal JA, Malkki M, McKallor C, Morishima Y, Oudshoorn M, Spellman SR, Villard J, Stevenson P, Carrington M, the, International Histocompatibility Working Group in Hematopoietic-Cell Transplantation. Role of HLA-DP Expression in Graft-Versus-Host Disease After Unrelated Donor Transplantation. J Clin Oncol. 2020 Aug 20;38(24):2712-2718. PMCID: PMC7430213
419. Petersdorf EW, Carrington M, O'hUigin C, Bengtsson M, De Santis D, Dubois V, Gooley T, **Horowitz M**, Hsu K, Madrigal JA, Maiers MJ, Malkki M, McKallor C, Morishima Y, Oudshoorn M, Spellman SR, Villard J, Stevenson P, International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematol. 2020 Jan;7(1):e50-e60. PMCID: PMC6948919
420. Muhsen IN, Hashmi SK, Niederwieser D, Kroeger N, Agrawal S, Pasquini MC, Atsuta Y, Ballen KK, Seber A, Saber W, Kharfan-Dabaja MA, Rasheed W, Okamoto S, Khera N, Wood WA, Koh MBC, Greinix H, Kodera Y, Szer J, **Horowitz MM**, Weisdorf D, Aljurf M. Correction: Worldwide Network for Blood and Marrow Transplantation (WBMT) perspective: the role of biosimilars in hematopoietic cell transplant: current opportunities and challenges in low- and lower-middle income countries. Bone Marrow Transplant. 2020 Apr;55(4):837.
421. Barrett AJ, Lucarelli G, Gale RP, Sobocinski A, **Horowitz M**, Bortin MM. Bone marrow transplantation for

thalassaemia--a preliminary report from the International Bone Marrow Transplant Registry. Prog Clin Biol Res. 1989;309:173-85.
422. . Report from the International Bone Marrow Transplant Registry. Advisory Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1989 May;4(3):221-8.
423. Gale RP, Butturini A, **Horowitz M**. What is the best strategy for autotransplants in cancer? Bone Marrow Transplant. 1992 May;9(5):303.
424. Mahon FX, Sadoun A, Benz-Lemoine E, Roblot-Casenave F, Guilhot F, Tanzer J. Possible prevention of Pneumocystis carinii pneumonia by pentamidine aerosol after bone marrow transplantation. Bone Marrow Transplant. 1991 Jul;8(1):64-5.
425. Ringdén O, **Horowitz MM**, Bortin MM. In Reply JAMA: The Journal of the American Medical Association. 1 December 1993;270(21):2560.
426. Dabrowska DM, Sun GW, **Horowitz MM**. Cox regression in a markov renewal model: An application to the analysis of bone marrow transplant data Journal of the American Statistical Association. September 1994;89(427):867-877.
427. Cook-Craig A, Owen A, Reeder G, Drobyski W, **Horowitz M**, Brunner J, Flomenberg N, Keever C. Component processing and intraoperative autotransfusion during bone marrow harvest. Prog Clin Biol Res. 1994;389:613-9.
428. Litzow MR, Tefferi A. Bone marrow transplantation for chronic myelogenous leukemia. Blood. 1994 May 01;83(9):2752-3.
429. **Horowitz MM**. Stat bite: Autologous bone marrow transplates for cancer, 1989–1993 Journal of the National Cancer Institute. 20 July 1994;86(14):1045.
430. Gale RP, Butturini A, **Horowitz MM**. HLA-identical sibling bone marrow transplants for acute lymphoblastic leukemia Bone Marrow Transplantation. 1995;15(SUPPL. 1).
431. Baxter-Lowe LA, Keever C, Dinauer D, Daniels T, Johnson K, Camitta B, Drobyski W, Garbrecht F, **Horowitz M**, Pietryga D. Use of solid phase automated sequencing to define HLA disparity between bone marrow donors and recipients. Transplant Proc. 1995 Feb;27(1):1377-8.
432. Shaw PJ. Bone-marrow transplantation for leukaemia. Lancet. 1995 May 13;345(8959):1235-6.
433. Casper J, Camitta B, Truitt R, Baxter-Lowe LA, Bunin N, Lawton C, Murray K, Hunter J, Pietryga D, Garbrecht F. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. Blood. 1995 May 01;85(9):2354-63.
434. Filipovich AH, Sobocinski K, Pelz C, Ireland M, Kollman C, **Horowitz MM**. Long-term outcome of allogeneic bone marrow transplantation (BMT) for wiskott aldr1ch syndrome (WAS) Experimental Hematology. 1996;24(9):1143.
435. Barlogie B, Anderson K, Berenson J, Crowley J, Cunningham D, Gertz M, Henon P, **Horowitz M**, Jagannath S, Powles R, Reece D, Reiffers J, Salmon S, Tricot G, Vesole D. Transplants for multiple myeloma Bone Marrow Transplantation. 1995;15(SUPPL. 1).
436. Heimpel H, Allan NC, Baccarani M, Guilhot F, Hehlmann R, **Horowitz M**, Kluin-Nelemans J, Schaefer U, Storb R, Thaler J. Current controversies on the role of interferon-alpha for therapy of chronic myeloid leukemia. Bone Marrow Transplant. 1996 May;17 Suppl 3:S39.
437. **Horowitz MM**, Giralt R Szvdlo S, Goldman J, Veum-Slone J. Effect of prior interferon therapy on outcome of hla-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in first chronic phase Experimental Hematology. 1996;24(9):1143.
438. Kawanishi Y, Passweg J, Drobyski WR, Rowlings P, Cook-Craig A, Casper J, Pietryga D, Garbrecht F, Camitta B, **Horowitz M**, Juckett M, Margolis D, Flomenberg N, Keever-Taylor CA. Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. Bone Marrow Transplant. 1997 Jun;19(11):1069-77.
439. Anderlini P, Körbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, Howe C, Leitman S, **Horowitz M**, Gluckman E, Rowley S, Przepiorka D, Champlin R. Allogeneic blood stem cell transplantation: considerations for donors. Blood. 1997 Aug 01;90(3):903-8.
440. Link CJ Jr, Burt RK, Traynor AE, Drobyski WR, Seregina T, Levy JP, Gordon L, Rosen ST, Burns WH, Camitta B, Casper J, **Horowitz M**, Juckett M, Lawton C, Margolis D, Pietryga D, Rowlings P, Taylor C, Furtado M, Stefka J, Gupta-Burt S, Kaiser H, Vesole DH. Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HGTRI 0103. Hum Gene Ther. 1998 Jan 01;9(1):115-34.
441. Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski WR, Hanson G, **Horowitz M**, Lawton C, Margolis J, Peitryga D, Vesole D. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up.

Bone Marrow Transplant. 1998 May;21(9):893-9.
442. Martin PJ, Schoch G, Gooley T, Anasetti C, Deeg HJ, Nash R, Sanders J, Storb R, Appelbaum F. Methods for assessment of graft-versus-host disease. Blood. 1998 Nov 01;92(9):3479-81.
443. Socié G, Stone JV, Wingard JR, Weisdorf D, Henslee-Downey PJ, Bredeson C, Cahn JY, Passweg JR, Rowlings PA, Schouten HC, Kolb HJ, Klein JP. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999 Jul 01;341(1):14-21.
444. Filipovich AH, Fasth A, Portal F, Landais P, Pelz C, Murphy S, Sobocinski K, **Horowitz M**, King R, Hegland J, Kollman C, Ireland M. Correction of primary immunodeficiencies with bone marrow transplantation from unrelated donors Cancer Research Therapy and Control. 1999;9(1-2):67-71.
445. Oki Y, Kami M, Muto Y. Long-term survival after bone marrow transplantation. N Engl J Med. 1999 Oct 28;341(18):1394; author reply 1395.
446. Barrett AJ, Ringdén O, Zhang MJ, Bashey A, Cahn JY, Cairo MS, Gale RP, Gratwohl A, Locatelli F, Martino R, Schultz KR, Tiberghien P. Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia. Blood. 2000 Jun 01;95(11):3323-7.
447. Jones R, **Horowitz M**, Wall D, Wingard J, Wolff S, McCarthy P, Hahn T, American Society for Blood and Marrow Transplantation. ASBMT policy statement regarding the methodology of evidence-based reviews in evaluating the role of blood and marrow transplantation in the treatment of selected diseases. American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2000;6(5):524-5.
448. Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A, Porter D, Giralt S, Levine JE, Drobyski W, Barrett AJ, **Horowitz M**, Collins RH. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant. 2000 Dec;26(11):1179-84.
449. Jones MR, **Horowitz M**, Wall D, Wingard JR, Wolff S, Steering Committee for Evidence-Based reviews of the American Society for Blood and Marrow Transplantation (ABSMT). Documenting the case for stem cell transplantation: the role of evidence-based reviews and implications for future research. Statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation (ASBMT). Biol Blood Marrow Transplant. 2001;7(6):306-7.
450. Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, **Horowitz M**, Zhang MJ, Juckett M, Drobyski WR. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. Biol Blood Marrow Transplant. 2001;7(11):620-30.
451. **Horowitz MM**. Uses and Growth of Hematopoietic Cell Transplantation Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation, Fourth Edition. 5 March 2009:15-21.
452. Petersdorf E, Bardy P, Cambon-Thomsen A, Goulmy E, Hansen J, Schwarer A, Velardi A, IHWG HCT. 14thInternational HLA and Immunogenetics Workshop: report on hematopoietic cell transplantation. Tissue Antigens. 2007 Apr;69 Suppl 1:17-24.
453. Keating A, Apperley J, **Horowitz M**, Horwitz E, Warkentin P, Weisdorf D. Blood and marrow transplant organizations Hematopoietic Stem Cell Transplantation in Clinical Practice. 2009:513-521.
454. Renner R, Carlis J, Maiers M, Rizzo JD, O'Neill C, **Horowitz M**, Gee K, Confer D. Integration of hematopoietic cell transplantation outcomes data : Data standards are not enough Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 2015;9162:139-146.
455. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC Jr, Bennett JM, Benz EJ Jr, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ Jr, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, **Horowitz M**, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-

Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug;90(8):996-1000. PMCID: PMC5365030

456. **Horowitz MM**. Uses and Growth of Hematopoietic Cell Transplantation Thomas' Hematopoietic Cell Transplantation: Fifth Edition. 1 January 2016;1-2:8-17.
457. Truitt RL, **Horowitz MM**, Atasoylu AA, Drobyski WR, Johnson BD, LeFever AV. Graft-versus-leukemia effect of allogeneic bone marrow transplantation: Clinical and experimental aspects of late leukemia relapse Cellular Immune Mechanisms and Tumor Dormancy. 1 January 2017:111-132.
458. Eapen M, Kurtzberg J, Zhang MJ, Hattersely G, Fei M, Mendizabal A, Chan KW, De Oliveira S, Schultz KR, Wall D, **Horowitz MM**, Wagner JE. Umbilical Cord Blood Transplantation in Children with Acute Leukemia: Impact of Conditioning on Transplantation Outcomes. Biol Blood Marrow Transplant. 2017 Oct;23(10):1714-1721. PMCID: PMC5605440
459. **Horowitz M**, Schreiber H, Elder A, Heidenreich O, Vormoor J, Toffalori C, Vago L, Kröger N. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant. 2018 Nov;53(11):1379-1389. PMCID: PMC6282701
460. Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, **Horowitz M**, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2018 Nov;5(11):e563-e598. PMCID: PMC6261436
461. Nikiforow S, Wang T, Hemmer M, Spellman S, Akpek G, Antin JH, Choi SW, Inamoto Y, Khoury HJ, MacMillan M, Marks DI, Meehan K, Nakasone H, Nishihori T, Olsson R, Paczesny S, Przepiorka D, Reddy V, Reshef R, Schoemans H, Waller N, Weisdorf D, Wirk B, **Horowitz M**, Alousi A, Couriel D, Pidala J, Arora M, Cutler C, GV12-02 Writing Committee on behalf of the CIBMTR® Graft-versus-Host Disease Working Committee. Upper gastrointestinal acute graft-versus-host disease adds minimal prognostic value in isolation or with other graft-versus-host disease symptoms as currently diagnosed and treated. Haematologica. 2018 Oct;103(10):1708-1719. PMCID: PMC6165812
462. Baldomero H, Aljurf M, Zaidi SZA, Hashmi SK, Ghavamzadeh A, Elhaddad A, Hamladji RM, Ahmed P, Torjemane L, Abboud M, Tbakhi A, Khabori MA, El Quessar A, Bazuaye N, Bekadja MA, Adil S, Fahmy O, Ramzi M, Ibrahim A, Alseraihy A, Ben Abdejalil N, Sarhan M, Huneini MA, Mahmal L, ElSolh H, Hussain F, Nassar A, Al-Hashmi H, Hamidieh AA, Pasquini M, Kodera Y, Kröger N, Mohty M, Jaimovich G, Rolon JM, Paulson K, Greinix H, Weisdorf D, **Horowitz M**, Nunez J, Gratwohl A, Passweg J, Koh M, Szer J, Niederwieser D, Novitzky N, East-Mediterranean (EMBMT) and African (AfBMT) Blood and Marrow Transplantation Groups and the Worldwide Network for Blood and Marrow Transplantation (WBMT). Narrowing the gap for hematopoietic stem cell transplantation in the East-Mediterranean/African region: comparison with global HSCT indications and trends. Bone Marrow Transplant. 2019 Mar;54(3):402-417. PMCID: PMC6363888
463. Aljurf M, Weisdorf D, Alfraih F, Szer J, Müller C, Confer D, Hashmi S, Kröger N, Shaw BE, Greinix H, Kharfan-Dabaja MA, Foeken L, Seber A, Ahmed S, El-Jawahri A, Al-Awwami M, Atsuta Y, Pasquini M, Hanbali A, Alzahrani H, Okamoto S, Gluckman E, Mohty M, Kodera Y, **Horowitz M**, Niederwieser D, El Fakih R. "Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries". Bone Marrow Transplant. 2019 Aug;54(8):1179-1188. PMCID: PMC6760540
464. Aljurf M, Weisdorf D, Hashmi SK, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas M, Ahmed SO, Novitzky N, Srivastava A, Seber A, Elsolh H, Ghavamzadeh A, Confer D, Kodera Y, Greinix H, Szer J, **Horowitz M**, Niederwieser D. Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): Clinical, technical and socio-economic considerations. Hematol Oncol Stem Cell Ther. 2020 Mar;13(1):7-16.
465. Pidala J, Martens M, Anasetti C, Carreras J, **Horowitz M**, Lee SJ, Antin J, Cutler C, Logan B. Factors Associated With Successful Discontinuation of Immune Suppression After Allogeneic Hematopoietic Cell Transplantation. JAMA Oncol. 2020 Jan 01;6(1):e192974. PMCID: PMC6763979
466. Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM,

Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, **Horowitz M**, Pasquini M, Lee DA, Champlin RE. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 Jan;36(1):155-164. PMCID: PMC8727305

467. Stewart MD, McCall B, Pasquini M, Yang AS, Britten CD, Chuk M, De Claro RA, George B, Gormley N, **Horowitz MM**, Kowack E, McCoy C, Morrow PK, Okoye E, Ricafort R, Rossi J, Sharon E, Theoret M, Vegni F, Yu T, Allen J. Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials. Cytotherapy. 2022 Jul;24(7):742-749. PMCID: PMC9721456
468. Petersdorf EW, Bengtsson M, **Horowitz M**, McKallor C, Spellman SR, Spierings E, Gooley TA, Stevenson P, International Histocompatibility Working Group in Hematopoietic Cell Transplantation. HLA-DQ heterodimers in hematopoietic cell transplantation. Blood. 2022 May 19;139(20):3009-3017. PMCID: PMC9121842
469. D'Souza A, Brazauskas R, Stadtmauer EA, Pasquini MC, Hari P, Bashey A, Callander N, Devine S, Efebera Y, Ganguly S, Gasparetto C, Geller N, **Horowitz MM**, Koreth J, Landau H, Brunstein C, McCarthy P, Qazilbash MH, Giralt S, Krishnan A, Flynn KE. Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma. Am J Hematol. 2023 Jan;98(1):140-147. PMCID: PMC9659666
470. Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, **Horowitz M**, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol. 2022 May;9(5):e374-e384. PMCID: PMC9241484
471. Phelan R, Chen M, Bupp C, Bolon YT, Broglie L, Brunner-Grady J, Burns LJ, Chhabra S, Christianson D, Cusatis R, Devine SM, D'Souza A, Eapen M, Hamadani M, Hengen M, Lee SJ, Moskop A, Page KM, Pasquini M, Pérez WS, Riches M, Rizzo D, Saber W, Spellman SR, Stefanski HE, Steinert P, Weisdorf D, **Horowitz M**, Auletta JJ, Shaw BE, Arora M. Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. Transplant Cell Ther. 2022 Jul;28(7):409.e1-409.e10. PMCID: PMC9840526
472. Morishima Y, Morishima S, Stevenson P, Kodera Y, **Horowitz M**, McKallor C, Malkki M, Spellman SR, Gooley T, Petersdorf EW, on-behalf-of-the-International Histocompatibility-Working-Group-in-Hematopoietic-Cell-Transplantation. Race and Survival in Unrelated Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Jul;28(7):357.e1-357.e6. PMCID: PMC9387555
473. Morishima Y, Morishima S, Stevenson P, Kodera Y, **Horowitz M**, McKallor C, Malkki M, Spellman SR, Gooley T, Petersdorf EW, on-behalf-of-the-International Histocompatibility-Working-Group-in-Hematopoietic-Cell-Transplantation. Race and Survival in Unrelated Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Jul;28(7):357.e1-357.e6. PMCID: PMC9387555
474. Brunstein CG, O'Donnell PV, Logan B, Dawson P, Costa L, Cutler C, Craig M, Hogan W, **Horowitz MM**, Horwitz ME, Karanes C, Magenau JM, Malone A, McCarty J, McGuirk JP, Morris LE, Rezvani AR, Salit R, Vasu S, Eapen M, Fuchs EJ, Blood and Marrow Transplant Clinical Trials Network. Impact of Center Experience with Donor Type on Outcomes: A Secondary Analysis, Blood and Marrow Transplant Clinical Trials Network 1101Open for Accrual June 2012Open for Accrual June 2012. Transplant Cell Ther. 2022 Jul;28(7):406.e1-406.e6. PMCID: PMC9253061
475. Vesole DH, Pérez W, Reece D, Akasheh M, **Horowitz M**, Bredeson C. High dose therapy with autologous hematopoietic stem cell transplantation (HSCT) for patients with primary systemic amyloidosis (AL): An ABMTR study Amyloid and Amyloidosis. 1 January 2004:164-166.
476. Gustafson JT, Cass H. Transplantation for acute leukemia in small versus large centers. Blood. 1993 Jan 01;81(1):265.
477. Ambinder A, Jain T, Tsai HL, **Horowitz MM**, Jones RJ, Varadhan R. HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age. Blood Adv. 2022 Jul 26;6(14):4335-4346. PMCID: PMC9327541
478. Hamilton BK, Cutler C, Divine C, Juckett M, LeMaistre C, Stewart S, Wilder J, **Horowitz M**, Khera N, Burns LJ. Are We Making PROGRESS in Preventing Graft-versus-Host Disease and Improving Clinical Outcomes? Impact of BMT CTN 1301 Study Results on Clinical Practice. Transplant Cell

Ther. 2022 Aug;28(8):419-425. PMCID: PMC9364468
479. DeZern AE, Eapen M, Wu J, Talano JA, Solh M, Dávila Saldaña BJ, Karanes C, Horwitz ME, Mallhi K, Arai S, Farhadfar N, Hexner E, Westervelt P, Antin JH, Deeg HJ, Leifer E, Brodsky RA, Logan BR, **Horowitz MM**, Jones RJ, Pulsipher MA. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022 Sep;9(9):e660-e669. PMCID: PMC9444987
480. Vasu S, Holtan SG, Shimamura A, Burnworth T, Whisenton S, Adams S, Nuechterlein B, Mortier N, Foster J, DiFronzo N, **Horowitz M**, Rizzo D, Foley A. Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report From the BMT CTN Patient and Caregiver Advocacy Task Force. Transplant Cell Ther. 2023 Jan;29(1):5-9. PMCID: PMC10008748
481. Cusatis R, Martens MJ, Nakamura R, Cutler CS, Saber W, Lee SJ, Logan BR, Shaw BE, Gregory A, D'Souza A, Hamilton BK, **Horowitz MM**, Flynn KE. Health-related quality of life in reduced-intensity hematopoietic cell transplantation based on donor availability in patients aged 50-75 with advanced myelodysplastic syndrome: BMT CTN 1102. Am J Hematol. 2023 Feb;98(2):229-250. PMCID: PMC9839494
482. D'Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, Devine S, Eapen M, Hamadani M, Hari P, Pasquini MC, Perez W, Phelan RA, Riches ML, Rizzo JD, Saber W, Shaw BE, Spellman SR, Steinert P, Weisdorf DJ, **Horowitz MM**. Corrigendum to 'Current Use and Trends in Hematopoietic Cell Transplantation in the United States' [Transplantation and Cellular Therapy 26/8 (2020) e177-e182]. Transplant Cell Ther. 2022 Oct;28(10):715-716.
483. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, **Horowitz MM**, Hari PN, Hamadani M. Corrigendum to 'Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation' [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885]. Transplant Cell Ther. 2022 Oct;28(10):717.
484. Eapen M, Brazauskas R, Williams DA, Walters MC, St Martin A, Jacobs BL, Antin JH, Bona K, Chaudhury S, Coleman-Cowger VH, DiFronzo NL, Esrick EB, Field JJ, Fitzhugh CD, Kanter J, Kapoor N, Kohn DB, Krishnamurti L, London WB, Pulsipher MA, Talib S, Thompson AA, Waller EK, Wun T, **Horowitz MM**. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. J Clin Oncol. 2023 Apr 20;41(12):2227-2237. PMCID: PMC10448940
485. Juckett M, Dandoy C, DeFilipp Z, Kindwall-Keller TL, Spellman SR, Ustun C, Waldman BM, Weisdorf DJ, Wood WA, **Horowitz MM**, Burns LJ, Khera N. How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy? Blood Reviews. 2023.
486. Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, **Horowitz MM**, Bolaños-Meade J. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial. Transplant Cell Ther. 2023 Mar;29(3):208.e1-208.e6. PMCID: PMC9992261
487. Hill JA, Martens MJ, Young JH, Bhavsar K, Kou J, Chen M, Lee LW, Baluch A, Dhodapkar MV, Nakamura R, Peyton K, Shahid Z, Armistead P, Westervelt P, McCarty J, McGuirk J, Hamadani M, DeWolf S, Hosszu K, Sharon E, Spahn A, Toor AA, Waldvogel S, Greenberger LM, Auletta JJ, **Horowitz MM**, Riches ML, Perales MA. SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study. EClinicalMedicine. 2023 May;59:101983. PMCID: PMC10133891
488. El Jurdi N, Martens MJ, Brunstein CG, O'Donnell P, Lee SJ, D'Souza A, Logan B, Hong S, Singh AK, Sandhu K, Shapiro RM, **Horowitz MM**, Hamilton BK. Health-Related Quality of Life in Double Umbilical Cord Blood versus Haploidentical Marrow Transplantation: A Quality of Life Analysis Report of BMT CTN 1101. Transplant Cell Ther. 2023 Jul;29(7):467.e1-467.e5. PMCID: PMC10330136
489. Juckett M, Dandoy C, DeFilipp Z, Kindwall-Keller TL, Spellman SR, Ustun C, Waldman BM, Weisdorf DJ, Wood WA, **Horowitz MM**, Burns LJ, Khera N. How do we improve the translation of new evidence into the practice of hematopoietic cell transplantation and cellular therapy? Blood Rev. 2023 Jul;60:101079. PMCID: PMC10330269
490. Cho C, Devlin S, Maloy M, **Horowitz MM**, Logan B, Rizzo JD, Giralt SA, Perales MA. Application of the

CIBMTR One Year Survival Outcomes Calculator as a tool for retrospective analysis. Bone Marrow Transplant. 2023 Oct;58(10):1089-1095. PMCID: PMC10592419

491. Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, Elmariah H, Rezvani AR, Gooptu M, Larkin KT, Shaffer BC, El Jurdi N, Loren AW, Solh M, Hall AC, Alousi AM, Jamy OH, Perales MA, Yao JM, Applegate K, Bhatt AS, Kean LS, Efebera YA, Reshef R, Clark W, DiFronzo NL, Leifer E, **Horowitz MM**, Jones RJ, Holtan SG, BMT CTN 1703 Investigators. Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. N Engl J Med. 2023 Jun 22;388(25):2338-2348. PMCID: PMC10575613
492. Versluis J, Saber W, Tsai HK, Gibson CJ, Dillon LW, Mishra A, McGuirk J, Maziarz RT, Westervelt P, Hegde P, Mukherjee D, Martens MJ, Logan B, **Horowitz M**, Hourigan CS, Nakamura R, Cutler C, Lindsley RC, Blood and Marrow Transplant Clinical Trials Network. Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study. J Clin Oncol. 2023 Oct 01;41(28):4497-4510. PMCID: PMC10552956
493. McCarthy PL, Attwood KM, Liu X, Chen GL, Minderman H, Alousi A, Bashey A, Lowsky R, Miklos DB, Hansen J, Westervelt P, Yanik G, Waller EK, Howard A, Blazar BR, Wallace PK, Reshef R, **Horowitz MM**, Maziarz RT, Levine JE, Mohammadpour H. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study Bone Marrow Transplantation. 2023.
494. Fein JA, Shouval R, Krieger E, Spellman SR, Wang T, Baldauf H, Fleischhauer K, Kröger N, **Horowitz M**, Maiers M, Miller JS, Mohty M, Nagler A, Weisdorf D, Malmberg KJ, Toor AA, Schetelig J, Romee R, Koreth J. Systematic evaluation of donor-KIR/recipient-HLA interactions in HLA-matched hematopoietic cell transplantation for AML. Blood Adv. 2024 Feb 13;8(3):581-590. PMCID: PMC10837477
495. Eapen M, Kou J, Andreansky M, Bhatia M, Brochstein J, Chaudhury S, Haight AE, Haines H, Jacobsohn D, Jaroscak J, Kasow KA, Krishnamurti L, Levine JE, Leung K, Margolis D, Yu LC, **Horowitz MM**, Kamani N, Walters MC, Shenoy S. Long-term outcomes after unrelated donor transplantation for severe sickle cell disease on the BMT CTN 0601 trial. Am J Hematol. 2024 Apr;99(4):785-788. PMCID: PMC10947844
496. Shaw BE, Flynn KE, He N, Cusatis R, D'Souza A, Hamilton BK, **Horowitz MM**, Mattila D, Phelan R, Lee SJ, Brazauskas R. Incorporating patient-reported outcome data into a predictive calculator for allogeneic hematopoietic cell transplantation recipients. Cancer. 2024 Jan 10.
497. McCarthy PL, Attwood KM, Liu X, Chen GL, Minderman H, Alousi A, Bashey A, Lowsky R, Miklos DB, Hansen J, Westervelt P, Yanik G, Waller EK, Howard A, Blazar BR, Wallace PK, Reshef R, **Horowitz MM**, Maziarz RT, Levine JE, Mohammadpour H. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study. Bone Marrow Transplant. 2024 Mar;59(3):334-343.

Books, Chapters, and Reviews

1. Bortin MM, **Horowitz MM**, Rimm AA, Baum SJ, Santos GW, Takaku F. Bone marrow transplantation: the difficulties ahead. Experimental Hematology Today. 1987 Jan 1; 134-140.
2. Bortin MM, **Horowitz MM**, Gale RP. Current status of bone marrow transplantation in humans: report from the International Bone Marrow Transplant Registry. Nat Immun Cell Growth Regul. 1988;7(5-6):334-50.
3. Bortin MM, **Horowitz MM**. Current status of bone marrow transplantation. Clinical Transplantation. 1989 Jan 1; 93-104
4. Barrett AJ, Lucarelli G, Gale RP, Sobocinski KA, **Horowitz MM**, Bortin MM, Buckner CD, Gale RP, Lucarelli G, Alan R. Bone marrow transplantation for thalassemia - a preliminary report from the International Bone Marrow Transplant Registry. Advances and Controversies in Thalassemia Therapy:Bone Marrow Transplantation and Other Approaches. 1989 Jan 1; 56:99-102
5. Weiden PL, **Horowitz MM**. Graft-vs-leukemia effects in clinical bone marrow transplantation. Graft-vs.-Host Disease:Immunology, Patho-physiology, and Treatment. 1990 Jan 1; 691-708
6. Gale RP, **Horowitz MM**, Butturini A, Dicke KA, Armitage JO. Autotransplants in leukemia: approaches to prevent leukemia relapse. Autologous Bone Marrow Transplantation IV. 1990 Aug 1; 255-257
7. **Horowitz MM**, Gale RP. Graft-versus-leukemia. New Strategies in Bone Marrow Transplantation. 1991 Jan 1; 275-280
8. Truitt RL, **Horowitz MM**, Atasoylu AA, Drobyski WR, Johnson LeFever AV. Graft- versus-leukemia effect

of allogeneic bone marrow transplantation: clinical and experimental aspects of late leukemia relapse. Cellular Immune Mechanisms and Tumor Dormancy. 1992 Jan 1;
9. **Horowitz MM**, Bortin MM, Gale RP, Starzl T, Shapiro R, Simmons RI. Allogeneic bone marrow transplantation. Atlas of Organ Transplantation. 1992 Jan 1; 11.1-11.21
10. **Horowitz MM**, Bortin MM. The role of registries in evaluating the results of bone marrow transplantation. Bone Marrow Transplantation in Practice. 1992 Jan 1; 367-377
11. **Horowitz MM**. Graft-versus-leukemia effects of bone marrow transplantation. Cambridge Medical Reviews: Haematological Oncology. 1992 Jan 1; 1-14
12. **Horowitz MM**, Passweg JR, Sobocinski KA, Nugent M, Klein JP. Bone marrow transplantation for severe aplastic anemia. A report from the International Bone Marrow Transplant Registry. Ontogeny of hematopoiesis. Aplastic anemia. 1995 Jan 1; 313-317.
13. **Horowitz MM**, Rowlings PA. An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation. Current Opinion in Hematology. 1997 Jan 1; 395-400.
14. Martin PJ, **Horowitz MM**. Developing areas: T cell depletion of donor marrow. Clinical Bone Marrow and Blood Stem Cell Transplantation. 1994 Jan 1; 653-657.
15. **Horowitz MM**, Truitt RL. Graft-versus-leukemia effects of bone marrow transplantation. Clinical Bone Marrow and Blood Stem Cell Transplantation. 1994 Jan 1; 704-714.
16. **Horowitz MM**, Gale RP, Buchner T, Keating A, Rowlings PA, Sobocinski KA, Zhang MJ, Klein JP, Buchner T. Bone marrow transplantation for acute myelogenous leukemia. Acute Leukemias VI:Prognostic Factors and Treatment Strategies. 1997 Jan 1; 807-809.
17. **Horowitz MM**, Spivak J. Bone marrow transplantation. 1998 Yearbook of Hematology. 1998 Jan 1; 319-377.
18. Fields KK, Vesole DH, Rowlings PA, **Horowitz MM**, Elfenbein G, Balducci L, Lyman G, Erschler W. Bone marrow transplantation in the older patient. Comprehensive Geriatric Oncology. 1998 Jan 1; 471-480.
19. **Horowitz MM**, Buchner T, Jurgens H, Berdel WE, van de Loo J, Ritter J, Kienast J, Vormoor J. Current status of blood and marrow transplantation. Transplantation in Hematology and Oncology. 1999 Jan 1; 11-21.
20. **Horowitz MM**. Uses and growth of hematopoietic cell transplantation. Hematopoietic Cell Transplantation. 1999 Jan 1; 12-18.
21. **Horowitz MM**, Truitt RL. Graft-versus-leukemia effects of bone marrow transplantation. Clinical Bone Marrow and Blood Stem Cell Transplantation. 1999 Jan 1; 1327-1338.
22. Sobocinski KA, Rowlings PA, Zhang MJ, Klein JP, **Horowitz MM**. The International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry. Clinical Bone Marrow and Blood Stem Cell Transplantation. 1999 Jan 1; 1423-1444.
23. **Horowitz MM**, Howe CWS, Armitage JO, Antman KH. Bone marrow transplantation using unrelated donors. High Dose Cancer Therapy:Pharmacology, Hematopoietins and Stem Cells. 2000 Jan 1; 221-242.
24. Giralt SA, Goldman J, Anasetti C, Cervantes F, Champlin RE, Cross N, Hochhaus A, Klein JP, Papadopoulos E, Sobocinski KA, Weisdorf DJ, **Horowitz MM**. Recommendations for assessment and definitions of response and relapse in CML: a report from the Chronic Leukemia Working Committee of the IBMTR. Chronic Myeloid Leukaemia - Biology and Treatment. 2001 Jan 1; 357-368.
25. Weisdorf DJ, Dharan B, **Horowitz MM**. Transplantation therapy for adults with acute lymphoblastic leukemia: comparative analysis of autologous and unrelated donor bone marrow transplantation. Autologous Blood & Marrow Transplantation X: Proceedings of the Tenth International Symposium. Autologous Blood & Marrow Transplantation X: Proceedings of the Tenth International Symposium. 2001 Jan 1; 380-384.
26. Freytes CO, Loberiza FR, Tsai TW, van Besien KM, Reece DE, Phillips GL, Bierman PJ, Vesole DH, Milone G, Pavlovsky S, Vose JM, Lazarus HM, **Horowitz MM**. Allogeneic stem cell transplantation in patients with Hodgkin's disease who relapse after autologous transplantation. Autologous Blood & Marrow Transplantation X: Proceedings of the Tenth International Symposium. Autologous Blood & Marrow Transplantation X: Proceedings of the Tenth International Symposium. 2001 Jan 1; 534-544.
27. **Horowitz MM**. Uses and growth of hematopoietic cell transplantation. Thomas' Hematopoietic Cell Transplantation, 4th Edition. 2004 Jan 1; 9-15.
28. **Horowitz MM**, Synder EL, Haley NR, Triulzi DJ. Center for International Blood and Marrow Transplant Research Cellular Therapy, A Physician's Handbook. 2004 Jan 1; 132-137.

29. Bredeson CN, **Horowitz MM**, Truitt RL. Graft-versus-leukemia effects of stem cell transplantation Clinical Bone Marrow and Blood Stem Cell Transplantation. 2004 Jan 1; 291-310.
30. **Horowitz MM**, Confer DL. Evaluation of hematopoietic stem cell donors. Hematology / the Education Program of the American Society of Hematology. 2005 Jan 1; 469-475.
31. Butturini A, **Horowitz MM**, Gale RP. Identical twin hematopoietic stem cell transplantation. Clinical Bone Marrow and Blood Stem Cell Transplantation. 2004 Jan 1; 773-779.
32. Petersdorf EW, **Horowitz M**. Overview of the Goals and Organization of the Component. In J Hansen and B Dupont, eds. HLA 2004: Immunobiology of the Human MHC. IHWG Press, Seattle. Proceedings of the 13th International Histocompatibility Workshop and Conference. 2007 Jan 1; Vol 1:1327-1335.
33. Petersdorf EW, Gooley T, Malkki M, **Horowitz M**. Impact of Donor-Recipient HLA Matching on Survival after Myeloablative Hematopoietic Cell Transplantation from Unrelated Donors. In: J Hansen, ed. Immunobiology of the Human MHC. IHWG Press, Seattle. Proceedings of the 13th International Histocompatibility Workshop and Conference. 2007 Jan 1; Vol 1:1336-1347.
34. **Horowitz M**. The role of registries in facilitating clinical research in BMT: examples from the Center for International Blood and Marrow Transplant Research. Bone Marrow Transplant. 2008 Aug;42 Suppl 1:S1-S2.
35. Spellman SR, Eapen M, Logan BR, Mueller C, Rubinstein P, Setterholm MI, Woolfrey AE, **Horowitz MM**, Confer DL, Hurley CK, National Marrow Donor Program, Center for International Blood and Marrow Transplant Research. A perspective on the selection of unrelated donors and cord blood units for transplantation. Blood. 2012 Jul 12;120(2):259-65. PMCID: PMC3398760
36. Shaw BE, Lee SJ, **Horowitz MM**, Wood WA, Rizzo JD, Flynn KE. Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN. Bone Marrow Transplant. 2016 Sep;51(9):1173-9.
37. Renner R, Carlis J, Maiers M, Rizzo JD, O?Neill C, **Horowitz M**, Gee K, Confer D. Integration of hematopoietic cell transplantation outcomes data: data standards are not enough. Data Integration in the Life Sciences. 2015 Jul 8; 9162:139-146.

Editorials, Letters to Editor, Other

1. Gale RP, **Horowitz MM**. How best to analyse new strategies in bone marrow transplantation. Bone Marrow Transplant. 1990 Dec;6(6):357-9.
2. Rowlings PA, Klein JP, Gale RP, **Horowitz MM** Response to Letter to the Editor regarding IBMTR severity index for grading acute graft-versus-host disease: Retrospective comparison with Glucksberg grade. Br J Haematol. 1998 June 1; 97:855-864
3. Nietfeld JJ, Pasquini MC, Logan BR, Verter F, **Horowitz MM**. On the probability of using cord blood. Biol Blood Marrow Transplant. 2008 Jun;14(6):724-5.
4. Hurley CK, Oudshoorn M, Setterholm M, Spellman SR, Petersdorf E, Lee SJ, Gooley T, Malkki M, **Horowitz MM**. Re: An approach to predicting HSCT outcome using HLA-mismatch information mapped on protein structure data. Biol Blood Marrow Transplant. 2010 Jun;16(6):865-6.
5. Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn KW, Sullivan KM, Carrum G, Andrey J, Bredeson CN, Cairo M, Gale RP, Hahn T, Storek J, **Horowitz MM**, McSweeney PA, Griffith LM, Muraro PA, Pavletic SZ, Nash RA. Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2012 Oct;18(10):1471-8. PMCID: PMC3950896
6. Giralt S, McCarthy PL, Anderson KC, Carter SL, Richardson PG, Rajkumar SV, Laport GG, Stadtmauer EA, Pasquini MC, **Horowitz MM**. Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. Biol Blood Marrow Transplant. 2013 Jun;19(6):858-9. PMCID: PMC4426902
7. Aljurf M, Rizzo JD, Mohty M, Hussain F, Madrigal A, Pasquini MC, Passweg J, Chaudhri N, Ghavamzadeh A, Solh HE, Atsuta Y, Szer J, Kodera Y, Niederweiser D, Gratwohl A, **Horowitz MM**. Challenges and opportunities for HSCT outcome registries: perspective from international HSCT registries experts. Bone Marrow Transplant. 2014 Aug;49(8):1016-21.
8. Yoshimi A, Baldomero H, **Horowitz M**, Szer J, Niederwieser D, Gratwohl A, Kodera Y, Worldwide Network of Blood and Marrow Transplantation (WBMT). Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure. JAMA. 2016 Jan 12;315(2):198-200.

Non-Refereed Journal Publications/Original Papers

1. Bortin MM, **Horowitz MM**. Current status of bone marrow transplantation. Clin Transpl. 1989:93-104.
2. **Horowitz MM**, Bortin MM. Current status of allogeneic bone marrow transplantation. Clin Transpl. 1990:41-52.
3. Rowlings PA, **Horowitz MM**, Rimm AA, Sobocinski KA, Zhang MJ, Bortin MM. Report from the International Bone Marrow Transplant Registry. Clin Transpl. 1992:83-90.
4. Rowlings PA, **Horowitz MM**, Armitage JO, Gale RP, Sobocinski KA, Zhang MJ, Bortin MM. Report from the International Bone Marrow Transplant Registry and the North American Autologous Bone Marrow Transplant Registry. Clin Transpl. 1993:101-8.
5. Rowlings PA, Passweg JR, Armitage JO, Gale RP, Sobocinski KA, Klein JP, Zhang MJ, **Horowitz MM**. Report from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry--North America. Clin Transpl. 1994:87-98.
6. Gale RP, **Horowitz MM**, Bortin MM. IBMTR analysis of results of bone marrow transplantation in acute leukemia. Acute Leukemias IV:Prognostic Factors. 1994 Jan 1: 681-685
7. Passweg JR, Rowlings PA, Armitage JO, Gale RP, Pelz CJ, Sobocinski KA, Klein JP, Zhang MJ, **Horowitz MM**. Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America. Clin Transpl. 1995:117-27.
8. **Horowitz MM**, Rowlings PA. An update from the International Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation. Curr Opin Hematol. 1997 Nov;4(6):395-400.
9. **Horowitz MM**, Confer DL. Evaluation of hematopoietic stem cell donors. Hematology Am Soc Hematol Educ Program. 2005:469-75.
10. Pasquini MC, Wang Z, **Horowitz MM**, Gale RP. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl. 2010:87-105.
11. Pasquini M, Wang Z, **Horowitz MM**, Gale RP. 2013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl. 2013:187-97.